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General introduction and outline of this thesis 
Cancer refers to a variety of diseases, characterized by the development of abnormal cells 
that divide in an uncontrollable way. Cancer cells have the ability to infiltrate and destroy 
normal body tissue and one of its characteristics is the tendency to metastasize throughout 
the body. Cancer is the leading cause of death in the Netherlands, directly followed by 
cardiovascular and pulmonary diseases. 
In almost all types of cancer, the liver is a common site for metastatic disease. Blood supply 
of the liver facilitates entrapment of circulating cancer cells, which can develop into liver 
metastases. This is known as: “the mechanical or hemodynamic hypothesis”, and was first 
described by Ewing in 1928.1 This hypothesis explains liver involvement particularly in 
gastrointestinal cancers as a result of the blood flow to the liver by the portal vein (Figure 
1). However, circulatory patterns alone do not explain liver metastases development for 
every primary tumour.
Figure 1. Blood supply to the liver by the portal system. Notice the drainage of the colon and small intestines by 
the colic, jejunal and ilial veins as well as the drainage of the upper gastrointestinal tract by the gastric, pancreatic 
and pancreaticoduodenal veins.
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Some primary tumours selectively target the liver as a preferred metastatic location. 
Patients with uveal melanomas with a loss of chromosome 3 have such a predisposition 
for liver metastases.2 Also in patients with breast cancer, different subtypes are associated 
with unique patterns of metastatic spread.3 These two examples may be explained by the 
so-called “seed and soil” hypothesis, which presumes special molecular affinity for certain 
metastatic locations. “The seeds of a plant are carried in all directions; but they can only live and 
grow if they fall on congenial soil”- Stephen Paget, 1889.4
Incidences of liver metastases
As a result of the different mechanisms of metastatic spread and variable aggressiveness 
of primary tumours, incidences of liver metastases vary per primary tumour location.5 
Remarkably, there are limited modern data about the origins of liver metastases and their 
incidences. In order to explore the origins of liver metastases, a population based overview is 
presented in chapter 2. This chapter provides population-based incidence data of histological 
confirmed liver metastases during the past 10 years in the Netherlands. 
Liver resection for metastatic disease
In most cancer patients, the development of liver metastases is considered to be an incurable 
condition, and palliative systemic treatments will be proposed. However, for patients 
with certain tumour types (neuroendocrine carcinoma and colorectal cancer (CRC) in 
particular) liver resection is a known treatment option with curative intent.6-8 Improvements 
in anesthetic techniques and post-operative care, led to decreased mortality rates after liver 
resection (<5%) in experienced liver surgery centers.9-11 As a result, indications for liver 
resections are expanding, pushing the boundaries, and therefore more liver resections are 
carried out nowadays.6,12 In chapter 3, all liver resections for metastatic disease between 
2001 and 2010 in the Netherlands, were analyzed. The primary aim of the study was to 
identify whether there was an increase in the number of liver resections, and in addition, it 
was explored whether trends in resection types or patient demographics during this decade 
could be identified. Furthermore, differences in liver resections were described between 
high and low volume centers. 
For patients with colorectal liver metastases (CRLM) the only curative treatment option 
is liver resection, with a 5-year overall survival of approximately 50% in specialized liver 
centers.6,7,13 In contrast, patients with non-colorectal liver metastases (non-CRLM) are rarely 
referred for surgery. Nevertheless, several small studies demonstrated an association between 
liver resection and improved survival in patients with non-colorectal liver metastases.14-18
Chapter 4 evaluates survival and prognostic factors after liver resection in patients with 
breast cancer liver metastases. This study aimed to identify possible risk factors and 
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prognostic factors for improved survival. Chapter 5 describes a population-based evaluation 
of survival after liver resection of patients with metastatic melanoma.
Only a minority of patients with CRLM undergoes liver resection as part of their treatment. 
In the majority, liver resection is not possible due to the presence of extra-hepatic disease, 
or location, number or size of the liver metastases.19,20 
In those cases of non-resectable CRLM treatment is limited to systemic therapy or palliative 
care. With the current combination of chemotherapy (fluoropyrimidines, oxaliplatin and 
irinotecan) and targeted agents (EGFR or VEGF antibodies), improvements in survival can be 
achieved with a median survival of 24 months. 21,22
The outcome of modern systemic therapy in patients with resectable CRLM, without 
extrahepatic disease, is unknown, but relevant in the era of personalized medicine. Although 
liver resection is considered to be the gold standard treatment for patients with CRLM, 
it is questionable whether this is still the case with the improvements in systemic therapy 
regimens. Chapter 6 aims to compare the survival of patients with resectable CRLM after 
either systemic therapy or liver resection in case-matched patient groups. 
Risk assessment in patients with CRLM; patient selection
Cancer relapse is a common phenomenon even after a curative liver resection (R0), 
with approximately 50% of recurrences occurring in the first 2 years after the initial liver 
resection.23 Various groups developed prognostic scoring systems to predict prognosis of 
patients with CRLM who were considered to be candidates for surgery. 20,24-27 The most used 
clinical risk score (CRS) was described by Fong et al.28 and consists of five clinical factors and 
all of these factors can be assigned with one point if present as stated below. The total score 
is highly predictive for outcome after surgery.29-31 The factors of the CRS28 are presented in 
Table 1.
The selection of patients with CRLM who may benefit from surgery may improve further 
by the use of pre-operative fluorine-18-deoxyglucose positron emission tomography 
(FDG-PET).32,33 It was hypothesized that patients where the FDG-PET scan did not identify 
extrahepatic disease were more likely to benefit from liver resection. This may be reflected 
in an improved disease-free and overall survival, compared to patients without preoperative 
staging with an FDG-PET scan. Chapter 7 described the use of FDG-PET scans in the work-
up of patients with CRLM. Survival was compared between patients with or without a pre-
operative FDG-PET scans and patients were stratified by CRS.
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Table 1. Clinical risk score according to Fong et al.28 
Factor 0 points 1 point
Nodal status of the primary tumour Lymph node-negative primary 
tumour
Lymph node-positive primary 
tumour
Interval between treatment of the
primary tumour and detection of liver 
metastases
12 months or more Less than 12 months 
Size of the liver metastases Smaller than 50mm 50 mm or larger 
Number of liver metastases Solitary liver metastasis Multiple liver metastases 
Carcinoembryonic antigen (CEA) 200ng/dl or less More than 200ng/dl 
In addition to clinical scoring systems and pre-operative FDG-PET scans, molecular 
and histopathological features of CRLM could have additional value in the prediction of 
prognosis after liver resection. For primary CRC many prognostic histological factors have 
been identified, and therapeutic decisions concerning adjuvant systemic therapy are made on 
these histopathological findings.34 Usually, only two factors are described in the histological 
evaluation of metastatic lesions: confirmation of malignancy, and involvement of resection 
margins. A more detailed histological report of the liver metastases may have additional 
predictive value for prognosis. Chapter 8 reviewed the literature of potential histopathological 
prognostic factors for improved survival in patients with CRLM. Most of the studies included 
in this review consisted of various histological parameters in heterogeneous patients groups. 
In order to identify reliable histological prognostic factors for overall survival in patients with 
CRLM after liver resection, chapter 9 described a study in a homogeneous group of patients 
with solitary CRLM, without neo-adjuvant treatment. Liver resection specimens of these 
patients were reviewed and evaluated for several histopathological factors in combination 
with clinical prognostic factors, and associated with survival.
The summary of this thesis, concluding remarks and future aspects are described in chapter 
10. 
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Abstract
Background: The liver is a common metastatic site for a large variety of primary tumours. 
For both patients with known and unknown primary tumours it is important to understand 
metastatic patterns to provide tailored therapies.
Objective: To perform a nationwide exploration of the origins of histological confirmed 
liver metastases. 
Methods: Data were collected using the nationwide network and registry of histo- and 
cytopathology in the Netherlands (PALGA). All histological confirmed liver metastases 
between January 2001 and December 2010 were evaluated for tumour type, origin of the 
primary tumour and were correlated with patient characteristics (age, gender). 
Results: A total of 23,154 patients were identified. The majority of liver metastases were 
carcinomas (n=21,400; 92%) of which adenocarcinoma was the most frequent subtype 
(n=17,349; 75%). Most common primary tumours in patients with adenocarcinoma were 
from colorectal (n=8,004), pancreatic (n=1,755) or breast origin (n=1,415). In women of 
50 years and younger, metastatic adenocarcinoma originated more frequently from breast 
cancer, while in women older than 70 years liver metastases originated more frequently from 
gastrointestinal tumours. Liver metastases in men older than 70 years originated often from 
squamous cell lung carcinoma. An unknown primary tumour was detected in 4,209 (18%) 
patients, although tumour type could be determined in 3,855 (92%) of them.
Conclusion: The current study provides an overview of the origins of liver metastases in a 
series of 23,154 patients. 
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Introduction
The liver is a common site for metastatic disease, however, little is known about the frequency 
in which various tumours present with liver metastases. Understanding these metastatic 
patterns is important for patients with a known primary tumour, as well as for patients with 
an unknown primary tumour. Knowledge of preferred metastatic sites in the first group of 
patients may direct staging and surveillance schemes, while in the group of patients with 
an unknown primary tumour the patterns can be used to predict the primary tumour site, 
which is important for treatment. 
The high frequency of liver involvement in metastatic disease can be explained by the 
different hypotheses of metastatic spread. The double blood supply of the liver by the portal 
vein and the hepatic artery facilitates entrapment of circulating cancer cells, according to the 
“mechanical or hemodynamic hypothesis”1, which explains the high incidence of liver metastases 
in patients with gastrointestinal carcinomas. However, some primary tumours selectively 
target the liver as a metastatic location, according to the “seed-and-soil” hypothesis 2; examples 
are patients with uveal melanoma with a loss of chromosome 3 3 , and patients with breast 
cancer with the human growth factor receptor 2 (HER-2) positivity in combination with 
estrogen (ER) and progesterone receptor (PR) positivity.4 
Metastatic patterns in colorectal cancer have recently been evaluated in a large nationwide 
autopsy study, describing all autopsies between 1991-2010.5 Hugen et al. demonstrated 
development of liver metastases in 32%-73% of the colorectal cancer patients, with significant 
differences between various histological subtypes. 5 While it is known that the majority of 
the liver metastases are of colorectal origin, exact data about incidences of non-colorectal 
liver metastases are scarce. 
Large scale autopsy studies could potentially provide information, but these studies are 
rare, and often based on much older cohorts.6, 7 An example is the study of DiSibio et al. 
which describes a cohort of autopsies between 1914 and 1943.6 Since 1943 changes in both 
surgical treatment and adjuvant therapy are profound and likely to have influenced detection 
and development of liver metastases. To date, it remains unclear which primary tumours, 
other than colorectal cancer, metastasize to the liver and in which frequency they do so. 
By analyzing all liver biopsies in an era of modern diagnostics and treatments, the incidences of 
liver metastases can be estimated for different primary tumours. This large scale, systematic, 
nationwide analysis of pathology reports generated between 2001 and 2010 showed new 
insights into the origins of liver metastases. 
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Methods
Patients and data collection
Data were collected using a search question in the PALGA-database; the nation-wide 
network and registry of histo-and cytopathology in the Netherlands. This network registers 
all pathology reports since 1971, with a nation-wide coverage since 1991.8 With the key 
words; “liver metastases”, “histology”, and limited to the years “2001-2010”, all pathology 
reports describing liver metastases were identified. 
Pathology reports were excluded when patients underwent a liver resection or liver biopsy 
for a benign liver condition or for a primary malignant liver tumour such as hepatocellular 
carcinoma. 
Per patient the following characteristics were collected from the pathology report: age and 
gender, the year of first histological diagnosis (in case of multiple biopsies, or a biopsy prior 
to liver resection), tumour type and subtype, and the location of the primary tumour. 
For age three categories were used: 50 years and younger; between 51 and 70 years; and 
over 71 years. The patient’s age at the first time of histological diagnosis was used in the 
analyses. 
Tumour type and subtype were defined according to the International Classification of Disease 
(ICD-10). When the origin of the primary tumour was not described in the conclusion of the 
pathology report, additional reports of that patient were collected and evaluated to identify 
the primary tumour. When, after this assessment, no primary tumour could be detected, the 
primary tumour was classified as an “unknown primary”. Anonymous data were used and 
both the privacy committee and scientific committee of PALGA approved the study design. 
Statistical analyses
The chi-square test was used to compare nominal variables and the Mann-Whitney U test 
was used to compare continuous variables.  A p-value of less than 0.05 was considered to 
be statistically significant. Multivariate regression analysis was used to determine differences 
in primary tumour locations between men and women in the age categories.  All descriptive 
and statistical analyses were performed using statistical package for social sciences version 
18.0 (SPSS, Inc., Chicago, Illinois, USA ). Cytoscape version 3.2.1. was used to perform clock 
plots to visualize the origins of liver metastases of the carcinoma type. Circle size is the 
square root of the total number of liver metastases. 
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Results
General patient characteristics
During the study period, 24,136 pathology reports (20,098 liver biopsies and 4,038 liver 
resections) were retrieved. Double counts were excluded for 982 patients who underwent 
both a liver biopsy and liver surgery (n=390), patients who underwent multiple liver 
resections (n=342) or patients who underwent more than one liver biopsy (n=250). A total 
of 23,154 patients were included in the study (47% female). Median age at the time of 
liver biopsy was 67 years (range: 0-97 years), and 63 years (range: 1-91years) at the time 
of liver resection. The patients who underwent a liver biopsy at the age of 0 (n=3), were 
diagnosed with neuroblastoma, while the one-year old patient underwent a liver resection 
for metastatic Wilms tumour. 
The amount of liver biopsies did not significantly increase over time. In 2001, 1,934 biopsies 
were performed, compared to 2,232 in 2010. In contrast, there was a significant decrease in 
pre-operative biopsies, from 10.8% in 2001 to 8.8% in 2010 (p<0.001). An increase of liver 
resections was observed; from 224 in 2001 to 596 in 2010 (p<0.0001). 
Tumour types and organs of origin
Carcinoma was the most frequent tumour type, diagnosed in 21,400 patients (92.4%), 
followed by melanoma in 547 patients (2.4%), and sarcoma in 235 patients (1.0%). In 33 
patients (0.1%) the tumour type was classified as ‘other’. The pathologist was unable to 
define the tumour type of the liver metastases in 939 patients (4.1%) (Table 1).
Carcinoma
Adenocarcinoma not otherwise specified (N.O.S.) was the most frequent subtype of 
carcinoma (n=17,349; 74.9%), followed by small cell carcinoma (n=1357, 5.9%), neuroendocrine 
carcinoma (n=1072; 4.6%), large cell carcinoma (n=877; 3.7%), and squamous cell carcinoma 
(n=335; 1.4%) (Table 1).
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Table 1. Tumour types and subtypes of liver metastases diagnosed by pathological evaluation. 
Tumour type Subtype n
(%)
Sex
M (%)              F (%)
Median age y
(range)
Carcinoma Total 21400
(92.4%)
11397
(53.3%)
10003
(46.7%)
66
(17-97)
Large cell carcinoma 877 (3.7%) 578 (65.9%) 299 (34.1%) 68 (1-90)
Small cell carcinoma 1357 (5.9%) 851 (62.7%) 506 (37.3%) 69 (25-91)
Squamous cell carcinoma 335 (1.4%) 199 (59.4%) 136 (40.6%) 65 (27-88)
Transitional carcinoma 262 (1.2%) 199 (76.0%) 63 (24.0%) 69 (41-89)
Adenocarcinoma N.O.S. 17349 (74.9%) 8892 (51.3%) 8457 (48.7%) 66 (20-97)
Adenoid cystic carcinoma 5 (0%) 1 (20%) 4 (80%) 58 (40-63)
Neuroendocrine carcinoma 1072 (4.6%) 590 (55.0%) 482 (45%) 65 (17-96)
Merkel cell carcinoma 8 (0%) 6 (71.4%) 2 (28.6%) 72 (48-82)
Renal cell carcinoma 102 (0.4%) 67 (65.7%) 35 (34.3%) 68 (37-87)
Medullary carcinoma 16 (0.1%) 11 (68.8%) 5 (31.3%) 49 (17-73)
Acinic cell carcinoma 1 (0%) 1 (100%) 0 31
Thymic carcinoma 4 (0%) 2 (50%) 2 (50%) 53 (35-59)
Granulosacell carcinoma 11 (0%) 0 11 (100%) 53 (39-71)
Malignant mixed mullerian 
carcinoma
1 (0%) 0 1 (100%) 79
Melanoma Total 547
(2.4%)
322
(58.9%)
225
(41.1%)
63
(20-88)
Uveal 213 (0.9%) 123 (57.7%) 90 (42.3%) 65 (30-88)
Cutaneous 251 (1.1%) 148 (59.0%) 103 (41.0%) 63 (20-87)
Mucosal 5 (0%) 3 (60.0%) 2 (40.0%) 66 (51-80)
Unknown primary 78 (0.3%) 48 (61.5%) 30 (38.5%) 61 (26-87)
Sarcoma Total 235
(1.0%)
113
(48.5%)
122
(51.5%)
60
(3-86)
Sarcoma N.O.S. 47 (0.2%) 21 (44.7%) 26 (55.3%) 61 (30-85)
GIST 107 (0.5%) 63 (58.9%) 44 (41.1%) 62 (22-86)
Angiosarcoma 3 (0%) 1 (33.3%) 2 (67.7%) 57 (3-75)
Liposarcoma 3 (0%) 3 (100%) 0 59 (37-72)
Leiomyosarcoma 64 (0.2%) 22 (34.4%) 42 (65.6%) 59 (33-85)
Rhabdomyosarcoma 1 (0%) 0 1 (100%) 13
Synoviasarcoma 2 (0%) 1 (50%) 1 (50%) 52 (41-93)
Osteosarcoma 1 (0%) 1 (100%) 0 61
Chondrosarcoma 2 (0%) 0 2 (100%) 72 (58-86)
Ewing sarcoma 1 (0%) 0 1 (100%) 14
Hemangiopericytoma 4 (0%) 1 (25%) 3 (75%) 45 (31-66)
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Other Total 33 
(0.1%)
22
(67.7%)
11
(33.3%)
45
(0-76)
Neuroblastoma 6 (0%) 1 (16.6%) 5 (83.3%) 0 (0-1)
Nefroblastoma 3 (0%) 2 (67.7%) 1 (33.3%) 6 (5-37)
Mesothelioma 6 (0%) 5 (83.3%) 1 (16.7%) 70 (55-76)
Chordoma 1 (0%) 1 (100%) 0 72
Ameloblastoma 1 (0%) 0 1 (100%) 50
Insulinoma/glucagonoma 2 (0%) 1 (50%) 1 (50%) 65 (55-74)
Brenner tumour 1 (0%) 0 1 (100%) 69
Non-seminoma 2 (0%) 2 (100%) 0 26 (17-35)
Germcell carcinoma 9 (0%) 8 (88.9%) 1 (11.1%) 33 (18-78)
Choriocarcinoma 2 (0%) 2 (100%) 0 36 (22-50)
Unknown 
tumour type
939 
(4.1%)
425
(45.2%)
514
(54.8%)
66
(1-90)
Total 23154
(100%)
12279
(53.0%)
10875
(47%)
66 
(0-97)
N.O.S.: not otherwise specified
The majority of adenocarcinoma N.O.S. originated from the digestive tract (n=11,829; 
68.2%), especially from colorectal origin (n=8,004; 46.1%). In 2,709 patients (15.6%), the 
primary tumour location was not specified (Figure1). For detailed information see Table 2.
Liver metastases of the small cell subtype were most often of pulmonary origin (n=1043; 
76.9%). Primary tumour location was not specified in 268 patients (19.7%) (Table 2).
Neuroendocrine liver metastases originated most frequently from the digestive tract 
(n=389; 36.3%), especially from the pancreas (n=137; 12.8%) and duodenum (n=110; 10.3%). 
Pulmonary origin was observed in 238 patients (22.2%), and in 416 patients (38.8%) the 
primary tumour location was not specified (Table 2, Figure 1).
The primary tumour in large cell carcinoma liver metastases was most frequently located in 
the lung (n=305; 34.8%), followed by digestive tract (n=97; 11.1%) and urological tract (n=41; 
4.7%). Primary tumour location was not specified in 376 patients (42.9%) (Table 2, Figure 1).
Squamous cell carcinoma liver metastases originated most often from the lung (n=118; 
35.2%) or the digestive tract (n=66; 18.6%), more specifically from the esophagus (n=39; 
11.6%). In 44 patients (12.4%) the primary tumour was located in the oropharynx. Primary 
tumour location was not specified in 72 patients (21.5%) (Table 2, Figure 1).
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Table 2. Primary tumour locations in patients with histological confirmed liver metastases from adenocarcinoma; 
small cell carcinoma; neuroendocrine carcinoma; large cell carcinoma and squamous cell carcinoma. 
Adeno-
carcinoma
Small cell 
carcinoma
Neuro-
endocrine 
carcinoma 
Large cell 
carcinoma
Squamous 
cell 
carcinoma
Head/Neck Total 19 
(0.1%)
- 2 
(0.2%)
23
(2.6%)
46 
(13.0)
Pharynx/Larynx 8 (0%) - - 18 (2.1%) 44 (12.4%)
Thymus 1 (0%) - - 3 (0.3%) 1 (0.3%)
Thyroid gland 10 (0.1%) - 2 (0.2%) 2 (0.2%) 1 (0.3%)
Digestive 
Tract
Total 11829 
(68.2%)
24 
(1.8%)
389 
(36.3%)
97
(11.1%)
66
(18.6%)
Colon/Rectum/Appendix 8004 (46.1%) 11 (0.8%) 86 (8.0%) 21 (2.4%) 7 (2.1%)
Anus 2 (0.0%) - 1 (0.1%) 1 (0.1%) 14 (4.2%)
Stomach 507 (2.9%) 3 (0.2%) 13 (1.2%) 9 (1.0%) 1 (0.3%)
Esophagus 349 (2.0%) 2 (0.1%) 3 (0.3%) 15 (1.7%) 39 (11.6%)
Gall bladder/biliary tract 237 (1.4%) 2 (0.1%) 1 (0.1%) 7 (0.8%) 2 (0.6%)
Pancreas 1755 (10.1%) 5 (0.4%) 137 (12.8%) 28 (3.2%) 2 (0.6%)
Duodenum/small intestine 76 (0.4%) - 110 (10.3%) 1 (0.1%) 1 (0.3%)
N.O.S. 899 (5.2%) 1 (0.1%) 38 (3.5%) 15 (1.7%) -
Lung 731 
(4.2%)
1043
 (76.9%)
238 
(22.2%)
305 
(34.8%)
118 
(35.2%)
Skin - - 1 (0.1%) 1 (0.1%) 6 (1.8%)
Breast 1417 (8.2%) 2 (0.1%) 4 (0.4%) 24 (2.7%) -
Gynecological 
tract
Total 314 (1.8%) 5 
(0.3%)
7 
(0.7%)
8
(0.9%)
26
(7.8%)
Ovary 212 (1.2%) 3 (0.2%) 5 (0.5%) 3 (0.3%) -
Uterus 87 (0.5%) 2 (0.1%) 1 (0.1%) 1 (0.1%) 2 (0.6%)
Cervix 15 (0.1%) - 1 (0.1%) 4 (0.5%) 24 (7.2%)
Urological 
tract
Total 319
(1.8%)
15 
(1.1%)
10 
(1.0%)
41 
(4.7%)
1 
(0.3%)
Kidney 144 (0.8%) - 2 (0.2%) 9 (1.0%) -
Urinary bladder 20 (0.1%) 8 (0.6%) 3 (0.3%) 23 (2.7%) 1 (0.3%)
Prostate 154 (0.9%) 7 (0.5%) 5 (0.5%) 7 (0.8%) -
Testis 1 (0%) - - 2 (0.2%) -
Adrenal 6 (0%) - 5 (0.5%) 2 (0.2%) -
Other 5 (0%) - - - -
Unknown 
primary 
2709 (15.6%) 268 (19.7%) 416 (38.8%) 376 (42.9%) 72 (21.5%)
Total 17349 1357 1072 877 335 
N.O.S.: not otherwise specified.
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Figure 1. Origins of liver metastases of the carcinoma type. Each clock plot shows the origins of liver metastases 
per carcinoma subtype (adenocarcinoma, small cell carcinoma, neuroendocrine carcinoma, large cell carcinoma, 
squamous cell carcinoma). Outer circles represent the location of the primary tumour. Circle size is proportional 
to the numbers of metastases. 
Melanoma 
Metastatic melanoma was observed in 547 patients (2.4%) with liver metastases. Uveal 
melanoma was the primary tumour in 213 patients (38.9%), and primary cutaneous melanoma 
was the origin of liver metastases in 251 patients (45.8%). Liver metastases from mucosal 
melanoma were rare, with primary locations in the colon (n=3), small bowel (n=1), and 
urinary bladder (n=1). In 78 patients, the primary melanoma location was unknown (Table 1).
Sarcoma
Metastatic sarcoma was observed in 235 patients (1.0%) with liver metastases. The most 
prevalent subtype of metastatic sarcoma was gastrointestinal stromal tumour (GIST) (n=107; 
45.5%), followed by leiomyosarcoma (n=64; 27.2%), and sarcoma N.O.S. (n=47; 20.0%) (Table 
1).
For GIST metastases, the following primary locations were described; colon or rectum 
(n=8), stomach (n=48), small bowel (n=22), and digestive tract N.O.S. (n=10). In 18 reports 
the primary GIST location was not specified. 
Primary tumour locations in patients with metastatic leiomyosarcoma were: colon (n=1), 
stomach (n=4), small bowel (n=6), uterus (n=14), ovary (n=1), kidney (n=2), bone/soft tissue 
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(n=33), or digestive tract (n=1). In 2 reports the location of the primary tumour location 
was not specified. 
Primary tumour locations in patients with metastatic sarcoma N.O.S. were: bone/soft tissue 
(n=16); brain/meningeal (n=4); skin (n=2); rectum (n=1); oropharynx/nasopharynx (n=1) and 
small intestine (n=1). There was an unknown primary tumour location in 19 patients. 
Gender differences in primary tumour locations
Histological confirmed liver metastases were more often observed in men than in women 
(n=12,280; 53.0% versus n=10,874; 47.0%; p<0.0001). Liver metastases from carcinoma 
(n=11,397; 53.3%; p=0.017), and melanoma (n=322; 58.9%; p=0.006) were more frequently 
diagnosed in men, whereas more women were diagnosed with liver metastases from an 
unknown tumour type (n=514; 54.8%; p<0.0001). In patients with liver metastases from 
carcinoma subtypes, male predominance was particularly observed in liver metastases with 
the subtypes: large cell carcinoma, small cell carcinoma, transitional carcinoma, and squamous 
cell carcinoma (Table 1, Figure 2).
Men presented relatively more often with liver metastases from colorectal adenocarcinoma 
compared to women [40.7% (n=4,625) versus 31.6% (n=3,379) (OR 1.63; 95%CI: 1.53-7.73; 
p<0.0001)]. 
Liver metastases from squamous cell lung carcinoma was more frequently observed in men 
than in women [45.7% (n=91) versus 19.9% (n=27) (95%CI: 2.052-5.638; p<0.0001)].
Figure 2. Differences in gender between tumour types. (A) and most important subtypes (B). #: no significant 
gender differences. 
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Age differences
Most of the patients with liver metastases were older than 50 years (90.2%; n=20,892). 
Metastatic adenocarcinoma from the digestive tract (including colorectal carcinoma liver 
metastases) were more common in older women (>70 years) than in younger women (≤50 
[62.6% (n=1,823), versus 45.5% (n=540) (OR: 2.00; 95%CI: 1.75-2.30; p<0.0001)]. 
In contrast, a relative increased frequency of breast adenocarcinoma liver metastases was 
observed in younger women (≤50 years), compared to older women (>70 years) [34.2% 
(n=406) versus 8.9% (n=251) (OR 5.35; 95%CI 4.49-6.38; p<0.0001)]. There was no difference 
between young and older women in metastatic gynecological adenocarcinomas; 3.3% (age 
<50 years) versus 4.2% (age 51-70) versus 3.2% (age >70) (Figure 3a).
However, metastatic squamous cell carcinomas and metastatic neuroendocrine carcinomas 
from the gynecologic tract were more frequently observed in young women (≤50 years, 
compared to women older than 50 years [38.9% (n=7) versus 16.1% (n=19) (OR: 4.13; 
95%CI: 1.47-11.57; p=0.007) respectively, 4.8% (n=3) versus 1.0% (n=4) (OR: 5.19; 95%CI: 
1.13-23.75; p=0.034)] (Figure 3b and 3c).
Metastatic adenocarcinoma originated relatively more frequent from urological tumours in 
men, and especially in men older than 50 years [3.1% (n=249) versus 0.9% in younger men 
(≤50 years) (n=6) (OR: 3.7; 95%CI: 1.51-8.94; p=0.04)] (Figure 3a).
In older men (>70 years), liver metastases from squamous cell lung carcinoma were more 
frequent than in younger men (≤50 years) [46.4% (n=26) versus 18.1% (n=4) (OR: 3.90; 
95%CI: 1.17-13.00; p=0.027)]; liver metastases from squamous cell lung carcinoma were 
most common in middle aged male patients (51-70 years) (n=61; 50.4%) (Figure 3c).
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Figure 3A.Relative incidences of primary tumour locations in women and men with metastatic adenocarcinoma. In 
young women, metastatic breast cancer was more frequently observed (p<0.0001). Liver metastases from urological 
tumours were more frequently observed in men older than 50 years (p<0.0001).
Figure 3B. Relative incidences of primary tumour location in women and men with metastatic neuroendocrine 
carcinoma. In young women (≤50 years), the primary tumour was significantly more often located in the gynecological 
tract (p=0.034).
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Figure 3C. Relative incidences of primary tumour locations in women and men with metatstatic squamous cell 
carcinoma. Liver metastases from the gynecological tract were more frequently observed in women ≤ 50 years 
(p=0.007). Primary tumour location in the lung was observed significantly more frequent in men older than 50 
years (p=0.041).
Unknown primary tumours
After reviewing all pathology history and follow up, there were 4,317 patients (18.6%) without 
a primary tumour location. In most of these unsolved cases, tumour type was reported 
(n=3,963; 91.8%). Carcinoma was the most common tumour type (n=3,847; 89.1%), and the 
most prevalent tumour subtype was adenocarcinoma N.O.S. (n=2,709; 62.8%). 
There was a small male predominance in patients with an unknown primary (n=2,262; 52.4%). 
Median age of patients with an unknown primary tumour was 68 years (range: 0-96 years). 
Patients with metastatic adenocarcinoma from an unknown primary tumour were 
significantly older at time of diagnosis, compared to patients with adenocarcinoma from a 
known primary tumour location; 68 years (range: 25-96 years) versus 66 years (range: 20-
97 years) (p<0.0001). Median age of patients with an unknown primary from other tumour 
types and subtypes did not significantly differ from the age of patients with a known primary 
tumour.
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Discussion
To the authors’ knowledge, this is the first population-based study that describes the origins 
of histological confirmed liver metastases in a systematic way, including more than 23,000 
patients during a 10-year time frame. The current study provides modern data on the origin 
and incidence of histological confirmed liver metastases from both biopsies and resection 
specimens in an era in which patients are treated according to modern standards. 
Older cohort studies may represent a close approximation for the progression of untreated 
malignancies in humans,6 but it is of no doubt that in time metastatic patterns of various 
malignancies have changed. In the autopsy study by DiSibio et al. the primary tumours that 
spread most frequently to the liver included testicular cancer and breast cancer.6 In that 
cohort testicular cancer spread to the liver in 75% of the patients, while in the present study 
the amount of liver metastases from testicular cancer was almost negligible, partly due to the 
fact that these tumours are currently diagnosed with markers in blood or by using imaging 
techniques.6 Moreover, with the current treatment of resection and systemic therapy, the 
prognosis of testicular cancer improved tremendously and as a result, histological confirmed 
liver metastases are diagnosed less frequently nowadays.9, 10
Reported incidences of breast cancer liver metastases also differed between autopsy studies 
and data of the present study.6, 11 In time, a major improvement for breast cancer patients 
was made by the introduction of breast cancer screening programs. 12 In addition, changes 
in chemotherapy, post-operative radiotherapy and hormonal therapy resulted in improved 
prognosis and led to decreased incidences in breast cancer liver metastases.6, 11, 13-15
As to be expected, carcinoma was by far the most common tumour type (92%), more 
specifically adenocarcinoma N.O.S. (75%), found in patients with liver metastases. The most 
common primary tumour was colorectal carcinoma (35%). Liver resection was most often 
performed in patients with metastatic colorectal cancer, as was recently reported.16 
In general, gender distribution of the primary tumours corresponded with gender 
distribution of the liver metastases, although some remarkable differences were observed. 
Liver metastases from thyroid cancer were more frequently diagnosed in male patients 
(51.3%) while, according to the Dutch National Cancer Registry, primary thyroid carcinoma 
is more prevalent in women (approximately 73% of all thyroid cancer types). Despite the 
small number of patients with liver metastases from thyroid cancer, this might suggest that 
the behavior of thyroid carcinoma in male patients is more aggressive, which is confirmed by 
a worse prognosis in male patients.17 Similar findings were observed in male patients with 
liver metastases from cutaneous melanoma. Although primary cutaneous melanoma is more 
frequently observed in female patients (58.3%, according to the Dutch National Cancer 
Registry), male patients are more frequently diagnosed with liver metastases (59%). Again 
this seems to be the result of aggressive tumour behavior in male patients.18,19 
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The clinical value of the present data might be questioned, but they can be used in the process 
of clinical decision making. In patients with multiple primary tumours and liver metastases, an 
approximation of the relative frequency of liver metastases can be derived from the current 
study. This could guide additional diagnostic (e.g. biopsy, immohistochemistry) or treatment 
strategies (e.g. surgery, systemic therapy). 
The current overview can also be used for clinical decision making in patients with cancer 
of an unknown primary tumour (CUP). CUP is defined as a presentation of histologically 
confirmed metastases, where, despite a standardized diagnostic approach, no primary tumour 
can be detected.20 In 24%-50% of the patients with CUP liver metastases are found.21-23 
Understanding the pathophysiological and molecular biology is needed to improve selective 
treatment strategies, based on the primary tumour and in the end to improve survival in 
patients with CUP. The current large dataset might be a basis for further research in this 
group of patients. 
Despite the size of this large, nation-wide population based study, selection bias should 
not be underestimated. Obviously, not all patients with liver metastases will undergo a 
liver biopsy. Especially in case of colorectal cancer liver metastases, the start of systemic 
treatment is often based on radiological diagnosis (CT-scan or FDG-PET scan) rather than 
on histological confirmation. Furthermore, although the liver is usually an easy access for 
biopsy, it is possible that histological or cytological confirmation was obtained from other 
metastatic sites such as: lymph nodes, ascites, pleural fluid, pulmonary lesions or any other 
metastatic location. Since these data and treatment, other than surgery, were not available 
in the current study, data on survival were not reported. On the other hand, many studies 
describe excellent results in patients diagnosed with liver metastases who underwent liver 
resection. This is not only the case in patients with colorectal cancer liver metastases, but 
improved survival has been reported in patients with other primary tumours, such as: breast 
cancer, melanoma, GIST or renal cell carcinoma.24-27
In conclusion, this study provides an overview of the origins of liver metastases, with regard 
to tumour type, age and gender, in an era of modern diagnostic and treatment modalities. 
These important data form a basis for future research, and can be used for the development 
of diagnostic strategies. 
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Abstract
Objective: The study aims to evaluate all patients who underwent liver resection for 
metastatic disease for demographics, characteristics of the primary tumour and metastasis, 
volume of liver resection specimens per pathology laboratory, and to describe trends in 
surgical treatment. 
Methods: Data were prospectively collected using the Dutch nationwide pathology network. 
All pathology reports containing details on liver resections for metastatic disease between 
January 2001 and December 2010 were evaluated. 
Results: A total of 3,916 liver resections were performed in 3,699 patients with a median 
age of 63 years (range: 1–91). The primary tumour was mainly colorectal (n = 3,256; 88.0%). 
The number of ‘high volume liver centers’ increased from 2 to 12 in the study period, 
whereas the number of ‘low volume centers’ decreased. The number of liver resections 
increased from 224 to 596 per year (p<0.0001). A significant increase was demonstrated in 
elderly patients, patients with multiple metastases, liver resections for smaller metastases, 
and minor liver resections. 
Conclusion: Although majority of patients were young and had solitary metastasis, 
indications for liver resection are expanding, as indicated by increasing numbers of elderly 
and patients with multiple liver metastases. Patients with non-colorectal liver metastases 
were seldom candidates for resection. 
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Introduction
Liver resection is considered standard treatment for patients with colorectal liver metastases 
(CRLM), with 5-year overall survival rates of 50% or more, depending on several clinical 
risk factors.1-3 In addition, liver surgery is accepted as a treatment option in patients with 
neuroendocrine liver metastases (NELM), with a 5-year survival ranging from 60%-80%.4-6 
Selected patients with non-CRLM, non-NELM may also be potential candidates for surgical 
treatment, since several studies demonstrated an association with improved survival after 
liver resection.7-12 
Improvements in anesthetic techniques and post-operative care led to decreased mortality 
rates of less than 3% in experienced liver surgery centers.13-15 With these improvements, 
indications for liver resection are expanding and more patients with liver metastases undergo 
surgical treatment. 3, 16 Besides perioperative management improvements, innovations in 
surgical and non-surgical techniques; such as radio frequent ablation (RFA) therapy, portal 
vein embolisation, and availability of effective neo-adjuvant systemic therapies contribute to 
an increase in number of liver resections.17, 18 In patients with initially irresectable CRLM, 
preoperative chemotherapy (often in combination with targeted agents such as bevacizumab 
and cetuximab) led to increased response rates and therefore to an increase of resectable 
CRLM.19, 20 All of these factors are important and might contribute to the growing number 
of liver resections. 
Population-based studies have described an increase in the amount of liver resections for 
metastatic disease, mainly in patients with colorectal cancer. In the UK, the number of 
patients who will undergo liver resection increased from 1.7% in 1998 to 3.8% in 2004.21 A 
similar French study reported an increase in liver resection from 2-7% between 1976 and 
1980 to 7-20% in the period between 1996 and 2000.22 In both studies, only patients with 
liver metastases from colorectal origin were evaluated, and only few nationwide studies are 
available on liver resections performed for non-CRLM.8, 10, 12
The aim of this study is to assess changes in the number of liver resections carried out in both 
patients with CRLM, and non-CRLM. Different factors (e.g., number or size of metastases, 
patient age and tumour type) were evaluated during the study period to study potential 
differences in indication for liver surgery. Furthermore, the number of resection specimens 
per pathology laboratory was evaluated, in order to demonstrate the centralisation of liver 
surgery.
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Methods
Patients and data collection
Data were collected using a query in the PALGA-database. This nationwide network and 
registry of histopathology and cytopathology in the Netherlands, has been collecting 
pathology reports since 1971, with a nationwide coverage since 1991.23 The search terms: 
“liver metastases” and “histology” were used in the PALGA-database to identify all pathology 
reports containing details of liver metastases between January 2001 and December 2010. 
Patients who underwent liver resection for a primary liver malignancy or a benign liver lesion 
were excluded from this study. When the origin of the primary tumour was not described in 
the pathology report, all pathology reports of that specific patient were critically reviewed in 
order to obtain the origin of the primary tumour. Both the privacy committee and scientific 
committee of PALGA approved the study design.
The following characteristics were collected from the pathology reports per patient: year of 
liver resection, age at time of resection, gender, location of the primary tumour, tumour type, 
number and size of the liver metastases and the completeness of the resection. 
Tumour typing was performed according to the International Classification of Diseases -10 
(ICD-10). Neuroendocrine carcinoma included all types of neuroendocrine tumours (low 
and high grade). Primary tumours were classified according to the organ system of the 
primary tumour. Primary tumours were classified as ‘not otherwise specified’ (N.O.S.), if no 
definite origin was reported.
 
The type of liver resection was derived from the pathology report. A minor resection 
was defined as a resection of 3 or less liver segments. A major resection was defined as a 
resection of more than 3 liver segments. A re-resection was considered to be a scheduled 
‘two-stage procedure’ when patients underwent a re-resection within 3 months after the 
initial liver resection. These procedures were classified by definition as major resections. 
Liver resection was considered a complete resection (R0) when the pathologist described 
free resection margins. Details regarding distance of resection margins were not described 
in all pathology reports and therefore not recorded in the current study. The difference 
between microscopic incomplete (R1) and macroscopic incomplete resections (R2) was 
not always clearly reported, and therefore, both were analyzed as one group of incomplete 
resections. The size of the largest liver metastasis was reported in patients with multiple 
liver metastases.
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
3
Liver resection for metastatic disease; a population-based analysis of trends
37
Pathology reports in the PALGA database are registered anonymously, without details and 
names of the hospitals and surgeons which delivered the resection specimen. The pathology 
laboratories where the specimens were assessed were registered. Since all hospitals in the 
Netherlands where liver surgery is performed have their own pathology laboratory, the 
number of laboratories is a reliable reflection of the number of hospitals. Laboratories that 
examine one or less liver resection specimen per year were defined as ‘incidental centers’. 
These centers were not included in the analyses of hospital volume. ‘Low volume centers’ 
were defined as laboratories which examine 2 to 9 liver resection specimens per year; 
laboratories which examine 10 to 19 liver resection specimens per year were defined 
as ‘middle volume centers’ and ‘high volume centers’ were defined as laboratories which 
examine more than 20 liver resection specimens yearly.
Statistics
The Mann-Whitney U test was used to compare medians between the group of patients 
with CRLM and the non-CRLM group. To compare nominal variables the Pearson chi-
square test was used. Multivariate logistic regression analysis was used to determine the 
independent effect of the time period of diagnosis on the chance to undergo a liver resection. 
Stratification was carried out for size and number of metastases, type of resection and 
resection margins. Multivariate regression analysis was used to assess differences in tumour 
and patient characteristics between ‘high’, ‘middle’ and ‘low volume centers’. A p-value of 
less than 0.05 was considered statistically significant. All descriptive and statistical analyses 
were performed using statistical package for social sciences version 18.0 (SPSS, Inc., Chicago, 
Illinois., USA). 
Results
General patient characteristics
A total number of 24,138 pathology reports describing histologically confirmed liver 
metastases between 2001 and 2010, were identified and reviewed from the PALGA database. 
The majority of these reports (n = 20,222) described results of liver biopsies for metastatic 
disease and were excluded from the present study. The remaining 3,916 pathology reports 
described liver resections for metastatic disease and were included in the present study. 
Resections were performed in 3,699 patients (59% male and 41% female). During the study 
period, 203 patients (5.5%) underwent a re-resection and 14 patients underwent a third 
resection. Median age at the time of the primary liver resection was 63 years (range: 1-91 
years). The 1-year old patient underwent liver resection for metastatic Wilms tumour. 
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Primary tumour characteristics
Most of the liver resections were performed in patients with metastatic carcinoma (n = 
3,557; 96.2%), mostly located in the colon or rectum (n = 3,238; 82.7%). Metastatic melanoma 
(n = 36; 1.0%) and metastatic sarcoma (n = 46; 1.2%) were rare indications for liver resection 
(Table 1). 
Table 1. Pathological evaluation of various tumour types found in initial liver resection specimens.
n (%) Sex Age, years, median 
(range)Male Female
Carcinoma
  Total 3,557 (96.2%) 2114 (59.4%) 1443 (40.6%) 64 (17-91)
  Adenocarcinoma N.O.S. 3,450 (97%) 2060 (59.7%) 1390 (40.3%) 64 (20-91)
  Neuroendocrine carcinoma 55 (1.5%) 24 (43.6%) 31 (56.4%) 59 (17-79)
  Squamous cell carcinoma 12 (0.3%) 4 (33.3%) 8 (66.7%) 54 (41-67)
  Other 40 (1.2%) 26 (65.0%) 14 (35.0%) 57 (17-77)
Melanaoma
  Total 36 (1.0%) 21 (58.3%) 15 (41.7%) 52 (28-69)
  Occular 11 (30.6%) 5 (45.5%) 6 (54.5%) 57 (34-66)
  Cutaneous 14 (38.8%) 10 (71.4%) 4 (28.6%) 45 (39-69)
  N.O.S. 11 (30.6%) 6 (54.5%) 5 (45.5%) 51 (28-66)
Sarcoma
  Total 46 (1.2%) 18 (39.1%) 28 (60.9%) 56 (3-75)
  Sarcoma NOS 4 1 (25.0%) 3 (75.0%) 58 (30-69)
  Angiosarcoma 1 - 1 (100%) 3
  GIST 21 13 (61.9%) 8 (38.1%) 59 (24-74)
  Leiomyosarcoma 18 4 (22.2%) 14 (77.6%) 56 (33-75)
  Rhabdomyosarcoma 1 - 1 (100%) 13
  Chondrosarcoma 1 - 1 (100%) 58
Other
  Total 6 (0.2%) 4 (66.7%) 2 (33.3%) 21 (5-37)
  Nefroblastoma 1 - 1 (100%) 5
  Germ cell tumour 4 3 (75%) 1 (25%) 28 (20-37)
  Non-seminoma 1 1 (100%) - 17
N.O.S. 54 (1.4%) 27 (50%) 27 (50%) 60 (1-83)
Total 3,699 (100%) 2,184 (59.0%) 1,515 (41.0%) 63 (1-91)
N.O.S.: not otherwise specified
Other locations of carcinomas are presented in Table 2. Tumour subtypes in CRLM from 
carcinoma, were adenocarcinoma N.O.S. (n = 3,224), neuroendocrine carcinoma (n = 11), 
and squamous cell carcinoma (n = 3). The tumour type was not reported in 15 patients with 
metastases from colorectal origin. In 3 patients, a GIST was diagnosed as the tumour subtype 
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in liver metastases originating from a colorectal primary tumour. Besides colon or rectum, 
other primary GIST locations were stomach (n = 7), duodenum or small intestine (n = 10), 
and digestive tract N.O.S. (n = 1). 
Table 2. Primary tumour location in patients with liver metastases from carcinoma who underwent liver resection
n Sex, n (%) Age, years, median 
(range)Male Female
Head/neck
  Total 12 9 (75.0%) 3 (25.0%) 49 (17-65)
  Pharynx/Larynx 3 3 (100%) - 56 (32-58)
  Thymus 2 2 (100%) - 44 (35-52)
  Thyroid gland 7 4 (57.1%) 3 (42.9%) 48 (17-65)
Digestive system
  Total 3,391 2,065 (60.9%) 1,326 (39.1%) 64 (52-76)
  Colon/Rectum/Appendix 3,238 1,983 (61.2%) 1,255 (38.8%) 64 (24-94)
  Anus 3 1 (33.3%) 2 (66.7%) 53 (45-59)
  Stomach 20 17 (85.0%) 3 (15.0%) 68 (36-79)
  Esophagus 15 11 (73.3%) 4 (26.7%) 60 (35-73)
  Gall bladder/biliary tract 22 7 (27.3%) 16 (72.7%) 66 (52-86)
  Pancreas 51 28 (54.9%) 23 (45.1%) 62 (34-82)
  Duodenum/Small intestine 25 9 (36.0%) 16 (100%) 59 (45-75)
  N.O.S. 17 9 (52.9%) 8 (47.1%) 62 (38-86
Lung 7 4 (57.1%) 3 (42.9%) 64 (52-76)
Skin 1 - 1 (100%) 47
Breast 32 - 32 (100%) 51 (31-82)
Genital tract
  Total 39 0 39 (100%) 58 (28-85)
  Ovary 35 - 35 (100%) 56 (28-85)
  Uterus 2 - 2 (100%) 66 (61-71)
  Cervix 2 - 2 (100%) 55 (51-58)
Urological tract
  Total 33 21 (63.6%) 12 (36.4%) 58 (31-82)
  Kidney 26 15 (57.7%) 11 (42.3%) 65 (20-79)
  Urinary bladder 4 3 (75.0%) 1 (25.0%) 68 (62-77)
  Prostate 1 1 (100%) - 61 
  Testis 2 2 (100%) - 48 (27-68)
Adrenal 4 2 (100%) 2 (100%) 64 (59-68)
Other 2 1 (50%) 1 (50%) 64 (59-68)
N.O.S. 36 12 (33.3%) 24 (66.7%) 62 (17-79)
Total 3557 2114 1443
N.O.S.: not otherwise specified
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Patients who underwent liver resection for non-CRLM were younger at time of operation 
(median 59 years; range: 1-86 years) compared to patients with CRLM (median 64 years; range: 
24-91 years; p<0.0001). Patients with CRLM were predominantly male (61.4%), whereas 
patients who underwent resection for non-CRLM were mostly female (58.1%; p<0.0001). 
Female predominance in patients with non-CRLM can be explained by 52 patients (11.9%) 
with metastatic gynecological tumours (cervix n = 3; uterus n = 9, and ovary n = 40) and 32 
patients (7.2%) with metastatic breast carcinoma. 
Liver resections
Minor resections were performed in 2,336 patients (59.7%), mostly a segmentectomy 
(n = 1,483; 63.5%). A non-anatomical resection was performed in 834 patients (35.7%). In 
19 patients (0.8%) the resection type was not specified. Hemihepatectomy was performed 
in 974 patients (24.9%); right-sided hemihepatectomy in 572 patients (14.6%), left sided 
hemihepatectomy in 171 patients (4.4%), and 117 patients (3.0%) underwent an extended 
hemihepatectomy. The side of the hepatectomy was not specified in 114 patients (2.9%).
A complete resection (R0) was performed in 3,058 patients (78.1%), 482 patients (12.3%) 
underwent an incomplete resection (R1 or R2), and in 376 patients (9.6%) the resection 
margins were not described. The median number of resected metastases was 1 (range: 1-19) 
and the median size was 34.0 mm (range: 1-280 mm). 
 
Re-resections and ‘two-stage procedures’
During the study period, 203 patients (5.5%) underwent a re-resection, mostly for CRLM (n 
= 183; 95.3%). Eleven patients underwent a re-resection as part of an intended ‘two-stage 
procedure’, after a median of 42 days (range: 21-84 days) from the initial liver resection. The 
remaining 192 patients underwent a re-resection as a result of disease recurrence; 14 patients 
underwent a third liver resection. Patients who underwent a re-resection were significantly 
younger (median 61 years; range: 24-78 years), compared to patients who underwent a 
single liver resection (median 63 years; range: 1-91 years) (p = 0.042). The re-resection was 
performed after a median of 12 months (range: 3-73 months) from the initial liver resection. 
Liver resections per pathology laboratory
The number of pathology laboratories examining liver resection specimens decreased from 
37 in 2001 to 31 in 2010. Especially the ‘low volume’ and ‘sporadic centers’ decreased from 
15 respectively 11 in 2001, to 10 respectively 2 in 2010 (Figure 1). A median of 28 resection 
specimens (range: 20-84) were evaluated annually in ‘high volume centers’. ‘Middle volume 
centers’ examined 13 resection specimens (range: 10-19) per year, and in ‘low volume 
centers’ 4 resection specimens (range: 2-9) were evaluated yearly. 
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Figure 1. Amount of liver resections performed in high (≥20 liver resections per year), middle (11-19 liver 
resections per year) and low volume centers (1-9 liver resections per year). Below the figure is the number of 
pathology (PA) laboratories involved in examining liver resection specimens per year.
In ‘high volume centers’, resection specimens with multiple metastases (OR 1.348; 95%-CI 
1.069-1.701), and non-CRLM (OR 1.397; 95%-CI 1.216-3.452) were more often examined, 
than in ‘middle’ and ‘low volume centers’. Furthermore, in ‘high volume centers’ patients were 
younger (<75 years) at the time of liver resection, compared to ‘low’ and ‘middle volume 
centers’ (OR 0.564; 95%-CI 0.423-0.754). No differences were observed in the amount of 
complete (R0) resections and in the size of the liver metastases between the ‘high’, ‘middle’ 
and ‘low volume centers’ (Table 3).
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Table 3. Patterns in resection chracteristics in low (1-9 liver resections per year), middle (10-19 liver resections 
per year) and high volume centers (≥20 liver resections per year) (logistic regression)
Low volume*
(n=390)
Middle volume
(n=723)
High volume
(n=2,629)
Size
  ≤50mm 111 (75.5%) 346 (82.0%) 1,201 (76.4%)
  >50mm 36 (24.5%) 76 (18.0%) 371 (23.6%)
  NR 243 301 1,057
  OR (≤50mm vs. >50mm) (95%-CI) - 1.477 (0.941-2.317) 1.050 (0.708-1.556)
Number of metastases
  Solitary 251 (67.8%) 443 (64.3%) 1,549 (61.0%)
  Multiple 119 (32.2%) 246 (35.7%) 990 (39.0%)
  NR 20 34 90
  OR (multiple vs. solitary) (95%-CI) - 1.171 (0.896-1.531) 1.348 (1.069-1.701)**
Resection margins
  R0
305 (87.1%) 597 (90.3%) 2,064 (85.6%)
  R1/2 45 (12.9%) 64 (9.7%) 348 (14.4%)
  NR 40 62 217
  OR (R1/2 vs. R0) (95%-CI) - 0.727 (0.484-1.090) 1.143 (0.819-1.594)
Type of metastases
  Colorectal 354 (90.8%) 661 (91.4%) 2,302 (87.6%)
  Non colorectal 36 (9.2%) 62 (8.6%) 327 (12.4%)
  OR (CRLM vs. non-CRLM) (95%-CI) - 0.922 (0.600-1.419) 1.397 (1.216-3.452)**
Age
  <75 years 322 (82.6%) 629 (87.0%) 2,349 (89.3%)
  ≥75 years 68 (17.4%) 94 (13.0%) 280 (10.7%)
  OR (<75 years vs. ≥75 years) (95%-CI) - 0.708 (0.504-.994) 0.564 (0.423-0.754)
NR: not reported, Values are n (%) unless otherwise indicated. * Low volume center was the reference for logistic 
regression. ** In bold: Statistically significant
Trends in liver resections
The annual number of liver resections increased from 224 in 2001 to 596 in 2010 (p<0.0001). 
This increase was mainly due to an increase in liver resections for CRLM. The number of 
liver resections performed for non-CRLM remained almost stable (Figure 2). The percentage 
of re-resections increased not significantly, from 3.9% in the period between 2001 and 2004 
to 5.0% between 2008 and 2010.
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Figure 2. Number of liver resections per year performed for metastatic disease. On the X-axis the year of liver 
liver resection, and on the Y-axis the number of liver resections. 
In 2001, the median age at the time of liver resection was 62 years (range: 1-85 years), 
which increased to a median age of 64 years (range: 28-89 years) in 2010 (p<0.0001). The 
higher age was also demonstrated by the percentage of elderly patients (> 75 years) who 
underwent liver resection. Between 2001 and 2004, 9.1% of the patients undergoing a liver 
resection were older than 75 years, which increased to 13.9% between 2008 and 2010 (OR 
1.61; 95%CI: 1.25-2.07).
Between 2001 and 2004, liver resections were mainly performed for solitary metastasis 
(67.2%), which decreased to 60.5% between 2008 and 2010. In this time period, more liver 
resections were performed for multiple liver metastases (OR 1.34; 95%CI: 1.13-1.58) (Table 
3). 
During the study period, an increase in percentage of small metastases (≤ 50 mm) was 
demonstrated. In the period between 2001 and 2004, 70.8% of the metastases were 50 mm 
or smaller, which increased to 79.7% between 2008 and 2010 (OR 1.62; 95%CI: 1.27-2.07). 
This coincided with an increase in minor resections from 63.5% between 2001 and 2004 to 
74.7% between 2008 and 2010 (OR 1.69; 95%CI: 1.41-2.03) (Table 4).
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
Chapter 3
44
Table 4. Annual patterns in resection characteristics (logistic regression)
2001-2004*
(n=1,061)
2005-2007
(n=1,238)
2008-2010
(n=1,617)
Size
  ≤50mm 364 (70.8%) 526 (79.1%) 798 (79.7%)
  >50mm 150 (29.2%) 139 (20.9%) 203 (20.3%)
  NR 547 573 616
  OR (≤50mm vs. >50mm) (95%-CI) - 1.559 
(1.194-2.036)**
1.620
(1.268-2.069)**
Number of metastases
  Solitary 684 (67.2%) 761 (63.9%) 940 (60.5%)
  Multiple 334 (32.8%) 429 (36.1%) 613 (39.5%)
  NR 43 48 64
  OR (multiple vs. solitary) (95%-CI) - 1.154 
(0.968-1.377)
1.335 
(1.132-1.576)**
Resection margins
  R0 796 (85.7%) 966 (87.1%) 1,296 (86.3%)
  R1/2 133 (14.3%) 143 (12.9%) 206 (13.7%)
  NR 132 129 115
  OR (R1/2 vs. R0) (95%-CI) - 0.886 
(0.687-1.142)
0.951
(0.752-1.204)
Type of resection
  Minor 540 (63.5%) 730 (68.9%) 1,066 (74.5%)
  Major
  NR
314 (36.5%)
207
332 (31.1%)
176
367 (25.5%)
184
  OR (major vs. minor) (95%-CI) - 1.279 
(1.057-1.546)**
1.689 
(1.407-2.028)**
NR: not reported, Values are n (%) unless otherwise indicated. * 2001-2004 was the reference period for logistic 
regression. ** Statistically significant with p-value <0.05. Note that all patients who underwent a 2-staged procedure 
had multiple metastases and underwent a major resection.
Discussion
The current study describes all liver resections performed in the last decade for metastatic 
disease in the Netherlands. A significant increase in number of liver resections was 
demonstrated, predominantly in patients with CRLM. Part of this increase may be explained 
by the increasing incidence of primary colorectal carcinoma and, as a result, CRLM.  Additional 
explanations for the increase in resections can be found in the expansion of indications for 
liver resection.
A significant increase in patients’ age at the time of resection was demonstrated, as well as an 
increase in the percentage of elderly patients (>75 years). There is controversy in literature 
whether these elderly patients have an increased risk of post-operative complications and 
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mortality. Some reports state that complication rates may be increased, whereas others 
report similar complication rates irrespective of age.24-26 The trend towards operating 
more elderly patients, as observed in the current study, suggests that age is not considered 
a contraindication for liver resection. Data on comorbidity and clinical condition of the 
patients were not available in the current study, but these factors may very well be more 
important in judging patients fit for surgery.
The percentage of patients with multiple liver metastases who underwent resection 
increased. Between 2001 and 2004, only 32.8% of the liver resections were performed 
for multiple metastases, which increased to 39.5% between 2008 and 2010. Until recently, 
surgery was usually only recommended for patients with up to three metastases, and no 
evidence of extrahepatic disease.27 A recent meta-analysis reported no correlation between 
number of metastases and survival rates.28 Nowadays, multiple liver metastases are less 
often considered a contraindication because of the emergence of effective neo-adjuvant 
systemic therapy 16, and improvements in surgical strategies. With combinations of portal 
vein embolisation 29, radiofrequent ablative (RFA) therapies 30 or two-staged resections 19, 31 
more patients become eligible for liver resection. 
Resected liver metastases were smaller in patients who underwent liver resection between 
2008 and 2010 compared to the size of metastases resected between 2001 and 2004. 
Although data on neo-adjuvant systemic therapy were not available, increased neo-adjuvant 
treatment may be an explanation for the smaller metastases found in the resection specimens. 
Other explanations could be improved imaging techniques, or more rigorous follow-up 
schedules for patients suffering from colorectal cancer. 
In the present study, there were no differences in the percentages of complete resections 
(R0) between high and low volume centers. There were also no differences in the number 
of R0 resections in patients during the study period. Due to the nature of the study and 
many different pathology laboratories where the liver resections were evaluated, it was 
impossible to discriminate between R1 and R2 resections. The exact free resection margin in 
millimeters was absent in many pathology reports; therefore, no definite conclusions could 
be drawn regarding exact resection margins. 
Although increasing numbers of patients in the Netherlands undergo liver resection, still 
relatively few patients developing CRLM undergo liver surgery. Data from the national 
cancer registry show an incidence of colorectal carcinoma of 12,755 patients in 2010. In 
recent years 21-24% of patients with colorectal cancer presented with metastatic disease 
(M1) at the time of diagnosis, which is approximately 3000 patients per year .32 33 These 
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synchronous metastatic lesions are limited to the liver in approximately 55% of these 
patients (3,000*0.55=1,650 patients in Dutch population annually).34 Recent data from the 
national cancer registry demonstrated that approximately 20% of colorectal cancer patients 
will develop metastases during follow-up.35 This would be approximately 1900 colorectal 
patients in the total Dutch colorectal cancer population, and half of these patients would 
have metastases limited to the liver, which should be approximately 950 patients. Of these 
annual 2,600 patients with liver only disease (950 metachronous and 1,650 synchronous), 
approximately 20% (498 patients with CRLM) underwent liver resection in 2010, according to 
the results of the present study. Although not all patients who develop liver only metastases 
will have resectable liver metastases, the number of patients with CRLM who underwent 
liver resection in the Netherlands seems low. This is comparable to data from Morris et 
al.21 and Manfredi et al.22, who reported similar data. A recent study from the Eindhoven 
Cancer Registry in the Netherlands reported all patients with stage IV colorectal cancer and 
demonstrated that from 2004 to 2012 the number of patients who underwent liver surgery 
increased from 4% to 24%.36
This percentage may be a result of the decision-making process in management of patients 
with liver metastases. In the Netherlands, approximately 25 hospitals are performing liver 
surgery, but colorectal surgery is performed in almost all hospitals (>85). When patients are 
diagnosed in these hospitals, they are discussed in multidisciplinary teams, but specialist liver 
surgeons are not always involved in these meetings. Also the presence of a dedicated medical 
oncologist is demonstrated to be important in considering patients with CRLM suitable for 
neo-adjuvant chemotherapy.37 Jones et al. demonstrated that even in a high-volume center 
(UK cancer network), almost two-thirds of patients with tumours deemed unresectable 
by non-liver surgeons, were considered potentially resectable by a panel of specialist liver 
surgeons.38 
On the other hand, there is also considerable inter-individual variation in the decision-
making process between liver surgeons.39 This highlights the heterogeneity of oncological 
liver surgery and emphasises the importance of multidisciplinary liver tumour boards, to 
optimise the timing of surgical intervention and systemic treatment. 
Although approximately 20% of the patients with CRLM undergo resection, non-CRLM 
patients are only considered to be candidates for liver resection in highly selected cases.10, 
12 The prevailing opinion that liver resection should not be considered as a curative option 
in non-CRLM patients may be insufficient, because 5-year disease-free survival after liver 
resection has been reported.10,12,40 One of the reasons that non-CRLM patients might not 
be considered eligible for surgery is the fact that metastases are often diagnosed in an 
advanced disease stage, because imaging of the liver is not part of routine follow up for many 
malignancies. Another reason may be that patients with non-CRLM are often not exposed 
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to liver surgeons. With the emergence of multidisciplinary tumour boards it may be assumed 
that surgeons take part in the decision-making process concerning the treatment of non-
CRLM patients more often than in the past, when this group of patients was mainly treated 
by medical oncologists. 
Centralisation of complex upper gastrointestinal surgery, especially liver surgery and the 
effect on outcome have been reported.41. Centralisation of liver surgery in the Netherlands 
led to more ‘high volume’ and less ‘low volume’ and ‘sporadic centers’, as observed in the 
current study. Although it may be assumed that centralisation of liver resections may have 
led to improved short- and long-term outcome, this could not be drawn from the present 
study, because follow-up data are lacking. 
In conclusion, the number of liver resections performed for metastatic disease increased 
over the past decade. Indications for liver resection seem to be expanding, reflected by the 
increasing percentage of elderly patients and the increasing amount of liver resections for 
multiple metastases. However, still only a minority of patients with liver metastases undergo 
a liver resection. Therefore we recommend that all patients with liver metastases (colorectal 
and non-colorectal liver metastases) should be discussed in a multidisciplinary tumour board, 
including an expert liver surgeon, in order to offer best possible treatment.
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Abstract
Aims: Patients with breast cancer metastasized to the liver have a median survival of 4-33 
months and treatment options are usually restricted to palliative systemic therapy. The aim 
of this observational study was to evaluate the effectiveness and safety of resection of liver 
metastases from breast cancer and to identify prognostic factors for overall survival.
Methods: Patients were identified using the national registry of histo- and cytopathology 
in the Netherlands (PALGA). Included were all patients who underwent resection of liver 
metastases from breast cancer in 11 hospitals in the Netherlands in the last 20 years. Study 
data were retrospectively collected from patient files.
Results: A total of 32 female patients were identified. Intra- and post-operative complications 
occurred in 3 and 11 patients, respectively. There was no post-operative mortality. After a 
median follow up period of 26 months (range: 0-188), 5-year and median overall survival 
after partial liver resection was 37% and 55 months, respectively. The 5-year disease-free 
survival was 19% with a median time to recurrence of 11 months. Solitary metastasis was 
the only independent significant prognostic factor at multivariate analysis.
Conclusion: Resection of liver metastases from breast cancer is safe and might provide a 
survival benefit in a selected group of patients. Especially in patients with solitary metastasis, 
the option of surgery in the multimodality management of patients with disseminated breast 
cancer should be considered.
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Introduction
In the management of metastatic disease, resection of liver metastases has been performed 
more frequently in the last decade. Partial liver resection in patients with colorectal and 
neuroendocrine liver metastases has become widely accepted and is safe and effective. A 
5-year overall survival of 20-50% has been reported, in comparison to only few patients 
surviving 5 years after systemic therapy for the liver metastases.1-3 In contrast, patients 
with disseminated non-colorectal, non-neuroendocrine liver metastases are only referred 
for surgical resection in selected cases. 
Liver metastases are present in 20-25% of the patients with stage IV breast cancer and 
are the initial sign of distant dissemination in 5% of the cases.4 Historically, these patients 
have a poor prognosis with a median survival of 4-14 months when treated with standard 
chemotherapy regimens.5, 6 More recent studies of patients treated with modern 
multimodality antihormonal- and chemotherapy, report a median survival of 24-33 months.7, 
8 In a nationwide cancer registry from the Netherlands patients with stage IV breast cancer 
diagnosed between 2003 and 2007 have a 5-year survival of 21% and a median survival of 
24 months. 
Metastatic breast cancer is a systemic disease and microscopic tumour deposits may exist 
in various sites of the body, though not always detected by standard and modern imaging 
techniques. As a result, partial liver resection has not often been proposed to metastatic 
breast cancer patients. Multimodality non-surgical treatment is generally considered as the 
most appropriate way to treat these patients, including chemotherapy, antihormonal therapy 
or directed targeted agents.5, 9, 10
However, partial liver resection in disseminated non-colorectal, non-neuroendocrine 
malignancies becomes more accepted, because of its additional effectiveness. With advances 
in surgical techniques, anesthesia management and post-operative patient care, morbidity 
and mortality are significantly reduced. Improved chemotherapy regimens allow a better 
control of metastatic disease and possibly reduce the number and/or diameter of liver 
metastases, which results in a favourable situation before resection.10 
The reports of partial liver resection in patients with breast cancer are heterogenous. The 
results show a tendency to an improved long term outcome in selected patients, with 5-year 
overall survival ranging from 21 to 61% and median overall survival between 24 and 63 
months.10-23 However, there is no clear consensus on selection criteria for referring patients 
for surgical resection. Few independent prognostic factors for post-operative survival have 
been identified with a wide variation between the various reports. 
In order to analyse a substantial cohort of patients with adequate follow up, we reviewed 
the outcome of patients after resection of breast cancer liver metastases in the Netherlands 
over the last 20 years. The aim of this study was to evaluate disease-free and overall and to 
identify prognostic factors for long-term survival.
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Patients and methods
Patients and data
Patients were identified using the results of a research question in the PALGA database which 
is the nationwide network and registry of histo- and cytopathology in the Netherlands, that 
registers all pathologic reports since 1991.24 All patients who underwent a resection of breast 
cancer liver metastases with potential feasibility to achieve a R0 resection were included. 
The hospitals were visited for retrospective collection of study data from the patient files. 
A data file was used, recording information of the primary tumour, liver metastases, surgery, 
post-operative stay, pathology and multiple other clinical factors. 
Surgery
Localisation of the metastases was specified in liver segments, according to Couinaud’s 
classification. Resection margins were defined as complete microscopic resection (R0), 
microscopic residual disease (R1) or macroscopic residual hepatic or extrahepatic disease 
(R2). 
Outcome variables
Post-operative morbidity and mortality were defined as complications and death within the 
first 30 days after surgery. Disease-free survival (DFS) was defined as the interval between 
partial liver resection and recurrence of disease. In case of an incomplete resection or 
extrahepatic metastases at the time of liver surgery, disease-free survival was defined as 0 
months. Overall survival (OS) was determined from the date of surgery until the date of last 
follow-up or death. Death was unspecified by cause, as it was in some cases impossible to 
require essential information because of the ethical guidelines by the central committee of 
research involving human subjects. 
Statistical considerations
Survival outcomes were calculated by Kaplan Meier survival analysis. Prognostic factors 
for long-term survival were identified by univariate survival analysis, according to Cox 
proportional hazards regression methodology. Factors with a p-value of <0.05 in univariate 
analysis were included in multivariate analysis. Statistical significance with a p-value of less 
than 0.05 was considered significant. All statistical analyses were performed using the 
Statistical Package for the Social Sciences version 16.0 (SPSS, Inc., Chicago, Illinois, USA).
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
4
Resection of liver metastases in patients with breast cancer: survival and prognostic factors
55
Results
Clinical characteristics
Using the PALGA registry, all 32 female patients were identified who underwent resection 
of liver metastases from breast cancer with curative intent over the last 20 years in 
the Netherlands. Surgery was performed in 11 different hospitals from January 1994 to 
September 2010. Median age was 50 years (range: 31-67). 
Primary breast tumour, treatment and histological diagnosis
All patients were operated for primary breast tumour with either breast conservative 
treatment or mastectomy. Twenty patients had invasive ductal carcinoma, 4 patients had 
lobular carcinoma and one patient had mixed ductal and lobular carcinoma. In one patient 
only ductal carcinoma in situ was found in the original specimen, suggesting the invasive 
component was missed or an occult breast cancer was present in the contralateral breast. 
In 6 patients, the primary tumour was only specified as ‘breast cancer’. In 25 patients, 
immunohistochemical data of the hormone receptor status of the primary tumour was 
available, reporting 11 ER+ PR+ tumours, 9 ER+ PR- tumours and 5 ER- PR- tumours. In 11 
patients, data was available on Her2 overexpression, which was demonstrated to be positive 
in 8 patients.
Locoregional metastases
At initial presentation 23 patients had regional lymph node metastases and underwent an 
axillary dissection. Three patients developed axillary metastases during follow up at 9, 13 and 
18 months, respectively. Two patients developed a local recurrence at 36 and 109 months, 
respectively. In 4 patients there was no evidence of locoregional metastatic disease or 
local recurrence.  Adjuvant radiotherapy was given in 22 patients, 19 patients were treated 
with adjuvant chemotherapy, 17 patients with antihormonal therapy and 4 patients with 
trastuzumab. Most patients received a combination of several adjuvant therapies.
Preoperative evaluation
Diagnosis of the liver metastases was based on ultrasound, CT-, MRI- or PET-scanning or a 
combination. Preoperative histological examination by needle biopsy was performed in 19 
patients. In 2 patients the biopsy was inconclusive, but liver surgery was performed because 
of high probability of malignancy on imaging. Median interval between treatment of the 
primary tumour and histological diagnosis of liver metastases was 33 months (range: 0-219). 
The presentation of liver metastases, based on histological diagnosis, was synchronous 
(within 6 months) in 6 patients and metachronous (after 6 months) in 26 patients. A solitary 
metastasis was identified in 22 patients. Median diameter of the largest metastasis was 2.5 
cm (range: 0.7 to 9 cm). Liver metastases were localised in one lobe in all but one patient.
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Preoperative evaluation of extrahepatic metastases 
The presence of extrahepatic dissemination was evaluated by chest X-ray or CT-scan only 
in 11 patients, PET-scan only in 1 patient, or a combination in 19 patients. Extrahepatic 
metastases were present during liver surgery in 5 patients (i.e. bone metastases in 3 patients, 
cervical lymph node in 1 patient and colon metastases in 1 patient). 
Neo-adjuvant therapy
Prior to liver resection, 13 patients received neo-adjuvant chemotherapy, 5 patients received 
antihormonal therapy and 2 patients received trastuzumab and bevacizumab, respectively.
Surgical procedure
A right subcostal incision was performed in most patients, allowing assessment of intra-
abdominal spread of disease, which would be a contraindication for liver resection. In one 
patient previously undiagnosed extensive intraabdominal disease was found. This patient 
did not undergo resection and was excluded from this study. In 32 of the 33 patients, 
intra-abdominal spread of disease was absent, and partial liver resection performed. In 21 
patients intraoperative ultrasound was performed. Major resection (3 segments or more) 
was performed in 13 patients, minor resection (less than 3 segments) in 19 patients. Liver 
resection was combined with radiofrequent ablation (RFA) in 2 patients. Pringle maneuver 
was performed in 12 patients with a median time of 25 minutes (range: 10-50). In 2 patients 
an iatrogenic lesion of the spleen occurred, which required splenectomy. In 1 patient an 
iatrogenic lesion of the left hepatic duct occurred, which required post-operative endoscopic 
retrograde cholangiographic (ERC) stenting of the duct.  A radical (R0) resection was 
performed in 29 patients whereas microscopically positive margins (R1) were present in 
3 patients. Of the 5 patients with extrahepatic disease, 3 were treated with curative intent 
for their extrahepatic metastases. The patients with the colonic metastasis and neck lymph 
node metastasis underwent a hemicolectomy and a modified neck dissection, respectively. 
One patient with a bone metastasis in the sternum received radiation therapy with curative 
intent.
Post-operative course
Post-operative complications occurred in 11 patients and treated conservatively in 4 patients 
(ileus n=1, pneumonia n=1, pleural effusion n=2). One patient with pleural effusion, two 
patients with a lesion of the sinus pleurae and one patient with an intra-abdominal abscess 
needed percutaneous drainage. One patient developed stenosis of the bile duct and another 
patient had bile leakage post-operatively. Both were treated with ERC drainage of the bile 
duct. In one patient who also underwent a hemicolectomy, anastomotic leakage and wound 
infection occurred, which were treated with reoperations and end colostomy. There was no 
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post-operative mortality. Median post-operative length of stay was 7 days (range: 4-58 days). 
Adjuvant systemic chemotherapy was given in 14 patients. 
Disease-free survival
Median follow-up of the entire cohort after liver resection was 26 months (range: 0-188 
months). The 5-year disease-free survival was 19% with a median time to recurrence of 11 
months. Four patients were classified as having no disease-free survival: 2 patients because 
of a non-radical resection (R1), 1 patient had non-treated extrahepatic disease at the time of 
liver resection, and 1 patient had both. Nineteen patients developed recurrences after liver 
surgery, of which 9 experienced new liver metastases, 5 had extrahepatic metastases, 3 had 
both and 2 unknown localisations. At the date of this analysis, 8 patients had no evidence of 
disease with a median follow-up of 27 months (range: 0-188).
Overall survival
The 5-year overall survival from the date of liver resection was 37% with a median survival 
of 55 months. Three patients were alive 5 years after liver surgery, including one patient with 
15 years follow-up without evidence of recurrent disease. The group of 3 patients with an R1 
resection had a median survival of 60 months and a 5-year overall survival of 33%.
Prognostic factors
Prognostic factors of overall survival were analysed and reported in Table 1. Significant 
factors for long-term survival in univariate analysis were estrogen positive receptor status of 
the primary tumour, solitary metastasis and unilobar distribution of the metastases. Solitary 
metastasis was the only independent prognostic factor in multivariate analysis. Patients who 
underwent resection of a solitary liver metastasis had a 5 years overall survival of 68% 
(Figure 1). This difference in the number of metastases was also significant when the limit 
was set on 3 metastases. Median and 5-year disease-free survival in the group of patients 
with solitary metastasis were 11 months and 22% respectively, versus 5 months and 0% in 
the group of patients with multiple metastases. This difference was not significantly different. 
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Table 1. Prognostic factors for overall survival in patients after resection of liver metastases from breast cancer
Factor n Median OS 
(months)
5-year OS
(%)
Univariate 
p-value
Multivariate 
p-value
Age
   <50years
   ≥50 years
16 60 38
16 55 37 0.283
Histology primary tumour
   Invasive ductal carcinoma 20 60 42
   Invasive lobular carcinoma 4 27 38 (at 44 months) 0.319
Hormone receptor status primary
   Estrogen + 20 60 49
   Estrogen - 5 12 25 (at 44 months) 0.008** 0.070
Her2 overexpression
   Present 8 60 31
   Absent 3 No events No events 0.370
Needle biopsy
   Not performed 13 47 0 (at 47 months)
   Performed 19 60 46 0.279
Interval between diagnosis of the 
primary tumour and liver metastases
   Synchronous 6 103 53
   Metachronous 26 47 32 0.254
Number of metastases
   Solitary 22 103 68
   Multiple 10 47 0 0.018** 0.047**
Number of metastases
   ≤3 metastases 28 55 48
   >3 metastases 4 12 0 0.016**
Size
   <5cm 27 55 34
   ≤5cm 5 27 50 0.870
Distribution
   Unilobar 31 55 38
   Bilobar 1 12 0 (at 12 months) 0.005** 0.754
Extrahepatic metastases
   Absent 26 60 46
   Present 5 34 0 0.074
Neo-adjuvant chemotherapy
   Yes 13 60 39
   No 19 55 36 0.948
Type resection
   <3 segments 19 47 42
   ≥3 segments 13 55 24 0.910
Resection margins
   R0 29 55 40
   R1 3 60 33 0.887
Adjuvant Tx
   Yes 12 47 33
   No 18 55 31 0.786
OS: overall survival; Tx: therapy.** In bold: statistically significant with p<0.05
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Figure 1. Overall survival in patients after resection of solitary versus multiple liver metastases from breast cancer 
(p<0.05).
Discussion
In the present study the 5-year overall survival after resection of liver metastases in patients 
with breast cancer was 37% with a median survival of 55 months. The survival data in 
the literature of patients with liver or visceral metastases from breast cancer receiving 
systemic therapy show a median survival of 4-33 months.4, 7, 8 Compared with these data, 
liver resection in selected patients might provide a relevant survival benefit. The survival 
outcomes of the present study are comparable with previously published reports (Table 
2).10-19, 21-23 Median overall survival in the literature ranges between 24 and 63 months and 
5-year overall survival between 21% and 61%.
In the present study a post-operative mortality rate of 0% and post-operative complication 
rates of 34% are described, respectively. In general, treatment of liver metastases aims to 
minimize intraoperative and post-operative morbidity.10 This morbidity is often one of the 
reasons to reject resection as a treatment option.  Although in this study minor complications 
occurred relatively frequent, most patients recovered completely. This relatively high 
complication rate might be a reflection of an independent registration of the results by an 
external reviewer, but also because of the relatively low number of patients treated in each 
center.  Although post-operative mortality did not occur in these series, centralisation of liver 
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surgery might possibly decrease the number of complications in future studies. Initiatives to 
further centralise and register patients in a nationwide database are now conducted in 
several countries including the Netherlands, in order to improve outcome.
Table 2. Review of reports describing the outcome in patients with metastatic breast cancer to the liver, treated 
with liver resection.
Author Year n Post-operative 
morbidity (%)
Post-operative 
mortality (%)
5-year OS (%) Median OS 
(months)
Selzner18 2000 17 0 6 22 24
Yoshimoto23 2000 25 - 0 27 34
Elias12 2003 54 12.9 0 34 34
Vlastos21 2004 31 - 0 61 63
Ercolani13 2005 21 20.5 0 25 40
Sakamoto17 2005 34 - 0 21 36
Weitz22 2005 29 - - - 48
Adam10 2006 85 26 0 37 32
Martinez16 2006 20 - - 33 32
Caralt11 2008 12 16.6 0 33 36
Lubrano15 2008 16 37.5 0 33 42
Thelen19 2008 39 13 0 42 -
Hoffman14 2010 41 21 0 48 58
Present series 2011 32 44 0 37 55
OS: overall survival
Significant prognostic factors of overall survival in univariate analysis were estrogen positive 
receptor status of the primary tumour, solitary metastasis and unilobar distribution of the 
metastases. Solitary metastasis was the only independent prognostic factor at multivariate 
analysis. Compared with previous reports (Table 3), prognostic factors differ in the various 
studies. This could possibly be explained by the small number and the diverse clinical 
characteristics of the patients. Similar as in the present study, positive estrogen receptor 
status was a significant factor for long-term survival in two other studies. Interestingly, in 
one report a negative status was a significant prognostic factor. Prognostic significance of a 
low number of metastases was confirmed by two other reports. According to the different 
levels of significance reported, the various factors are no absolute criteria to in- or exclude 
patients for liver surgery, but can be taken into account in providing optimal treatment for 
individual patients. 
Response to preoperative chemotherapy was an important factor in patient selection for 
surgery by Adam et al. (Table 3).10 Several studies recommend neo-adjuvant chemotherapy 
for patients planned for partial liver resection.10, 12 In the present study only a proportion of 
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patients were treated with neo-adjuvant systemic therapy. Analysing this factor, regardless of 
the degree of response, treatment with neo-adjuvant systemic therapy showed no significant 
difference in survival outcome. However, in unresectable tumours, it might be worth 
considering chemotherapy to downsize the metastatic lesion to facilitate complete resection. 
In addition, neo-adjuvant or adjuvant chemotherapy may treat potential micro-metastases. 
On the other hand, care should be taken with neo-adjuvant chemotherapy making well-
responsive metastases difficult to locate for surgery. Chemotherapy also puts enormous 
strain on the liver parenchyma which potentially compromises the quality of residual liver 
after resection. Therefore, discussing patients with liver metastases in a multidisciplinary 
team before starting with chemotherapy is essential.
The results of this study are the first nationwide data available in the Netherlands, including 
all patients treated surgically for liver metastases from breast cancer over the last 20 years. 
According to the Dutch Cancer Registry the total incidence of invasive breast cancer in 
the previous 10 years was 10,000 – 13,000 patients each year. Of them, approximately 20-
30% will develop disseminated disease. Thus, in the last 20 years in the Netherlands only a 
very small portion of the patients with stage IV breast cancer underwent surgery of liver 
metastases with curative intent. 
Although this study contains a low number of patients, as most similar studies, it confirms 
previous results and provides additional data. Especially the results of surgery in patients 
with solitary metastasis are promising with a 5-year overall survival of more than 50%. 
A limitation of this study, however, is the possibility of bias in selecting patients with 
favourable prognostic features for liver resection. It cannot be concluded whether the 
prolonged survival is the effect of the liver resection itself or the favourable biology of the 
highly selected patients.
In two patients radiofrequent ablation (RFA) was performed. Limited data is reported in the 
literature on the treatment of liver metastases of breast cancer with RFA. For colorectal 
liver metastases several studies have been performed, concluding that survival rates are 
similar between surgery and RFA for tumours less than 3 cm.25, 26 Prospective studies with 
long-term follow-up are lacking to compare resection and RFA with respect to recurrence, 
disease-free survival and overall survival rates. Data of RFA in breast cancer liver metastases 
are limited to small retrospective series that have demonstrated an improvement in survival 
with adjuvant RFA compared to chemotherapy alone. 27 Until new data will become available, 
surgery remains the option of choice to completely remove the metastatic lesions in 
resectable metastatic breast cancer confined to the liver. 
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Conclusion
Resection of liver metastases from breast cancer is safe and might provide a survival benefit 
in a selected group of patients. The option of partial liver resection in the multimodality 
management in patients with liver disseminated breast cancer, especially in case of solitary 
metastasis, should be considered. Various clinical factors are not absolute contraindications 
for resection, but can be helpful in decision making for resection in individual cases. 
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Abstract
Aims: Patients with liver metastases of melanoma have a very poor prognosis, with a median 
overall survival of less than 6 months. There are several small heterogeneous studies that 
have shown an association with prolonged survival in those patients treated with liver 
resection, but the role of surgery remains unclear. We evaluated the safety and efficacy of 
liver resection in a population-based study in the Netherlands for patients with metastatic 
melanoma and assessed factors that could affect disease-free and overall survival. 
Methods: Patients with liver metastases from melanoma who underwent potentially 
curative resection were identified between 1994 until 2010 using the PALGA-database; a 
nationwide network and registry of histo- and cytopathology in the Netherlands. They were 
retrospectively evaluated for clinical and pathological factors with respect to recurrence and 
survival using Kaplan Meier curves to assess survival and univariate regression analyses for 
assessing potential prognostic factors. 
Results: A total of 32 patients were identified in 15 hospitals; 19 men and 13 women. The 
median age of the patients at the time of liver resection was 52 years (range: 27-69 years). 
Post-operative complications occurred in 5 patients (15%), without post-operative mortality. 
The median follow-up was 21 months (range: 3-65 months). The median disease-free survival 
was 11 months (range: 0-57 months) and the median overall survival was 29 months (range: 
4-66 months). Significant prognostic factors for overall survival in univariate analysis were 
the distribution and number of metastases, as well as the type of liver resection (major or 
minor). 
Conclusion: Liver resection in patients with resectable metastatic melanoma is safe and 
might be associated with a prolonged survival in a highly selected group of patients. 
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Introduction
Depending on the clinical and pathological characteristics of the primary tumour, up to one 
third of patients with melanoma develop distant metastases.1-3 A common site for distant 
metastases is the liver. Especially patients with ocular melanoma may have liver metastases 
present at the time of diagnosis, in 40% of the cases, and the liver becomes involved in 95% 
of patients who develop metastatic disease.4 Cutaneous melanoma also metastasises to the 
liver in 15% to 20% of the patients who develop metastatic disease and, on autopsy liver 
involvement is demonstrated in 55-75% of patients.3,5 
Patients with liver metastases have a very poor prognosis, with a median survival of 
approximately 4 months and a 5-year survival of less than 5%.6 Response rates on traditional 
DTIC-based chemotherapy regimens are often low, with percentages below 10%.7 Recent 
treatment with BRAF inhibitors or anti-CTLA4 has yielded response rates with a significant 
improvement in 1-year survival, but long-term survival benefits are to be awaited.8,9 
Moreover, these new agents may induce complications, with considerable morbidity and 
development of other skin cancers. The optimal treatment strategy for patients with isolated 
liver metastases from melanoma remains unclear, even with these new treatment options. 
In patients with colorectal liver metastases, liver resection is widely accepted as proven 
effective with 5-year survival of 20-50%.10-12 With improvements in surgical techniques 
and anesthetic management, the perioperative mortality and morbidity have decreased, 
which makes partial liver resections relatively safe. However, patients with disseminated 
malignancies of non-colorectal, non-neuroendocrine origin to the liver are only referred for 
surgical therapy in selected cases. 
The objective of this study was to evaluate all patients in the Netherlands in the past 20 
years with metastatic melanoma of the liver who were treated with liver resection for 
safety, survival and to identify potential prognostic factors to predict long-term survival after 
resection. 
Patients and methods
Patients and data collection
Patients were identified by the results of a nation-wide research question in the PALGA-
database; a nationwide network and registry of histo- and cytopathology in the Netherlands, 
which registers all pathologic reports since 1991.13 All patients who underwent a potentially 
curative liver resection for metastatic melanoma between 1994 until 2010 were included. 
Hospitals were visited to collect retrospective data from the patient files. The following 
data were collected for each patient from the file: demographics, anatomical location and 
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histological characteristics of the primary melanoma, details of the primary treatment of 
the melanoma, time interval from initial treatment of the melanoma to metastasis, surgical 
procedures, number, location and size of the liver metastases, recurrence, death date, 
mortality and morbidity.
Outcome variables
Post-operative mortality and morbidity included all deaths or complications attributed to 
liver resection and all deaths or complications within 60 days of the operative procedure. 
Disease-free survival was defined as the time from liver resection until disease recurrence. 
In some patients, resection was not complete and disease-free survival was defined as 0 
months. Overall survival was defined as the time between liver resection until the date of 
last follow up or death. Death was not specified by cause, because it was not possible to 
detect this because of the ethical guidelines of using de-identified data.
Statistical analyses 
All statistical analyses were carried out using the Statistical Package for the Social Sciences 
version 16.0 (SPSS, Inc., Chicago, Illinois, USA). Survival outcomes were calculated using 
Kaplan-Meier survival curves. Prognostic factors for long-term survival were identified by 
univariate analysis according to Cox proportional hazard regression methodology. Because 
of the small number of patients, multivariate analysis was not performed. We considered a 
p-value of less than 0.05 significant. 
Results
Patient and tumour characteristics
A total of 49 patients were identified in 15 hospitals using the PALGA database; eight patients 
underwent only a diagnostic liver biopsy only, two patients underwent an isolated liver 
perfusion and seven patients were found to have unresectable disease per-operatively. A total 
of 32 patients who underwent liver resection between 1994 and 2010 were evaluated in the 
present study. The median follow up was 21 months (range: 3-65 months). The median age 
during liver resection was 52 years (range: 27-69 years). There were 19 men and 13 women. 
The median interval between resection of the primary tumour and liver resection was 62 
months (range: 15-188 months). The origin of the primary tumour was ocular melanoma in 
12 patients and cutaneous melanoma in 16 patients; in four patients, the primary location of 
the tumour was unknown. The median Breslow thickness of the primary tumour was 2.0mm 
(range: 0.5 – 11.0mm). Before liver resection, 13 patients were treated with a therapeutic 
lymph node dissection for regional metastatic disease (inguinal lymph node dissection n=5, 
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axillary lymph node dissection n=10, cervical lymph node dissection n=1). In 16 patients liver 
metastases were the first and only site of metastases. 
Surgery characteristics
The number of metastases ranged from 1-10; 18 of the patients (52%) had a solitary liver 
metastasis. The distribution of the metastases was unilobar in 23 patients and bilobar in 
nine patients. The median size of the largest metastasis was 24 mm (range: 10-160 mm). 
Patients were treated with a hemihepatectomy (n=9), extended hemihepatectomy (n=2), 
segmentectomy (n=11) or with a non-anatomical resection (n=10). Resection was radical 
(R0) in 23 patients, microscopically irradical (R1) in six patients, macroscopically irradical 
(R2) in one patient and unknown in two patients. 
Post-operative mortality was not observed. Post-operative complications occurred in five 
patients (15%). Four patients developed liver failure, ileus, pneumonia or pleural effusion. 
All of these complications resolved with conservative treatment. One patient developed an 
intra-abdominal infected hematoma, which required percutaneous drainage and antibiotic 
treatment. The seven patients who underwent explorative laparotomy and were found to 
have unresectable disease did not experience post-operative morbidity. 
Overall survival and disease-free survival
The median disease-free survival was 11 months (range: 0-57 months) and the median overall 
survival was 29 months (range: 4-64 months) (Figure 1a and b). There was one patient with 
a survival of more than 5 years, and 5-year overall survival was 3%. 
Figure 1A. Disease-free survival of patients who underwent liver resection for metastatic melanoma in months. 
Median disease-free survival: 11 months. 
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Figure 1B. Overall survival of patients who underwent liver resection for metastatic melanoma in months. Median 
overall survival 29 months. 
Prognostic factors 
Significant factors for prolonged disease-free survival in univariate analysis were the number 
of liver metastases and a cutaneous location of the primary melanoma (Table 1). Significant 
factors associated with prolonged overall survival in univariate analysis were the number (p= 
0.023) and the distribution of liver metastases (p= 0.002), as well as a minor resection (p= 
0.021) (Figure 2a-c). There was a trend towards prolonged survival in male versus female 
patients (p= 0.054). 
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Table 1. Potential prognostic factors in univariate analysis for disease-free survival and overall survival after liver 
resection in patients with metastatic melanoma in the Netherlands from 1994-2010
Factors n
Median DFS 
(months) p-value
Median OS 
(months) p-value
Sex 0.153 0.054
     Male 19 14 38
     Female 13 8 25
Primary tumour 0.033** 0.996
     Cutaneous 16 15 25
     Ocular 12 8 34
    Unknown 4 9 29
Breslow’s dept 0.875 0.623
     <2mm 8 8 22
     ≥2mm 7 15 25
Number metastases 0.030** 0.023**
     Solitary 18 14 38
     ≥2 13 8 25
Distribution 0.301 0.002**
     Unilobar 23 14 38
     Bilobar 9 8 22
Resection 0.687 0.021**
     ≤3 segments 13 13 38
     >3 segments 19 7 22
Resection margins 0.000** 0.905
     R0 23 15 25
     R1/R2 7 0 29
Age at time of liver resection 0.715 0.623
    <60 years 25 10 31
   ≥60 years 7 4 25
Size metastasis 0.279 0.453
    <50 mm 27 8 29
   ≥50 mm 5 2 11
DFS: disease-free survival; OS: overall survival; **Bold indicates p<0.05
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
Chapter 5
74
Figure 2A. Overall survival (OS) in months after liver resection for metastatice melanoma in patients with an 
unilobar (n=23; median OS 38 months) or a bilobar distribution (n=9; median OS 22 months) (p=0.002).
Figure 2B. Overall survival (OS) in months after liver resection for metastatic melanoma in patients with solitary 
(n=18; median OS 38 months) or multiple liver metastases (n=13; median OS 25 months) (p=0.023).
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Figure 2C. Overall survival (OS) in months after minor liver resection, which includes less than 3 liver segments 
(n=13; median OS 38 months) or major liver resection, which includes three or more liver segments (n=19; OS 22 
months) for metastatic melanoma (p=0.021).
Discussion
This study describes the first nationwide series of melanoma patients in the Netherlands 
treated surgically for liver metastases in the last 20 years. A histological diagnosis was 
available in 49 patients and only 32 (65%) patients underwent a potentially curative surgical 
resection. The median overall survival in this small and highly selective group of patients 
was 29 months. In univariate analysis, patients with solitary metastasis, unilobar disease, 
or a minor resection (less than 3 segments) had a significantly improved overall survival. 
Although this study contains a low number of patients it confirms results from previous 
studies in the literature and provides additional data. 
In the literature, metastatic melanoma patients receiving systemic treatment without 
surgical treatment have a median survival of less than 6 months.6 Several surgical studies 
have shown an association between liver resection in melanoma patients and improved 
survival in patients with stage IV disease.14-38 Adam et al. reported a large series of patients 
with metastatic melanoma who underwent liver resection; they found a median disease-free 
and overall survival rate of 11 and 35 months, respectively.23 Pawlik et al. also reported a 
series of 40 patients who underwent liver resection for metastatic melanoma. They found a 
median disease-free and overall survival of 8 and 28 months, respectively.25 Multiple other 
studies reported similar overall survival (Table 2). 
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Data from the present study support the results found in previous studies, although 5-year 
overall survival was only 3% in the present study, whereas in other studies, these percentages 
range between 36% and 10%.23,25 This may partly be explained by the short median follow-
up time of 21 months. The 3-year-overall survival and 4-year-overall survival rates are 
22%, respectively, 12.5% which are more in agreement with data found in the literature. 
Several investigators have attempted to identify criteria to make the decision for liver 
resection in metastatic liver disease. For colorectal liver metastases Fong et al. have made 
specific recommendations on the basis of the number and size of metastases, disease-free 
interval from primary to metastases, presence of lymph node positivity, and pre-operative 
carcinoembryonic antigen levels.39 There are fewer reports on the selection of patients for 
liver resection in non-colorectal, non-neuroendocrine metastases and even less reports 
specifically for metastatic melanoma. 
Table 2. Review of reports describing factors associated with improved survival in patients with metastatic 
melanoma who underwent liver resection. 
Reference Year n OS in months DFS in months Prognostic factors
Adam et al.23 2006 148 35 11
Age ≤60
DFI≥12 months
No extra-hepatic disease
R0/1-resection
Minor liver resection**
Pawlik et al.25 2006 40 28 8.3
Unilobar distribution
Neo-adjuvant chemotherapy
Size ≤5cm 
Metachronous metastases
Solitary metastasis*
Frenkel et al.24 2009 35 15-55 35-37
R0-resection
≤6 metastases*
Rose et al.21 2001 24 28 12 R0-resection
O’Rourke et al.18 2007 20 42 18
R0-resection
DFI ≥24 months**
Weitz et al.20 2005 17 42 17
Size ≤5cm
No extrahepatic nodal disease**
Reddy et al.37 2007 11 44 13
DFI≥6 months
Adjuvant chemoradiotherapy**
Herman et al.36 2006 10 22 NR NR
Elias et al.32 1998 10 18 NR NR
Present study 2011 32 29 11
Solitary metastasis
Unilobar distribution
Minor liver resection*
OS: overall survival; DFS: disease-free survival; DFI: Disease-free interval between detection of primary tumour and 
liver resection; NR not reported. *: Statistically significant (p<0.05) in univariate analysis; ** Statistically significant 
(p<0.05) in multivariate analysis
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In previous studies, a number of different prognostic factors have been shown to be important 
for survival.17,18,20,21,24,28-30,37 These differences could possibly be explained by the small number 
and the diverse clinical characteristics, particularly the origin of the primary tumour, in the 
patients reported. Pawlik and colleagues reported a significantly improved long-term survival 
in patients with primary cutaneous melanoma, with 5-year survival rates in this group of 
20.5% versus no survivors in the patients with primary ocular melanoma. They did not find 
other clinico-pathological factors to be predictive for an improved long term survival.25 
Unlike the results of Adam et al. the size of the liver metastases was not a prognostic factor 
for long-term survival in the present study.23 This might be explained by the fact that only 
five patients with a diameter of more than 5 cm were identified and 27 had a diameter of 
less than 5cm. R0 resection was also not a significant predictive factor for long-term survival. 
According to the different levels of significance reported, the various factors are no absolute 
reasons to include or exclude patients for liver resection, but can be taken into account in 
providing optimal treatment for individual patients.
In the present study there was no mortality, but five of the 32 patients (15%) experienced 
post-operative complications. This complication rate might be a reflection of an independent 
registration of the results by an external reviewer, but may also relate to the relatively 
low number of patients treated in each center. Mortality did not occur in this series, but 
centralisation of liver surgery might possibly decrease the number of complications in the 
future. Initiatives to further centralise and register patients in a nationwide database are now 
being conducted in several countries including the Netherlands.
Especially in melanoma patients, immunological treatment modalities have been studied 
intensively, with promising results.8,40,41 Recent reports show an improved survival in patients 
treated with ipilimumab or activated, mutated BRAF inhibitors.42 The role of surgery in 
patients with stage IV who become resectable after treatment with these new agents has to 
be established. Besides systemic treatment, other modalities such as isolated liver perfusion 
have been explored in patients with melanoma metastases in the liver. Various reports 
show survival benefit in patients treated with melphalan or TNF, but these treatments are 
still experimental and survival benefit is limited, with a median survival of approximately 
10 months.43-45 The ideal therapeutic approach for melanoma patients with limited liver 
metastases is unclear; however, complete metastasectomy must be considered as a treatment 
option in highly selected patients.46
Conclusion
Liver resection is safe in resectable metastatic melanoma and might be associated with a 
prolonged survival in highly selected patients.
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Abstract
Objective: To evaluate and compare the overall survival (OS) in case-matched patient-groups 
treated either with systemic therapy or surgery for colorectal liver metastases (CRLM). 
Methods: Patients with CRLM, without extra-hepatic disease, treated with chemotherapy 
with or without targeted therapy in two phase III studies (n=480) were selected and case-
matched to patients who underwent liver resection (n=632). Matching criteria were sex, 
age, established prognostic factors for survival (clinical risk score). Available computed 
tomography (CT)-scans of patients treated with systemic therapies were reviewed by three 
independent liver surgeons for resectability. Survival was compared between patients with 
resectable CRLM (based on CT-scan review) who were treated with systemic therapy versus 
patients who underwent liver resection. 
Results: A total of 96 patients treated with systemic therapy were included. Pre-treatment 
CT-scans of the liver were available for review in 56 of the systemically treated patients, 
and metastases were unanimously considered resectable in 36 patients (64.3%) (complex 
resectable: n=25; 69%). These 36 patients were case matched with 36 patients who underwent 
liver resection (wedge resection or segmentectomy: n=26; 72%). Median OS in the patient 
group treated with systemic therapy was 26.5 months (range: 0-81 months), which was 
significantly lower than in case-matched patients who underwent liver resection (median OS 
56 months; range: 6-116) (p=0.027). 
Conclusions: In this case-matched control study, surgery provided superior OS rates 
compared to systemic therapy for CRLM. Resection of CRLM should always be considered, 
preferably in a dedicated liver centre, since not all patients that qualify for resection are 
identified as such.
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Introduction
Colorectal cancer (CRC) is one of the leading causes of cancer-death worldwide.1 CRC 
patients develop metastases in 30-40%, depending on various factors such as T-stage, N-stage 
or histological subtype of the CRC (i.e. mucinous, signet ring cell or adenocarcinoma).2 
Approximately 20% of patients present with synchronous distant metastases (stage IV 
disease) and another 20% will develop metachronous metastases, predominantly located in 
the liver.3-4
In terms of treatment, liver resection is considered the standard of care in patients with 
resectable colorectal liver metastases (CRLM), with 5-year survival rates ranging from 35-
60%.5-7 In recent years an increasing number of patients are considered eligible for surgical 
resection of CRLM due to improved treatment strategies, both surgical and non-surgical. 
These improvements include two-staged liver resections, portal vein embolisation and 
preoperative systemic therapy downsizing initially unresectable CRLM.8-10 
In order to predict prognosis of patients with CRLM considered for surgery, various groups 
have assessed risk factors and multiple prognostic scoring systems have been developed.11-17 
The clinical risk score (CRS) by Fong et al. is the most used scoring system, and its prognostic 
value has been validated by several independent investigators.18-21 According to this CRS the 
following items are assigned one point: positive nodal status of the primary tumour, tumour 
size >50mm, >1 metastases, CEA-level >200ng/ml and an interval between primary tumour 
and development of liver metastases <12 months. Patients with extrahepatic disease are 
excluded. The total sum of the CRS divides patients into ‘low risk’ (0-2 points), and ‘high risk’ 
(3-5 points) of disease recurrence and overall survival after surgery.18
Due to extra-hepatic disease and location, number or size of the liver metastases, only 
a minority of patients is, or will become, eligible for liver resection.13, 22 There are two 
issues that play an important role in the treatment of patients with CRLM. First, there is 
no consensus on the criteria for resectability. Blinded retrospective reviews on this topic 
illustrated great variability in the assessment of resectability, even between dedicated liver 
surgeons.10, 23 Second, chemotherapy regimens combining multiple drugs enriched with 
targeted agents, resulted in median OS of >30 months in patients with initially unresectable 
CRLM.24, 25 Despite these survival rates in patients treated with systemic therapy, there is 
little doubt that surgical resection of CRLM offers the best chance for long-term survival.26 
27 A randomised clinical trial on this topic is not considered to be ethical. 
So, the challenge remains to identify all patients who may be candidates for radical 
surgery of CRLM. Although the majority of cancer patients are currently being assessed in 
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multidisciplinary teams (MDT), specific expertise in liver surgery is often lacking in these 
teams. 
Therefore, we investigated the baseline resectability status in the subgroup of patients 
with CRLM in two well-defined and prospectively established patient cohorts, who were 
considered to have unresectable CRLM and received systemic therapy within a clinical trial. 
The survival of patients who were considered resectable at baseline was compared to a 
matched control group of patients who underwent surgical resection of CRLM. 
Methods
Patient population and data-collection
Patients treated with systemic therapy
We analysed patients with presumed unresectable CRLM at baseline who were included in 
two phase III randomised clinical trials from the Dutch Colorectal Cancer Group (DCCG). 
Starting in 2003, the CAIRO study randomised 820 metastatic CRC patients between first-
line sequential and a combination treatment with capecitabine, irinotecan and oxaliplatin.28 
The CAIRO2 study included 755 metastatic CRC patients, who were randomly assigned 
to receive first-line treatment with capecitabine, oxaliplatin, and bevacizumab, or the same 
schedule with the addition of weekly cetuximab.29 One of the inclusion criteria in both 
studies was that the metastases were unresectable. However a discussion of the individual 
patient in a multidisciplinary liver team was not mandatory for inclusion in both studies. 
Patients in the CAIRO study were required to have a World Health Organisation (WHO) 
performance status of 0-2, and in the CAIRO2 study of 0-1. The details of both studies have 
been presented previously.28, 29 
Since patients with more than 10 CRLM are rarely candidates for curative surgery, CAIRO 
and CAIRO2 patients with less than 10 CRLM and without extra-hepatic disease were 
selected. Patients in both trials who underwent liver resection after initial systemic therapy 
were excluded, as well as patients with the primary colorectal tumour still in situ. Another 
criterion for exclusion was incomplete data on the items of the CRS.18 These criteria were 
pre-treatment CEA level, number of CRLM, size of the CRLM, lymph node status of the 
primary tumour, and the time between surgery of the primary tumour and treatment 
(systemic therapy) of the liver metastases. These data were not necessary to be known 
for inclusion in the CAIRO and CAIRO2 studies, and therefore were not available in the 
majority of patients.
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Patients treated with liver resection
Radboud University Medical Center Nijmegen and Erasmus Medical Center Cancer Institute 
Rotterdam are tertiary referral hospitals for CRLM surgery. Post-operative follow-up 
consisted of clinical examination, measurement of CEA levels, and imaging using computed 
tomography (CT). In order to compare patients from similar time periods, all patients who 
underwent primary liver resection for CRLM between January 2003 (start of the CAIRO 
study) and September 2011 were analysed in the present study. Patients who received 
induction, neo-adjuvant systemic therapy were excluded from the present analyses. Patients 
who underwent liver resection together with radio frequent ablation (RFA) of other lesions 
during the same operation were also excluded. Liver resection was considered to be 
complete (R0) when the pathologist assessed free resection margins. 
Data-collection and matching
Demographics and clinical-pathological factors of the primary tumour and the liver meta-
stases were collected. Fong’s CRS was used for matching patients’ oncological risk profiles. 
18 Therefore, all five variables included in this CRS were collected: CEA level, tumour size 
and number of metastases recorded at baseline, the disease-free interval between resection 
of the primary tumour and treatment of liver metastases (either surgery or randomisation 
for systemic therapy) and nodal status of the primary tumour. Systemically treated patients 
were selected and case-matched to patients who underwent liver resection only, in terms of 
gender, age, CRS and the absence of extra-hepatic metastases. 
Review of resectability 
In order to assess the potential surgical options and agreement on proposed treatment 
for CRLM, all baseline CT-scans of patients treated with systemic therapy were requested. 
Review of resectability, based on radiological images only, was performed by 3 dedicated liver 
surgeons. After reviewing the images of the CT-scans, liver lesions were classified: 
- resectable
- complex resectable (e.g. two-staged procedures, including portal vein embolisation, 
resection in combination with RFA, or the need for induction chemotherapy) 
- unresectable
- CT-images were of insufficient quality for the assessment of resectability. Quality of 
images was based on the system used by Jones et al.23 
Outcome variables
The primary end-point of the current analysis was OS. This was defined as the time from 
liver resection or from randomisation to systemic therapy, until date of last follow-up or 
death. As described in the protocols of CAIRO and CAIRO II, the maximum time to start 
systemic treatment had to be within 7 days from randomisation.28, 29
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Statistical analyses
The comparison between categorical variables was performed using the chi-square tests. 
Means and medians of the items from the CRS were compared using the Mann-Whitney-U 
test. Survival analyses were performed by using the Kaplan Meier survival analysis, and 
compared by using log-rank tests. A p-value of <0.05 was considered statistically significant. 
All statistical analyses were performed using the Statistical Package for the Social Sciences 
version 18.0 (SPSS, Inc., Chicago, Illinois, USA).
Results
Patients and treatment characteristics 
Systemic therapy
A total of 480 patients with CRLM, without extra-hepatic metastases, were treated with 
systemic therapy between January 2003-December 2004 (CAIRO, n=256) and between 
June 2005-December 2006 (CAIRO2, n=224). The majority of patients (n=259; 54%) could 
not be included in the present study due to missing or incomplete data with respect to 
the clinical risk score items. The CEA-level before starting systemic treatment was most 
frequently absent. Other reasons for exclusion are listed in Figure 1a. Eventually 36 patients 
were eligible for inclusion from either the CAIRO (n=14), or CAIRO2 (n=22). Of these 36 
patients, six patients were treated with first-line sequential chemotherapy, eight patients 
received first-line combination therapy, 16 patients were treated with first-line chemotherapy 
with bevacizumab, and six patients received first-line chemotherapy in combination with 
bevacizumab and cetuximab. 
Retrospective review of resectability
Baseline CT images of 57 patients (out of 96 patients selected from the CAIRO studies) 
could be retrieved from the different hospitals. These images were not available in 39 patients, 
because they were stored on microfilm only, or not stored digitally. In one patient, all three 
surgeons considered the CT images of “insufficient quality for review”, which left 56 patients 
(58.3%) eligible for analyses. In five patients one or more surgeons were unable to make a 
decision on resectability as a result of insufficient quality of the CT images. The majority of 
patients were considered (complex) resectable (n=36; 64.2%), while only two patients were 
considered unresectable by all three reviewers (Figure 2).
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Figure 1A. Selection process of patients with colorectal liver metastases treated with systemic therapy. Tx: 
treatment. CRLM: colorectal liver metastases. Figure 1B. Selection process of patients with colorectal liver 
metastases treated with liver resection. Tx: treatment; CRS: clinical risk score.
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Figure 2. Plot showing decisions of three surgeons on resectability of colorectal liver metastases in 56 patients who 
were treated with systemic therapy, based on computer tomography images. The number of reviewers who made a 
decision is shown on the Y-axis and each bar on the X-axis represents one patient. 
Complex resectability was defined as the need for neo-adjuvant treatment or complex surgery (two-staged 
procedures including portal vein embolisation or resection in combination with radiofrequent ablation). 
Liver resection
A total of 632 patients underwent liver resection between January 2003 until September 
2011. After excluding patients treated with neo-adjuvant systemic treatment (n=222), 
patients of whom data were missing on one of the items of the CRS (n=25), or patients 
with extra-hepatic disease (n=26), 359 patients were eligible and could be included in the 
current study. 
Case-matching
A total of 36 patients who were considered (complex) resectable by the liver surgeons were 
matched with patients who underwent liver surgery. The clinical-pathological characteristics 
used to case-match both treatment groups are summarised in Table 1. The types of performed 
liver resection were: wedge resection (n=15); segmental resection (n=11); hemihepatectomy 
(n=10).  A microscopic incomplete resection (R1) seemed to be present in 6 patients (16.7%). 
After resection, seven patients (19.4%) were treated with adjuvant systemic therapy 
(fluoropyrimidine only (n=1) and fluoropyrimidine plus oxaliplatin (n=6)), of which, 1 patient 
was also treated with bevacizumab as part of a multicentre randomized clinical trial.30 
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
6
Management of liver metastases in colorectal cancer patients
89
Table 1. Demographic, tumour and clinical-pathological factors of case-matched patients treated with systemic 
therapy or liver resection. CEA: carcinoembryonic antigen
Systemic therapy 
n=36
Surgery 
n=36
p-value
Gender
  Male
  Female
20 (55.6%) 20 (55.6%)
16 (44.4%) 16 (44.4%)
Median age in years (range) 66.5 (36-79) 66 (32-79) 0.813
Primary tumour
  Colon
  Rectum
  Unknown
29 (80.6%) 22 (61.1%) 0.023**
5 (13.9%) 14 (38.9%)
2 (5.5%) 0
T-stage primary tumour
  T1-3
  T4
26 (72.2%) 30 (83.3%) 0.257
10 (27.8%) 6 (16.7%)
Lymph node
  Negative 
  Positive
16 (44.4%) 11 (30.6%) 0.224
20 (55.6%) 25 (69.4%)
Liver metastases  
  Median CEA level (range)
  Median interval (range)*
  Median number metastases 
  (range)      
  Median size largest    
  metastasis in mm (range)
18.5 (1-635) 26.6 (1-910) 0.907
4 (1-109) 3 (0-91) 0.907
4 (1-7) 3 (1-10) 0.009**
30 (12-160) 39 (12-120) 0.044**
Fong-score18 1 5 (13.9%) 4 (11.1%) 0.907
2 10 (27.8%) 12 (33.3%)
3 18 (50.0%) 16 (44.5%)
4 3 (8.3%) 4 (11.1%)
* Interval between treatment of the primary tumour and the liver metastases (either systemic therapy or liver 
resection)
** and in bold: significant with p<0.05
Survival
Median follow-up of all patients treated with systemic therapy was 43 months (range: 0-81 
months) and 31 months (range: 0-101 months) for patients who were surgically treated. 
Median OS in the total group of patients treated with systemic therapy (n=480) was 21 
months (range: 0-84 months), and 52 months (range: 0-101 months) in the total group 
of patients who underwent liver resection (n=632). The 5-year OS was 11.9% in patients 
treated with systemic therapy only versus 45.6% in surgically treated patients.
In the matched cohort of patients treated with systemic therapy (n=36) median OS was 
27 months (range: 0-81 months), which was significantly higher (p=0.002) than in the total 
group of patients treated with systemic therapy (n=480). However, the OS in the matched 
cohort of patients treated with systemic therapy was significantly lower (p=0.027) compared 
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to the median OS of 56 months (range: 1-116 months) in case-matched patients treated with 
liver resection (n=36) (Figure 3).
Figure 3. Overall survival in case-matched patients with colorectal liver metastases (considered resectable based 
on reviewing the computed tomography images) treated with either systemic therapy or liver resection (p=0.027). 
On the Y-axis the proportion of patients, on the X-axis survival in months. Tx: treatment. Nrs: numbers
Discussion
This study showed that patients with CRLM are not always identified and offered surgery with 
curative intent. In the retrospective evaluation of CT images performed by dedicated liver 
surgeons in a patient group treated with systemic, palliative regimens for CRLM, a significant 
number appeared to be resectable. The case-matched patient groups with resectable liver 
only disease showed significant differences in OS after surgical or systemic treatment 
strategies. Patients undergoing surgery for CRLM had superior OS rates, as compared to 
patients in whom systemic therapies were administered. The current study suggests that 
surgery is the preferred treatment strategy in patients with CRLM. These findings emphasise 
the importance of adequate patient selection for surgery. 
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
6
Management of liver metastases in colorectal cancer patients
91
In the current study, patients were selected from two completed multicentre randomised 
clinical trials focusing on systemic therapy for CRLM, and from two large liver surgery 
databases. On ethical grounds, a true randomised clinical trial comparing both treatment 
strategies in patients with resectable CRLM has not been, and will not be performed. By 
case-matching the patients for known prognostic factors, this study is the second best 
alternative to compare both treatment strategies in patients with resectable CRLM. 
After liver surgery a significantly longer OS (median 56 months) was demonstrated compared 
to treatment with systemic therapy for (retrospectively) resectable liver metastases (median 
27 months). 
Kopetz et al. (2009) previously reported a survival benefit in patients with CRLM who 
underwent liver resection compared to patients treated with systemic therapy.26 Patients 
undergoing liver surgery in that study received pre-operative systemic therapy, which we 
excluded in the present study. Also, data were derived from unmatched patient cohorts, 
which could make the results susceptible for additional bias and should be interpreted 
cautiously. Brouquet et al. (2011) performed an intention-to-treat analysis to evaluate OS 
of ‘high risk patients’ with CRLM (patients undergoing at least the first stage of a two-
staged surgical approach) after treatment with systemic agents versus patients treated with 
systemic therapy only.27 In the surgery group, only non-progressors on systemic therapy 
were selected for comparison. In the group of patients treated with systemic therapy only, 
responders were selected, suggesting that only patients with favourable tumour biology were 
used for comparison. This could induce a potential bias for the survival rates demonstrated 
in the group of patients receiving systemic therapy only (favourable tumour biology). 
However, even though patients with excellent response to systemic therapy were selected 
for comparison, surgery proved to yield superior OS. 
In the present study patients who underwent neo-adjuvant systemic therapy were excluded 
to prevent a potential bias selecting only these patients who did not progress on systemic 
therapy. On the other hand, a recent study by Ayez et al. describing 363 patients who 
underwent liver surgery showed no significant difference in median OS between patients 
who did or did not receive neo-adjuvant systemic therapy in low risk patients (CRS ≤2 
points).31 Patients with a high risk profile (CRS >2) had a significant survival benefit after 
neo-adjuvant systemic therapy (46 months versus 33 months).31 By including and matching 
patients who underwent systemic therapy followed by surgery, survival will probably only be 
slightly different (perhaps higher) in the surgery group. Despite this, the effect of neo-adjuvant 
or adjuvant systemic therapy remains subject of many debates, since data from the EPOC 
study did not show an OS difference32, while Rahbari et al. and Ayez et al. demonstrated only 
a potential effect of (neo-) adjuvant therapy in high risk CRC patients.31, 33
For this reason a randomised clinical trial was recently started in the Netherlands comparing 
neo-adjuvant systemic therapy, followed by surgery versus surgery alone in high risk CRC 
patients.34 
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In the group of patients treated with systemic therapy only, patients with favourable 
characteristics (< 10 liver only metastases) were selected from the CAIRO studies. This was 
demonstrated by a median OS of 27 months, which was significantly higher compared to the 
complete group of patients with treated with systemic therapy in both CAIRO studies (21 
months; p=0.002).28, 29 Moreover, it has been previously demonstrated that patients treated 
in the CAIRO studies or outside the study but with similar therapeutic drugs have a better 
survival than patients not treated with these medications.35 Matching of the surgical and 
systemic patient groups was performed using the CRS, age and gender. After case-matching, 
the OS of systemically treated patients with resectable CRLM (based on reviewing the CT 
images, n=36), was compared to the OS of patients who underwent liver resection. Median 
OS was 56 months (range: 1-101 months) in patients who were treated with liver resection, 
which was superior compared to systemically treated patients (median OS 27 months; range: 
0-81) (p=0.027). Moreover, 5-year survival in the surgically treated group was 46.4% which is 
comparable to survival rates in the literature after liver resection with a median OS of 43-64 
months and 5-year OS rates of 51%-58%.7, 36 The results of this study support the concept 
of a surgical treatment strategy as the gold standard for CRLM, although this has never been 
validated in a prospective randomised clinical trial. 
Unfortunately, there was no information available whether patients treated with systemic 
therapy only were discussed in multi-disciplinary teams (MDT), and evaluated for potential 
resectability. Jones et al. reported the importance of MDTs, and especially the involvement 
of specialist liver surgeons in those teams.23 In their study, 63% of the patients with liver only 
CRLM, who were treated with palliative systemic treatment, were retrospectively considered 
to have potentially resectable CRLM by a majority of the reviewing liver surgeons. In the 
present study the CT images of the systemically treated patients were reviewed and at least 
two out of three liver surgeons agreed on CRLM being resectable in 79% of cases. On the 
other hand, this analysis was retrospectively performed and a more aggressive treatment 
strategy by surgeons over time could also be an important factor for this difference. This has 
been demonstrated by a recent study from the Netherlands showing a significant increase in 
the number of patients undergoing liver surgery for metastatic disease in the last decade.37
In the CAIRO studies only 4.8% (n=23) of all systemically treated patients with liver only 
metastases underwent subsequent liver resection after a good response. For the comparison 
of survival in the present study, patients were only included if they continued systemic 
treatment and if they did not undergo liver surgery or other local therapies. Data from 
the CLOCC trial demonstrated that patients treated with RFA as local ablative therapy 
showed an improved disease-free survival and a trend towards improved OS.38 Importantly, 
the decision on whether to perform a liver resection for CRLM is subject to bias as 
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demonstrated by 13 of 56 patients (23.2%) in which at least one of the liver surgeons 
(being the expert panel of this study) considered liver lesions unresectable, while one of the 
other surgeons considered the same lesions (potentially) resectable. Folprecht et al. (2010) 
previously demonstrated critical disagreement between experienced liver surgeons in 7% of 
assessed patients, when they evaluated resectability on CT images of patients and decided 
whether surgery or (induction) chemotherapy was the preferred treatment strategy.10 
These results of the present study emphasise the importance of assessing each patient with 
CRLM by a dedicated MDT, including specialised liver surgeons. Structural assessment of 
all patients with CRLM by specialist teams, might ensure that potentially all that qualify for 
surgery are identified as such, offering those patients the best prospects in terms of survival. 
A useful tool to assess resectability might be the Met-Assist program, which was developed 
to indicate the likelihood that experts in the field would judge surgery as feasible under 
given circumstances.39, 40 Currently, the CAIRO5 trial is performed in which patients with 
potentially resectable CRLM are selected for different induction chemotherapy regimens.39 
This prospective trial uses a central panel consisting of one radiologist and three liver 
surgeons. Possibly, this trial will add to the definition of resectability of CRLM in the future. 
Apart from the (retrospective) observation that resection for CRLM yields superior survival 
rates as compared to systemic therapy; another point of interest is the cost effectiveness of 
treatment strategies. Recently, Roberts et al. performed a cost-utility analysis of operative 
versus non-operative treatment for CRLM.41 The results of their study show surgery is more 
effective and less costly than non-operative treatment for CRLM.  Again, this emphasises the 
importance of patient selection for resection. 
A limitation of the present study may be that patients who underwent systemic therapy 
in the CAIRO and CAIRO2 trial underwent CT imaging demonstrating liver only disease, 
but did not all receive additional diagnostics for extra-hepatic metastases (e.g. fluoro-
deoxyglucose (FDG) positron emission tomography (PET)-scan). A recent randomised 
clinical trial evaluating the treatment changes in patients with CRLM scheduled for surgery 
after FDG-PET CT-scan, reported cancellation of the suggested surgical procedure in only 
2.7% of the patients.42 Additionally, survival in patients who underwent liver surgery did 
not differ between patients who were selected with or without FDG-PET.43 Because of the 
retrospective character of the current study and despite the thorough case-matching, the 
performance status and co-morbidity may differ between surgery and systemically treated 
patients. However, the systemically treated patients all had a WHO performance status of 
0-2 in the CAIRO study and WHO status of 0-1 in the CAIRO2 study, which is probably not 
inferior to the surgically treated patients. 
Despite the case-matching based on gender, age and the CRS by Fong et al.18, there is still 
an imbalance between the two patient cohorts. Patients who were treated with systemic 
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therapy were considered ‘complex resectable’ in most of the patients (n=25; 69%), while 
most of the patients in the surgical cohort were treated with a segmentectomy or wedge 
resection (n=26; 72%). Also, in patients who were treated with systemic therapy were 
considered ‘resectable’ on the basis of reviewing the CT-scan, and especially in complex 
resectable patients there is always a risk that the liver resection is not possible, e.g. due 
to small liver metastases that were not detected by CT-scan, or no liver hypertrophy after 
portal vein embolisation. 
Another limitation is that patients were included in the CAIRO studies from 2003-2006, 
whereas patients who underwent liver surgery were selected from a liver database from 
2003-2011. Although some patients in this study have been operated on more recently, it is 
unlikely that this explains the differences in OS demonstrated in the present study.
In conclusion, this case-matched controlled comparison of patients undergoing either 
systemic therapy or surgery for resectable CRLM demonstrates a significant survival 
benefit in patients treated with liver resection. Surgery should remain the gold standard 
treatment for patients with CRLM. This finding emphasises the importance of adequate 
patient selection for surgery. Consensus on resectability and standardised assessment of all 
patients presenting with CRLM by dedicated liver surgeons in specialised MDTs optimises 
patient selection for surgery. 
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Abstract
Background: The aim of this study was to determin whether the selection with fluorine-
18-deoxyglucose positron emission tomography (FDG-PET) imaging would result in an 
improved outcome in surgically treated patients with curative resection of colorectal liver 
metastases (CRLM), stratified by the clinical risk score (CRS) of Fong et al. (Ann Surg 1999; 
230:309-318).
Patients and methods: Between January 2000 and December 2009, all patients who 
underwent resection for CRLM from two different university teaching hospitals in the 
Netherlands were analysed. Patients were stratified by the clinical risk score (CRS).
Results: In total 613 patients were eligible for analyses. There was no statistical difference in 
median disease-free survival (DFS) between patients with and without an FDG-PET-scan in 
both low CRS [17 months (95%CI: 12-22) versus 14 months (95% CI: 11-17), p=0.332] and 
high CRS [14 months (95% CI: 7-21) versus 9 months (95% CI: 8-10), p=0.073]. There was 
no statistical difference in median overall survival (OS) between patients with and without a 
FDG-PET-scan in both low CRS [64 months (95% CI 54-74) versus 54 months (95% CI 42-
66), p=0.663] and high CRS [39 months (95% CI 23-55) versus 41 months (95% CI 34-48), 
p=0.903].
Conclusion: The present study could not demonstrate that patients selected by an FDG-
PET-scan before liver resection, and stratified by the CRS have an improvement in DFS or 
OS.
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Introduction
Colorectal cancer is one of the leading causes of cancer death worldwide.1 Approximately 
half of the patients with colorectal cancer will develop metastatic disease at some point 
during the course of the disease. If metastases are confined to the liver, resection of these 
metastases is at present the standard of care and it has a positive impact on survival.2,3 After 
a curative resection of colorectal liver metastases (CRLM), cancer relapse is a common 
phenomenon, with approximately 50% of recurrences occurring in the first 2 years.4 In 
general, 5-year overall survival ranges between 20-60%, depending on tumour and patient 
characteristics. In an attempt to identify subgroups with a variable risk for relapse and 
survival, several clinical risk scores (CRS) have been introduced.5-9 The most widely used 
CRS was described by Fong et al.10 and the prognostic value of this scoring system has been 
verified by independent investigators.11-13 
Preoperative staging is important for the selection of patients who can potentially undergo 
resection of CRLM. To identify the number and location of colorectal metastases, contrast-
enhanced CT or MRI of the liver is generally used. In addition, an abdominal and chest CT 
is usually performed to exclude extrahepatic disease. To further improve the selection of 
patients for surgery, fluorine-18-deoxyglucose positron emission tomography (FDG-PET) 
has been assessed in patients with CRLM.14 Some studies suggest that a change in clinical 
management could be expected after FDG-PET, whereas other authors claim that the addition 
of staging with an FDG-PET/CT prior to planned liver resection has substantially less impact 
on surgical management than expected.14-16 If FDG-PET is able to identify the patients with 
extrahepatic disease who are unlikely to benefit from liver resection, patients with a negative 
extrahepatic FDG-PET should represent a selected subgroup that is more likely to benefit 
from surgery. This might be reflected in an improved disease- free survival (DFS) and possibly 
overall survival compared to patients who have not undergone preoperative staging with 
FDG-PET. In the present study we analysed whether this selection with FDG-PET would 
result in an improved outcome in surgically treated patients with CRLM, stratified by the 
CRS of Fong et al.10
Patients and methods
Between January 2000 and December 2009, all patients who underwent liver resection for 
CRLM from two different university teaching hospitals in the Netherlands were analysed 
retrospectively. In these two hospitals more than a quarter of all colorectal liver metastases 
undergo surgery. Patients were assessed with the CRS according to Fong et al.10 and excluded 
from the analyses if they had missing data required to calculate the CRS. The criteria that 
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are incorporated in this CRS system are: (1) nodal status of primary, (2) disease-free interval 
from the primary to discovery of the liver metastases <12 months, (3) number of tumours 
>1, (4) size of the largest tumour >5 cm, and (5) preoperative carcinoembryonic antigen 
(CEA) level >200 ng/ml.10 Each criterion is assigned 1 point in this CRS and we defined two 
risk groups: low CRS (0-2 risk factors) and high CRS (3-5 risk factors).
Treatment protocol
The Erasmus MC University Medical Center Rotterdam and Radboud University Nijmegen 
Medical Center are tertiary referral hospitals for CRLM. All patients were discussed in 
multidisciplinary tumour boards. In their protocols, perioperative chemotherapy is not 
considered standard of care in all patients with primarily resectable CRLM (i.e. the possibility 
of an R0 resection, the vascular inflow and outflow must be secured, as well as biliary 
drainage to the remaining segments, and a future liver remnant of at least 20-30%).
Patients receive neo-adjuvant chemotherapy in case liver metastases are initially unresectable 
or difficult to resect (due to adverse location or being close to vascular or biliary structures) 
or when multiple (≥4) synchronous metastases are present.
A large proportion of patients in this study already had already received neo-adjuvant 
chemotherapy in the referring hospitals, according to local treatment protocols. Patients 
treated with neo-adjuvant chemotherapy received a combination of 5-fluorouracil/
capecitabine and oxaliplatin or irinotecan, with or without bevacizumab. The response to 
neo-adjuvant chemotherapy was assessed after 2 or 3 cycles by CT scan and CEA levels. 
Further treatment was considered depending on tumour response and extent of the 
disease. If liver metastases were considered resectable, a laparotomy was planned at least 3 
weeks after the last course of systemic neo-adjuvant chemotherapy. Bevacizumab had to be 
excluded from the last course of chemotherapy to ensure an interval of at least 6 weeks.
FDG-PET was performed within 5 weeks before surgery in a selection of patients, based 
on a multicentre study or by physician’s choice. The abdomen was examined at laparatomy 
for extrahepatic disease. In case of extrahepatic disease (confirmed by frozen sections) any 
further surgical treatment was only carried out if all tumour deposits could be resected. A 
minority of patients received adjuvant chemotherapy as part of a trial in the Netherlands 
(HEPATICA) irrespective whether or not preoperative FDG-PET was performed.17 Post-
operative follow-up consisted of a clinical examination and measurement of CEA every 
3 months. In the Erasmus MC University Medical Center Rotterdam, abdominal imaging 
(ultrasound, CT of the chest and abdomen) was usually performed every 3 months in the 
first year and every 6 months the second year and once per year thereafter. In the Radboud 
University Nijmegen Medical Center this was every 3 months in the first 3 years and every 6 
months in the 4th and 5th year. If recurrent disease occurred, a decision on further treatment, 
surgical or systemic, was made by the multidisciplinary tumour board.
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FDG-PET Imaging
Patients fasted for at least 6 hours and were hydrated with sugar-free liquids. Patients 
received a dose of approximately 4 MBq of 18-F-FDG per kilogram of body weight. Scans 
were acquired 60–90 min after 18-F-FDG injection and processed according to the protocols 
of the respective center. All scans were visually analysed by experienced nuclear medicine 
physicians. Standardised uptake values were not calculated. At the time when the data were 
collected, integrated PET/CT scanners were not available in the participating centers.
Outcome
Overall survival (OS) was defined as the interval in months between resection of CRLM and 
death, or the date of last follow-up. Disease-free survival (DFS) was defined as the interval 
in months between resection of CRLM and recurrence, death without recurrence, or date 
of last follow-up without recurrence.
Statistics
Descriptive values are expressed as median with the interquartile range (IQR). Comparison 
between categorical variables was determined by the chi-square test. Survival analysis was 
performed by the Kaplan-Meier method. Comparison between survival curves was made 
by log-rank tests. Univariate analysis was performed with Cox regression analysis. For the 
multivariate analysis only parameters with a p value <0.10 in the univariate model were 
entered into the Cox regression model. Backward elimination was applied. Variables were 
included if p-values were ≤0.05 and were removed if p-values were >0.10. The SPSS statistical 
package version 17.0 (SPSS, Inc., Chicago, Illinois, USA) was used for statistical analysis, where 
a p-value of <0.05 was considered statistically significant.
Results
Between January 2000 and December 2009, 665 patients underwent liver resection for 
CRLM. Of these, 52 patients (8%) were excluded due to missing data for calculation of the 
CRS, leaving 613 patients eligible for analyses. 
Neo-adjuvant chemotherapy was given in 196 (32%) patients. The median number of 
chemotherapy cycles was 6 (IQR 4-7). Adjuvant chemotherapy was administered in 41 
patients (7%). Patient and tumour characteristics were statistically comparable between both 
groups. PET scans were significantly more often performed in patients with a longer interval 
between primary tumour and liver resection, and in patients with a low CRS. Patients in the 
non-PET group received significantly more often chemotherapy. The patient characteristics 
are displayed in Table 1. 
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Table 1: Characteristics of patients with and without FDG-PET scan.
 With FDG-PET 
scan
(n=206)
Without FDG-PET 
scan
(n=407)
p-value All participants
(n=613)
Male 119 (58) 262 (64) 0.111 381 (62)
Median age, years 62 (57-70) 64 (57-70) 0.236 63 (57-70)
Rectal cancer 79 (38) 173 (43) 0.323 252 (41)
Primary tumour characteristics
T stage 0.624
     T3 149 (72) 293 (72 442 (72)
     T4 18 (9) 41 (10) 59 (10)
Positive lymph node 126 (61) 223 (55) 0.132 349 (57)
CEA, ug/L 0.181
     Median 10.6 (3.3-28.6) 71.0 (5.6-61.3) 15.0 (4.7-50.5)
     Mean 60.8 99.9 86.7
Liver metastases
Interval>12 months 116 (56) 266 (65) 0.029** 382 (62)
Diameter, cm 0.141
     Median 3.5 (2.0-4.6) 3.4 (2.2-5.0) 3.4 (2.2-5.0)
Metastases, n 0.061
     Median 1 (1-3) 2 (1-3) 2 (1-3)
Bilobar 71 (34) 148 (36) 0.628 219 (36)
R1 resection 39 (19) 75 (18) 0.680 114 (19)
Extrahepatic disease 9 (5) 35 (8) 0.055 44 (7)
Chemotherapy 54 (26) 179 (44) <0.001** 233 (38)
CRS 0.033**
     Low 146 (71) 253 (62) 399 (65)
     High 60 (29) 154 (38) 214 (35)
CEA: carcinembryonic antigen; CRS: clinical risk score.  Values in parentheses are either percentage or IQR; ** 
Bold indicates p<0.05
DFS and recurrence
The median follow-up was 36 months (IQR 22-59). During follow up, 414 patients (68%) 
developed a recurrence. For patients with a low CRS the median DFS was 15 months (95% 
CI: 12-18) and for patient with a high CRS it was 9 months (95% CI: 7-11), p<0.001. DFS 
was influenced by tumour distribution in low CRS patients and by the number of metastases 
in high risk patients after multivariate analysis. Chemotherapy did not influence DFS in this 
study. There was no statistical difference in median DFS between patients with and without 
an FDG-PET-scan in both low CRS [17 months (95% CI: 12-22) versus 14 months (95% CI: 
11-17), p=0.332] and high CRS [14 months (95% CI: 7-21) versus 9 months (95% CI: 8-10), 
p=0.073] (Figure 1).
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Figure 1. Disease-free survival (DFS) and overall survival (OS) in patients after liver resection with a low and high 
clinical risk score (CRS) with or without pre-operative FGD-PET scan. 
Overall Survival
For patient with a low CRS the median OS was 57 months (95% CI: 49-65) and for patients 
with a high CRS it was 39 months (95% CI: 34-44), p=0.004. OS was influenced by the 
tumour stage of the primary tumour in low-CRS patients and by age, tumour distribution 
and chemotherapy in high-CRS patients after multivariate analysis. There was no statistical 
difference in median OS between patients with and without a FDG-PET-scan in both low 
CRS [64 months (95% CI 54-74) versus 54 months (95% CI 42-66), p=0.663] and high CRS 
[39 months (95% CI 23-55) versus 41 months (95% CI 34-48), p=0.903] (Figure 1). The 
univariate and multivariate analyses for DFS and OS are depicted in Tables 2 and 3.
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Discussion
FDG-PET is used for patients with colorectal cancer to demonstrate extrahepatic disease 
and as a consequence it may improve patient selection for surgical resection of the liver 
metastases. In the present study we analysed whether this selection with FDG-PET would 
result in an improved outcome in surgically treated patients with CRLM, stratified by the 
CRS of Fong et al.10 FDG-PET prior to liver resection did not significantly improved DFS or 
OS in patients with both low and high CRS in the present series.
The role of FDG-PET in staging CRLM has been evaluated in several large studies. Perhaps 
the most important clinical impact of FDG-PET is the demonstration of extrahepatic disease 
and as a consequence the reduction of futile laparotomies, which has been demonstrated 
in several studies.14,15,18-21 The magnitude of this on surgical management is questioned by 
the largest randomised-controlled trial on this subject, which demonstrated that a futile 
laparotomy was avoided in only 3.8% of patients.16 The present study could not evaluate 
whether FDG-PET caused a change in clinical management or whether the number of futile 
operations was reduced compared to patients without a FDG-PET, because only patients 
who underwent resection of liver metastases were evaluated.
Besides a change in treatment strategy, FDG-PET might lead to better patient selection and 
as a consequence improved patient outcome after surgery. To our knowledge, the present 
data are the first to investigate the benefit of FDG-PET on patient outcome stratified by the 
CRS. DFS was not different between patients with and without a FDG-PET scan with a low 
CRS. In patients with high CRS similar results are shown, although there was a trend toward 
a difference in DFS [14 months (95% CI: 7-21) versus 9 months (95% CI: 8-10), p=0.073]. 
However, in the multivariate analysis this was not an independent factor. 
It has been demonstrated that patients with a high CRS are expected to have a poor tumour 
biology and, therefore, could potentially have more intra- and extrahepatic disease compared 
to patients with a low CRS.10 By means of an FDG-PET these metastases might have been 
detected, resulting in less disease recurrence, which might explain the trend towards a 
different DFS. In patients with a low CRS there is a minimal risk of occult metastatic disease 
and the added value of a FDG-PET is therefore limited, if not absent.22 
Engledow et al. evaluated the yield of the FDG-PET in an attempt to stratify the use of the 
FDG-PET in patients with CRLM depending on CRS.23 The influence on management failed 
to reach statistical difference between low- and high-CRS patients. Based on this series, the 
Fong et al. CRS10 should not be used to rationalise the use of FDG-PET in those patients 
being investigated for potential resection of CRLM.23 Schüssler-Fiorenza et al. evaluated 
whether the CRS correlates with yield of FDG-PET in patients with CRLM.22 There was 
a significant association between the CRS and the yield on the FDG-PET-scan and they 
concluded that patients with a low CRS do not benefit from an FDG-PET. 
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
7
Preoperative FDG-PET-scan in patients with resectable colorectal liver metastases does not improve OS
111
In the present series, the observation that patients with a high CRS selected by FDG-PET do 
not have a trend towards OS may partially be explained by the fact that currently excellent 
local and systemic treatment therapies for recurrent disease are available.24 Patients in the 
group without an FDG-PET can undergo adequate treatment for recurrence of cancer, 
resulting in survival rates as high as patients in whom occult metastases were potentially 
detected preoperatively. Comparable results were found in a recent randomised-controlled 
trial, the largest to date on CRLM, which compared perioperative chemotherapy with 
surgery alone.25 Although perioperative chemotherapy improved DFS in these patients, the 
mature OS data of this trial were recently presented and no survival difference was reported 
after a median follow-up of 7 years.26 
In the study by Ruers et al. fewer futile laparotomies were performed in the FDG-PET group 
than in the conventional group, and this also did not translate in a difference in DFS or OS.14 
Some authors, however, have reported an improved OS for patients who underwent an 
FDG-PET compared to those in whom an FDG-PET was not performed.27,28 These authors 
conclude that FDG-PET helped in selecting patients who are appropriate for resection and 
thus have a more favourable prognosis.28,29
A strength of the present study is that it presents data from two tertiary referral centers 
and tried to correct for bias by stratifying patients according to the CRS. However, this 
retrospective study from two combined databases also has its limitations, because patients 
were not randomised to undergo FDG-PET. Moreover, this study only focused on resected 
patients, information on the number of patients who had a futile laparotomy (open and 
closed) is lacking. Moreover, the number of patients who were not operated on due to 
unresectable disease preoperatively is also missing in these analyses. 
Conclusion
Preoperative imaging modalities are of paramount importance for liver surgeons to select 
the right patients for surgery and plan the appropriate surgical strategy for removing all 
metastatic disease. Especially patients with CRLM and a high CRS have a higher risk of 
extrahepatic disease and early recurrence. This retrospective study demonstrated no 
difference in DFS or OS when patients are selected by an FDG-PET-scan in low-CRS patients. 
Despite a trend towards an improved DFS, we could not demonstrate a benefit of FDG-PET 
selection in high risk patients, but future prospective studies should focus on this patient 
category. 
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Abstract
Background: Histological reporting of liver resections of colorectal liver metastases 
(CRLM) is limited to confirmation of diagnosis and evaluation of resection margins. A more 
exhaustive diagnostic reporting might be warranted. Here we critically and systematically 
review the potentially important histological prognostic factors in CRLM. 
Methods: Potential important histological features have been defined, like intrahepatic 
spread, resection margins and tumour response to neo-adjuvant chemotherapy. Intrahepatic 
spread (venous, lymphatic, bile duct and perineural invasion) was evaluated in a number of 
studies. 
Results: Meta-analysis demonstrated a clear correlation with 5-year overall survival of 
portal vein invasion (RR 1.8, 95%-CI 1.3-2.5) and lymphatic invasion (RR 1.7, 95%-CI 1.4-
2.0). The impact of hepatic vein invasion and bile duct invasion on outcome is not clear. 
Perineural invasion was linked to survival in one study. Resection margins is an important 
prognostic factor, however the extent of negative margins remains controversial. Various 
studies evaluated tumour response to neo-adjuvant chemotherapy, but different grading 
systems were used, and definite recommendations cannot be made. 
Conclusion: With the high incidence of CRLM and the increase of the number of liver 
resections, we need well defined prognostic factors, studied in homogenous patient 
populations to optimise diagnostic work-up. This review identifies several of these factors. 
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Introduction
Liver metastases are the major cause of death in colorectal cancer patients, with an overall 
survival in untreated patients of less than 10 months.1,2 Surgery is the only way to achieve 
long-term survival, with 5-year survival rates ranging from 40-60%.3-6 These survival rates are 
almost the same as those of patients with TNM Stage III colorectal cancer. 
Because of improvements in radiological imaging techniques, surgical techniques, perioperative 
care and the availability of effective systemic therapy, increasing numbers of patients are being 
selected for resection of their colorectal liver metastases (CRLM). However, there is no 
clear consensus on the resectability of liver metastases.1,7-9 Several clinical scoring systems 
have been developed for patient selection and to predict overall survival (OS) after liver 
resection, with size, number and the interval between the treatment of the primary tumour 
and development of CRLM, as important prognostic items.4,10,11 In addition to the clinical 
scoring systems, it seems highly probable that molecular and histopathological features of 
resected CRLM could have potential value in the selection of patients who may benefit from 
adjuvant systemic treatment. For primary colorectal carcinoma, many prognostic histological 
factors have been identified and therapeutic decisions concerning adjuvant systemic therapy 
are made on the basis of these histopathological findings.12 However, in reporting metastatic 
lesions usually only confirmation of the malignancy, and the (lack of) involvement of resection 
margins is mentioned. A more exhaustive diagnostic reporting of the metastases might be 
warranted. In this article we critically review potentially important prognostic factors for 
resected CRLM and focus specifically on histopathological features. 
Resection margin
The surgical margin of liver metastases is an important prognostic factor. Patients with 
positive margins usually have a worse outcome.3,13-15 Although patients with a negative 
resection margin have an improved outcome, the significance of the width of the negative 
margins remains controversial. Traditionally, anatomical resection was proposed in liver 
surgery in order to achieve minimal margins of 10 mm.16 Dhir et al. conducted a meta-
analysis of 18 studies with 4821 patients, to determine whether negative resection margins 
of ≥10 mm confer a survival advantage over negative resection margins <10mm. The 5-year 
overall survival rate for the subgroup with margins of ≥10 mm was 46% (95% CI, 44%-48%), 
as compared to 38% in the subgroup <10mm (95% CI, 36%-40%), suggesting that a margin of 
10mm should be pursued. However, owing to anatomical restrictions, these margins cannot 
always be achieved and might not always be necessary, especially in the era of neo-adjuvant 
chemotherapy.9,18 Ayez et al. described similar disease-free and overall survival rates in 
patients with either R0 or R1 resection treated with neo-adjuvant chemotherapy, suggesting 
that microscopic tumour remnants after treatment are no longer of major importance, and 
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that survival after neo-adjuvant chemotherapy is more related to tumour biology than to 
resection margins.18 A molecular approach in a limited number of patients (n=12) showed 
that DNA of tumour cells could still be detected at 4 mm from the tumour.19 Biopsies of 
surrounding liver tissue at 8, 12 and 16 mm from the tumour border showed no tumour 
DNA, suggesting that a resection margin >4 millimeters is adequate.
Intrahepatic invasion
Theoretically, metastatic tumour cells can spread within the liver using different pathways. 
Tumour cells might use preexisting portal and hepatic veins, lymphatic vessels, bile ducts 
and nerves for dissemination within and outside the liver. Multiple studies investigated the 
incidence of intrahepatic spread; however, the exact definitions of intrahepatic spread and 
the methods used to detect it were not described in most articles.20-29 Only two studies 
defined the different forms of intrahepatic spread24,28, of which one also specified the 
methods used for detection.28 The study by Sasaki et al. defined portal vein, hepatic vein 
and bile duct invasion as cancer cells growing in the lumen of a vessel or bile duct branches 
within the liver.24 Intrahepatic lymphatic invasion was described as cancer cells in the luminal 
structure in the portal area, which is lined by endothelial cells. The study by Korita et al. 
defined lymphatic invasion as single tumour cells or cell clusters visible within vessels that 
show immunoreactivity for D2-40 monoclonal antibody.28 Other forms of intrahepatic 
spread (portal vein, hepatic vein, sinusoidal and bile duct invasion) were not defined in this 
study.28 With standard HE staining lymphatic vessels cannot be distinguished from blood 
vessels (Figure 1A). D2-40 staining of the lymphatic vessels could be helpful in detecting 
tumour cells within lymphatic vessels (Figure 1b). This staining was used in one study,28 
and, because other studies did not mention their method to visualise lymphatic invasion, 
it remains unclear how they differentiated between invasion of blood or lymphatic vessels.
Portal vein invasion
Eight studies investigated the incidence of portal vein invasion in colorectal liver metastases 
(Figure 2).20-24,26’28’29 These studies included 607 patients in total. The mean incidence of portal 
vein invasion was 26.2% (range: 10-49%). Four studies (n=247) reported data on 5-year OS 
in patients with and without portal vein invasion.20,23,24,29 Although the sample sizes of these 
studies are relatively small, leading to significant heterogeneity, there seems to be a better 
overall survival in patients without portal vein invasion (RR 1.77, 95%CI 1.26-2.47) (Figure 
3a). 
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Figure 1A. Haematoxylin and eosin staining at the border of a tumour. Small vessels are present, but differentiation 
between blood and lymphatic vessels is difficult. Figure 1B. Immunohistochemical staining with the D2-40 
monoclonal antibody reveals tumour cells within lymphatic vessels. 
Hepatic vein invasion
Seven studies investigated the incidence of hepatic vein invasion (Figure 2).20-24, 26,28 They 
included 523 patients, 62 of whom had hepatic vein invasion (11.9%, range: 5-24%). Three 
studies (n=192) investigated the impact of hepatic vein invasion on 5-year OS.20,23,24 Because 
of the small number of patients, the impact of hepatic vein invasion remains unclear (RR 1.53, 
95%CI 0.81-2.89) (Figure 3b). 
Lymphatic invasion
Two studies investigated the incidence of lymphatic invasion (Figure 2), with a total number 
of 170 patients. Lymphatic invasion was found in 12% and 15% of CRLM.24,28 Both studies 
showed a negative impact for lymphatic invasion on survival (1.66, 95%CI 1.42-1.95) (Figure 
3c).
Bile duct invasion
Nine studies investigated the incidence of bile duct invasion (Figure 2).21-28 These studies 
covered 781 patients, 30.2% of whom had bile duct invasion (range: 13-42%). Five studies 
(n=382) reported data on 5-year OS in patients with and without bile duct invasion of the 
CRLM.20,23-26 There seems to be no correlation between bile duct invasion of the CRLM and 
clinical outcome (1.22, 95% CI 0.94-1.58) (Figure 3d). 
Perineural invasion
Three studies investigated the incidence of perineural growth in CRLM (Figure 2).20,21,26 
Perineural invasion was found in 40 of 285 patients (14.0%) (range: 12-17%). One study by 
Yamamato investigated the impact of perineural invasion of colorectal liver metastases on 
5-year OS and found a negative impact of perineural invasion.20
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Figure 2. Frequency of different types of intrahepatic spread
Presence of micrometastases
In analogy with primary colorectal tumour, micrometastases may occur in liver metastases. 
Micrometastases are defined as discrete microscopic cancerous lesions ranging from a 
single cell to clusters of cells within the liver parenchyma or portal tracts surrounding the 
dominant macroscopic hepatic tumour. Yokoyama et al. detected micrometastases in 32 of 
46 patients using CK20 staining.30 Patients with micrometastases were reported to have a 
higher probability of intrahepatic recurrence and poorer survival. They had a 10-year survival 
rate of 21.9%, versus 64.3% in patients without micrometastases. In the definition used by 
Yokoyama, there is an overlap between micrometastases and intrahepatic spread. 
Presence of fibrous capsule
The presence of a fibrous capsule has been recognised as a favourable prognostic factor in 
hepatocellular carcinomas.31 A study by Okano et al. investigated the prognostic value of 
fibrous capsule in liver metastases of colorectal origin.32 Fibrotic tissue between the tumour 
and surrounding liver parenchyma was classified as thick (≥10 layers of collagen bundles) or 
thin (several layers of collagen bundles). Fibrotic tissue was observed in 61% of patients and 
was associated with improved survival. Patients with a thick pseudocapsule reached 5-year 
survival rates of 88%, as compared with 64% in patients with a thin pseudocapsule and 31% 
in patients without a pseudocapsule. Yamamoto et al. confirmed the prognostic value of a 
fibrous pseudocapsule after hepatectomy for colorectal metastases.20 A thick pseudocapsule 
was associated with 5-year survival rate of 71%, a thin pseudocapsule with 5-year survival 
rate of 63% and the absence of a pseudocapsule with a 5-year survival rate of only 19%. 
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Figure 3. Forest plots for the prognostic value of intrahepatic spread. A. Portal vein invasion (PVI). B.Hepatic vein 
invasion (HVI). C. Lymphatic invasion (LI). D. Bile duct invasion (BDI). CI: confidence interval, OS: overall survival.
Response to neo-adjuvant chemotherapy
Tumour regression grading 
Five studies have investigated histological response of liver metastases to preoperative 
chemotherapy (Table 1).33-37 All studies showed some effect on survival, but different grading 
systems were employed to assess pathologic response to chemotherapy. Two studies used 
complete pathological response versus all other responses, including non-responses.33,37 In 
the study by Adam et al. each nodule was sampled for histological examination, one block for 
each centimeter of diameter of the nodule.33 Complete pathological response was defined 
as the absence of any viable tumour cells irrespective of the proportions of necrosis and 
fibrosis. In the study by Tanaka et al. complete pathological response was defined as the 
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absence of any viable tumour cells, irrespective of the proportions of necrosis and fibrosis, 
in the largest cut surface of macroscopically confirmed metastatic tumours, or at sites in 
resected specimens corresponding to areas where metastases initially were detected in 
preoperative images.37 A limitation of those grading systems is the inability to identify partial 
responders who may also have better survival. In addition, even complete pathological 
response is sensitive to bias, because it depends on the number of lesions assessed and the 
interpretation of the pathologist. Other pathologic response grading systems are based on a 
semi-quantitative analysis of the proportion of viable cancer cells remaining and are therefore 
subject to variability in interpretation.34,35 It is impossible to determine the percentage of 
remaining cancer cells, because there is no data on the baseline percentage of tumour cells 
prior to chemotherapy. Moreover, liver metastases frequently show necrosis surrounded by 
adenocarcinoma cells, regardless of neo-adjuvant therapy, and the value of necrosis has not 
been established. A large area of necrosis will decrease the percentage of remaining cancer 
cells in most grading systems and does not represent the efficacy of chemotherapy. 
The grading system of Rubbia-Brandt et al. seems to be the most accurate, because it takes 
into account the necrotic areas, fibrotic areas and residual cancer cells.36 Moreover, for its 
establishment chemotherapy-naïve tumours were used as a control. Although this seems 
essential, this is the only study that incorporates these controls. This system is a modified 
version of the tumour regression scheme of Mandard et al. for esophageal carcinomas.38 The 
score identifies five tumour regression grades (TRG) on the basis of the presence of residual 
tumour cells and the extent of fibrosis. TRG1 corresponds to the absence of tumour cells 
replaced by abundant fibrosis; TRG2 to rare residual tumour cells scattered throughout 
abundant fibrosis; TRG3 a greater number of residual tumour cells with a predominant 
fibrosis; TRG4 to large number of tumour cells predominating over fibrosis; and TRG5 to 
tumour cells without fibrosis. 
Tumour thickness at the tumour-normal interface 
Maru et al. measured the tumour thickness at the tumour-normal interface of 103 patients 
with CRLM resected after preoperative chemotherapy.39 Recurrence-free survival rates were 
70% for patients with a tumour thickness <0.5mm, 51% for patients with a tumour thickness 
between 0.5mm and 5mm, and 35% for patients with a tumour thickness ≥5mm.  A limitation 
of this study is that the role of tumour thickness in chemotherapy-naïve liver metastases 
was not investigated. Therefore, it could be that tumour thickness at the tumour-normal 
interface is a prognostic factor, rather than a predictive factor for response to chemotherapy. 
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Number of lesions to be assessed for chemotherapy response 
There is conflicting literature on the histological response to chemotherapy of different 
liver metastases within one patient. Rubbia-Brandt et al. showed 89% concordance in 
histological response.36 However, Tanaka et al. found that, within the same patient, some 
liver metastases showed a complete response, whereas other metastases did not. Better 
survival was demonstrated in patients with a pathological complete response in at least one 
liver metastasis than in patients with no pathological complete responses. The best overall 
survival was reached in patients with all lesions showing complete responses. Until there 
are more data on the variation in histological response of multiple liver metastases within 
a patient, histological sampling of each lesion is recommended to assess the pathological 
response to chemotherapy.
Discussion 
The benefits of liver resection for survival in patients with CRLM are well established; 
however there still is a challenge in selecting the right patients and preventing recurrence. 
Macroscopic features of resected metastases, such as size, number and synchronous or 
metachronous disease are important prognostic factors in many studies. These, together 
with staging of the primary tumour, are factors in clinical risk scores (CRS), such as that of 
Fong et al.4 This CRS is widely used to stratify patients in high-risk and low-risk groups for 
overall survival.40,41
In analogy with primary tumours, histopathological factors such as vascular or perineural 
invasion and response to chemotherapy, have been investigated in CRLM. Whereas 
studies in primary colorectal cancer typically consist of large series of patients, in which 
well-defined histological factors are investigated, pathological research in liver metastases 
is still in its infancy. Potentially useful factors have been investigated in relatively small, 
sometimes heterogeneous, groups of patients, but the evaluation of promising factors, such 
as intrahepatic invasion and tumour regression grade, will require study of larger series, with, 
for investigation of tumour response to neo-adjuvant chemotherapy, use of well-defined 
grading systems with chemotherapy-naïve liver metastases as controls. 
With the high frequency of CRLM and the increasing number of liver resections, there is a 
need for well-defined prognostic histopathological factors. Prospective studies of populations 
of patients with CRLM are warranted to evaluate prognostic and/or predictive factors such 
as histopathological features and (novel) biomarkers, in order to assist treatment decisions.
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Abstract
Background: For a selection of patients with colorectal liver metastases (CRLM), liver 
resection is a curative option. In order to predict long-term survival clinico-pathologic risk 
scores have been developed, but little is known about histologic factors and their prognostic 
value for disease-free and overall survival. The objective of the present study was to assess 
possible prognostic histologic factors in patients with solitary CRLM treated with liver 
resection who did not receive neo-adjuvant treatment. 
Methods: Patients with solitary CRLM who underwent liver resection between 1992 and 
2011 were evaluated for clinical prognostic factors. Histologic analyses on tumour-thickness 
at the tumour normal interface, presence of a fibrotic capsule, intrahepatic vascular invasion, 
lymphatic invasion, or bile duct invasion and perineural growth were performed, using 
immunohistochemistry. 
Results: A total of 124 patients were analysed with a median follow-up of 41 months (range: 
1-232 months). There was no association between histologic factors and disease-free survival 
in multivariate analysis. In multivariate analysis, intrahepatic lymphatic invasion was associated 
with a decreased overall survival (41.9 months versus 61.0 months) (p=0.041), especially in 
combination with vascular invasion (n= 15) (28.1 months versus 62.2 months; p<0.0001). In 
addition, size over 50mm (29.2 months versus 65.9 months; p=0.004) and interval less than 
12 months between resection of the primary tumour and diagnosis of liver metastasis (49.0 
months versus 91.5 months: p= 0.019) were also independent adverse prognostic factors. 
Conclusion: Intrahepatic lymphatic invasion, especially in combination with vascular invasion, 
is an important adverse prognostic factor for overall survival in patients with solitary CRLM 
after liver resection. 
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Introduction
Colorectal cancer is one of the leading causes of cancer death worldwide as a result of its 
considerable risk of development of metastases.1 When metastatic disease is confined to the 
liver, partial liver resection is the only curative therapeutic option, with 5-year overall survival 
percentages (OS) between 20 and 60%, depending on patient and tumour characteristics.2-4 
In order to explain these varying survival rates, different clinicopathologic risk scores have 
been developed. In many of these risk scores, nodal status of the primary tumour, size and 
number of the colorectal liver metastases (CRLM), disease-free interval from treatment of 
the primary until detection of the CRLM and preoperative level of carcinoembryonic antigen 
(CEA) are combined to predict long-term survival.5-9 These scoring systems are relevant 
with respect to prediction of survival, but to our knowledge, have not been used for risk 
stratification in controversial areas such as the administration of neo-adjuvant or adjuvant 
systemic therapy or surveillance. 
 
In primary colorectal cancer histologic factors such as extramural venous invasion, perineural 
growth, lymphatic invasion, angioinvasion and diffuse growth pattern have been associated 
with poorer survival outcomes.10,11 Extramural venous invasion in particular is considered 
a poor prognostic factor, and as a result, patients with extramural venous invasion in stage 
II colon cancer are considered candidates for adjuvant systemic treatment.12 Very little is 
known about the impact of histologic features of colorectal liver metastases on OS, as 
described in a recent review.13
Vascular invasion, bile duct invasion, or lymphatic invasion by tumour cells in CRLM have 
all been suggested as prognostic factors for long-term survival. 5,14-23 Perineural growth, the 
presence of a fibrous capsule, and tumour thickness at the tumour-normal interface have 
also been linked to survival in patients with CRLM. 14,15,19, 24-26 Variations in definitions and 
selection of patients have limited the impact of these studies. Furthermore, none of these 
previous studies has evaluated multiple histologic factors of the liver resection specimens, in 
combination with established risk scores in a homogenous group of patients. Most studies 
included patients who underwent neo-adjuvant therapy as well as chemotherapy-naïve 
patients, patients with multiple liver metastases, or patients with extrahepatic disease.5,14-21, 
23,24 
The results of these previous studies might be biased because of the known changes in 
histologic features observed in liver metastases after systemic therapy, and the possible 
heterogeneous nature of multiple metastases.27-30 
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The objective of the current study was to assess possible prognostic histologic factors for 
long-term survival in patients with solitary colorectal liver metastasis who underwent a 
complete liver resection (R0) without neo-adjuvant systemic therapy. 
Materials and methods
Patients
Patients were identified who underwent complete liver resection (R0) for a solitary CRLM 
between 1992 and 2011 in a tertiary referral hospital. R0 resections were defined as liver 
resections with clear resection margins in patients that did not have evidence of disease in 
any other locations. Demographics and clinico-pathologic factors with regard to the primary 
tumour, as well as the liver metastasis, were collected per patient. Special attention was given 
to the four different items from the clinical risk score according to Fong et al.: nodal status of 
the primary tumour; preoperative CEA level and size of the metastasis, and interval between 
resection of the primary tumour and diagnosis of CRLM. 9 It is unknown whether systemic 
treatment influences the presence of certain histopathologic factors and therefore patients 
who were treated with neo-adjuvant systemic therapy were excluded from the current study. 
Patients who died from post-operative complications, defined as within 30 days after liver 
resection, were also excluded. Patients underwent follow-up according to our current Dutch 
follow-up guidelines, with regular outpatient visits, CEA testing and computed tomographic 
scans of chest and abdomen. 
Histopathology
R0 liver resection specimens with a solitary CRLM were selected from the archive. Routine 
work up consisted of sampling of macroscopically normal liver tissue, invasive front of 
the metastasis, and additional tumour blocks, depending on the size of metastasis. Slide 
revision was performed independently by two investigators (JdR, NK). Discrepancies were 
resolved by simultaneous re-examination of the slides by both investigators using a two-
headed microscope. In case of discrepancy, the senior pathologist (IN) made the final call. 
Tumour thickness at the tumour-normal interface was determined in routine slides. Tumour-
normal interface was defined as the interface between tumour and normal liver tissue, as 
described by Maru et al. and validated by others.26,31,32 In all tumours, tumour thickness was 
measured with a ruler at multiple foci, and maximum tumour thickness was used and defined 
as uninterrupted layers of tumour cells without admixed fibrotic stroma, acellular mucin or 
non-neoplastic liver parenchyma. The median tumour thickness at tumour-normal interface 
was used to divide the patient group in a group with a larger and a smaller layer of vital 
tumour cells (Figure 1).
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
9
Lymphatic invasion is an independent adverse prognostic factor in patients with CRLM
131
Figure 1. Tumour thickness at the tumour-normal interface; the arrow indicates correct measurement with an 
uninterrupted layer of tumour cells. Original magnification x 10.
 
The presence of a fibrotic capsule around the metastasis was evaluated in routine slides. The 
fibrous tissue between tumours and liver parenchyma was classified as absent (no fibrous 
tissue observed) or present (the tumour was separated from the liver parenchyma by several 
layers of collagen bundles in histological sections) (Figure 2).
Figure 2a.Colorectal liver metastasis without a fibrous capsule. Original magnification x 20. Figure 2b. Colorectal 
liver metastasis with a fibrous capsule (arrow). Original magnification x 20.
Immunohistochemistry and scoring methods
Immunohistochemistry was performed as previously described.33 Antibodies, clones, dilution 
and retrieval methods are summarised in Table 1.
Perineural growth was defined as a nerve, identified by S-100 staining, being surrounded 
by tumour cells for at least three quarters of the circumference and was scored as being 
present or absent (Figure 3a).
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
Chapter 9
132
Lymphatic invasion was defined as single tumour cells or cell clusters visible within vessels 
that show immunoreactivity for D2-40 but not for CD31.
Lymphatic invasion was scored as being present or absent (Figure 3b). Vascular invasion was 
defined as single tumour cells or cell clusters visible within vessels that show immunoreactivity 
for CD31 but not for D2-40. It was scored as being present or absent (Figure 3c). Bile duct 
invasion was defined as single tumour cells or cell clusters (CK7 negative) visible within bile 
ducts which show immunoreactivity for CK7. It was also scored as being present or absent 
(Figure 3d).
Table 1. Antibodies, clones, dilution and retrieval methods used in the current study to evaluate intrahepatic 
vascular invasion (CD-31), lymphatic invasion (D2-40), bile duct invasion (CK-7) and perineural growth (S-100).
Antibody Clone Dilution Ab-retrieval Source
CD-31 M0823 1:40 EDTA Dako, Denmark
D2-40 CM266C 1:50 EDTA Biocare Medical, Belgium
CK-7 MU255-UC 1:800 Pronase Klinipath, Netherlands
S-100 Z0311 1:2000 EDTA Dako, Denmark
Outcome
Primary outcomes were disease-free (DFS) and overall survival (OS). DFS was defined as the 
interval in months between liver resection and disease recurrence, death or last follow-up. 
OS was defined as the interval in months between liver resection and death or date of last 
follow-up. 
Statistical analyses
Pearson‘s Chi square test was used to calculate correlations between the various histologic 
features. Survival curves were estimated by the Kaplan-Meier method and compared by 
log-rank testing. Multivariate analysis was performed using Cox proportional hazard model, 
and variables were included that were associated with survival in univariate analysis with a 
p-value < 0.10. The SPSS statistical package, version 18.0 (SPSS, Inc., Chicago, Illinois, USA) 
was used for all statistical analyses. A p-value of < 0.05 was considered statistically significant.
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Figure 3. Different forms of intrahepatic invasion by tumour cells. a: Perineural growth showing S-100 reactivity. 
b: Lymphatic invasion showing D2-40 reactivity. c: Vascular invasion showing CD-31 reactivity. d: Bile duct invasion 
showing CK-7 reactivity. Original magnification x 20.
Results 
Patients
Between January 1992 and March 2011, a total of 383 patients underwent liver resection for 
metastatic disease.  After excluding patients with multiple metastases, 135 patients remained 
who were surgically treated (R0) for solitary CRLM. Eleven patients were excluded because 
they received neo-adjuvant chemotherapy (n=5), were lost to follow-up (n=2), or died within 
30 days after liver resection (n=4).  A total of 124 patients were eligible to be included in the 
current study, 76 men (61.3%) and 48 women (38.7%). Median age at time of resection was 
64 years (range: 40-80 years). Liver metastases were detected at a median of 8.8 months 
(range: 0-82 months) after resection of the primary tumour. Median size of the metastasis 
was 35 mm (range: 10-130mm). Median follow-up was 41 months (range: 1-232 months). In 
the complete study population, median DFS was 28 months (range: 1-228 months) with a 
median OS of 57 months (range: 1-232 months) and a 5-year survival of 48.1%. 
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Histopathological tumour features
Fibrous capsule and tumour thickness
In 34.4% of patients (n=43) the liver metastasis was surrounded by a fibrous capsule. Presence 
of a fibrous capsule was not associated with DFS, but it was associated with an improved OS of 
109.3 months, versus 56.7 months in patients without a fibrous capsule (p=0.037). In multivariate 
analysis, presence of a fibrous capsule was not an independent risk factor for OS (Tables 2 and 3). 
Tumour thickness at tumour-normal interface varied between 0.1 and 7.2 mm, with a median 
of 3 mm, and was not correlated with the size of the liver metastasis (p=0.213). Although 
there was a significant association of increased thickness with decreased outcome (both 
DFS and OS) in univariate analysis, it was no longer significant in multivariate analysis (Tables 
2 and 3). 
Intrahepatic spread
Frequency of different forms of intrahepatic invasion varied; perineural growth (n=11; 8.9 
%) and bile duct invasion (n=11; 8.8%) were both relatively uncommon, whereas vascular 
and lymphatic invasion were seen more frequently (n=46; 37.1%, respectively n=33; 26.6%). 
In univariate analysis, the presence of bile duct invasion was associated with improved 
OS (76.7 versus 55.9 months; p=0.048), but this was not the case in multivariate analysis 
(p=0.094). Presence of intrahepatic lymphatic invasion was correlated with a decreased 
median OS (41.9 versus 62.2 months, p=0.013), which remained significant in multivariate 
analysis (p=0.041) (Figure 4a).
Figure 4a. Overall survival in months after liver resection for solitary colorectal liver metastases in patients with 
and without intrahepatic lymphatic invasion (p=0.013). Survival in months on the X-axis and survival in percentages 
on the Y-axis
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In the current study no correlation between different forms of intrahepatic spread or 
between any of the histologic features and the various items of the clinical risk score was 
observed. However, there was a correlation between presence of a fibrous capsule and 
absence of intrahepatic vascular invasion (p=0.014) and between presence of a fibrous 
capsule and presence of intrahepatic bile duct invasion (p=0.013).
In 15 patients, a combination of intrahepatic lymphatic invasion and intrahepatic vascular 
invasion was present, and this combination was associated with a decreased OS (median 
28.1versus 62.2 months) in univariate and multivariate analyses (p<0.0001) (Figure 4b).
Figure 4B. Overall survival in months after liver resection for solitary colorectal liver metastases in patients with 
the combination of intrahepatic lymphatic and vascular invasion and without this combination (p<0.0001). Survival 
in months on the X-axis and survival in percentages on the Y-axis
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Table 2. Relation of clinical and histologic factors with disease-free survival after liver resection in patients with 
solitary liver metastasis.
n % Median DFS p-value
UV analysis
p-value
MV analysis
Size ≤50mm 93 75% 50.1 0.002** 0.020**
>50mm 31 25% 14.5
CEA ≤200ng/ml 121 97.6% 27.5 0.508 -
>200ng/ml 3 2.4% 40.6
DFI (months) ≤12 72 58.1% 27.8 0.232 -
>12 52 41.9% 25.4
Nodal state primary N0 54 43.5% 35.7 0.446
N+ 70 56.5% 27.5 -
Adjuvant Tx No 106 85.5% 20.2 0.013** 0.025**
Yes 18 14.5% >50
Tumour thickness at TNI ≤3mm 60 48.4% >51 0.023** 0.118
>3mm 64 51.6% 19.4
Fibrous capsule Present 43 34.4% 27.8 0.468 -
Absent 81 65.6% 25.8
Perineural growth Present 11 8.9% 50.2 0.539 -
Absent 113 91.1% 27.5
Vascular invasion Present 46 37.1% 18.0 0.055 0.287
Absent 78 62.9% 40.8
Lymphatic invasion Present 33 26.6% 19.4 0.280 -
Absent 91 73.4% 29.2
Bile duct invasion Present 11 8.8% 27.8 0.624 -
Absent 113 91.2% 27.5
DFS: disease-free survival, UV: univariate analysis, MV: multivariate analysis, CEA: carcinoembryonic antigen, DFI: 
disease-free interval between treatment of the primary tumour and detection of the colorectal liver metastases, 
TNI: tumour-normal interface.
**p-value of < 0.05 was considered statistically significant
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Table 3. Relation of clinical and histologic factors with overall survival after liver resection in patients with solitary 
colorectal liver metastasis
n % Median OS p-value UV 
analysis
p-value MV 
analysis
Size ≤50mm 93 75% 65.9 0.050** 0.004**
>50mm 31 25% 29.2
CEA ≤200ng/ml 121 97.6% 57.3 0.912 -
>200ng/ml 3 2.4% 28.9
DFI (months) ≤12 72 58.1% 49.0 0.059 0.019**
>12 52 41.9% 91.5
Nodal state primary N0 54 43.5% 61.0 0.231 -
N+ 70 56.5% 44.6
Adjuvant Tx No 106 85.5% 57.2 0.955 -
Yes 18 14.5% 29.2
Tumour thickness at TNI ≤3mm 60 48.4% 95.3 0.043** 0.068
>3mm 64 51.6% 48.8
Fibrous capsule Present 43 34.4% 109.3 0.037** 0.240
Absent 81 65.6% 56.7
Perineural growth Present 11 8.9% 109.3 0.652 -
Absent 113 91.1% 55.9
Vascular invasion Present 46 37.1% 48.8 0.483 -
Absent 78 62.9% 58.2
Lymphatic invasion Present 33 26.6% 41.9 0.013** 0.041**
Absent 91 73.4% 62.2
Bile duct invasion Present 11 8.8% 76.7 0.048** 0.094
Absent 113 91.2% 55.9
OS: overall survival, UV: univariate, MV: multivariate, CEA: carcinoembryonic antigen, DFI: disease-free interval 
between treatment of the primary tumour and detection of the liver metastases, TNI: tumour-normal interface * 
*p-value of <0.05 was considered statistically significant
Discussion 
The current study describes the association between multiple histologic features in 
combination with clinical factors and survival in 124 patients who underwent liver resection 
for CRLM.  An homogenous group of patients was evaluated because all patients underwent 
a complete resection (R0), for a solitary metastasis without neo-adjuvant systemic treatment. 
The only significant histologic factor associated with decreased survival in multivariate 
analysis was the presence of intrahepatic lymphatic invasion, especially in combination with 
intrahepatic vascular invasion.
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Other authors also described lymphatic invasion as a negative predictor for survival.13,18,20 
In the current study, we observed a relative high frequency of lymphatic invasion 
(26.6%) compared to earlier studies (12%-15%).18,20 This might be due to the use of 
immunohistochemistry, which is supported by a recently published study with the same 
methodology and a similar frequency of lymphatic invasion (29%).18,20,34-36 Presence of 
lymphatic invasion has been associated with spread to hepatic lymph nodes, which often 
leads to incurable disease.20,37 In the current study, the worse prognosis was demonstrated in 
patients with a combination of vascular and lymphatic invasion. This unfavourable combination 
has been observed before and might reflect a tumour with aggressive behavior.23 
Another interesting finding from the current study was that the median tumour thickness 
at tumour-normal interface in patients who were not treated with neo-adjuvant systemic 
therapy was 3.0 mm. This was only slightly higher than the tumour thickness of 2.8mm 
described in patients treated with neo-adjuvant chemotherapy.26 This raises the question 
whether tumour thickness at tumour-normal interface reflects chemotherapy response or 
tumour biology; this would be an interesting subject for further research.
A major strength of the present study is the inclusion of patients with solitary CRLM only, 
who were operated with complete margins (R0) to create a homogenous group of patients. 
Previous studies on histologic prognostic factors included patients with multiple CRLM 
and R1 resections as well, which might lead to significant bias of the results.18,20,36 First, 
heterogeneity of histologic features between the different liver metastases might exist and 
could lead to bias studying prognostic factors for survival. Second, patients who undergo R1 
resection usually have a higher risk on local recurrences and have an impaired survival.38,39 
Third, patients with multiple metastases have a significantly decreased survival, and number of 
metastases is the most important factor in the Fong classification for survival.9 By excluding 
these potential biases in the present study, the assessment of the prognostic histologic 
factors is more reliable.
Another strength of the present study is that this homogenous group of patients with 
solitary metastasis were not treated with neo-adjuvant systemic therapy. In recent studies, 
patients with and without neo-adjuvant systemic therapy were mixed, and conclusions were 
drawn from a population highly susceptible to bias. 25,36,40 Neo-adjuvant systemic therapies 
have a significant impact on tumour histology, and even prognostic factors such as resection 
margins might be less important. 27,28,41 Because the detection of histologic prognostic factors 
in metastatic disease is still in its infancy and the effects of neo-adjuvant systemic therapy 
on lymphatic invasion are unknown, a study with a homogeneous population should be 
a first step. However, there seems to be an increasing preference to utilise neo-adjuvant 
systemic therapy for high risk patients, despite a lack of convincing evidence on survival 
benefit in patients with limited metastases.42-44 Therefore, a limitation of the present study is 
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that the impact of lymphatic invasion on survival has to be confirmed in patients treated with 
neo-adjuvant systemic therapy. In the total group of patients treated in our institution only 
5 patients (3.8%) with solitary metastasis were treated with neo-adjuvant chemotherapy, 
which made it impossible to compare, but this should be the goal for future research. 
In conclusion, intrahepatic lymphatic invasion, based on immunohistochemical detection of 
lymphatic vessels, is an adverse prognostic factor for OS in patients with a solitary CRLM. 
Therefore, we recommend evaluating the presence or absence of intrahepatic lymphatic 
and vascular invasion in the histologic assessment of CRLM. Future research is needed 
to determine whether adjuvant treatment strategies should be based on these adverse 
prognostic histological factors. 
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
Chapter 9
140
References
1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin 2011; 61(2): 
69-90.
2. Choti MA, Sitzmann JV, Tiburi MF, et al. Trends in long-term survival following liver resection for hepatic 
colorectal metastases. Ann Surg 2002; 235(6): 759-66.
3. Zakaria S, Donohue JH, Que FG, et al. Hepatic resection for colorectal metastases: value for risk scoring 
systems? Ann Surg 2007; 246(2): 183-91.
4. House MG, Ito H, Gonen M, et al. Survival after hepatic resection for metastatic colorectal cancer: trends in 
outcomes for 1,600 patients during two decades at a single institution. J Am Coll Surg 2010; 210(5): 744-52, 
52-5.
5. Hayashi M, Inoue Y, Komeda K, et al. Clinicopathological analysis of recurrence patterns and prognostic 
factors for survival after hepatectomy for colorectal liver metastasis. BMC Surg 2010; 10: 27.
6. Iwatsuki S, Dvorchik I, Madariaga JR, et al. Hepatic resection for metastatic colorectal adenocarcinoma: a 
proposal of a prognostic scoring system. J Am Coll Surg 1999; 189(3): 291-9.
7. Konopke R, Kersting S, Distler M, et al. Prognostic factors and evaluation of a clinical score for predicting 
survival after resection of colorectal liver metastases. Liver Int 2009; 29(1): 89-102.
8. Nagashima I, Takada T, Adachi M, Nagawa H, Muto T, Okinaga K. Proposal of criteria to select candidates with 
colorectal liver metastases for hepatic resection: comparison of our scoring system to the positive number 
of risk factors. World J Gastroenterol 2006; 12(39): 6305-9.
9. Fong Y, Fortner J, Sun RL, Brennan MF, Blumgart LH. Clinical score for predicting recurrence after hepatic 
resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999; 230(3): 309-18; 
discussion 18-21.
10. Shirouzu K, Isomoto H, Kakegawa T, Morimatsu M. A prospective clinicopathologic study of venous invasion 
in colorectal cancer. Am J Surg 1991; 162(3): 216-22.
11. Krasna MJ, Flancbaum L, Cody RP, Shneibaum S, Ben Ari G. Vascular and neural invasion in colorectal 
carcinoma. Incidence and prognostic significance. Cancer 1988; 61(5): 1018-23.
12. Benson AB, 3rd, Schrag D, Somerfield MR, et al. American Society of Clinical Oncology recommendations on 
adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 2004; 22(16): 3408-19.
13. Knijn N, de Ridder JA, Punt CJ, de Wilt JH, Nagtegaal ID. Histopathological evaluation of resected colorectal 
cancer liver metastases: what should be done? Histopathology 2013; 63(2): 149-56.
14. Yamamoto J, Shimada K, Kosuge T, Yamasaki S, Sakamoto M, Fukuda H. Factors influencing survival of patients 
undergoing hepatectomy for colorectal metastases. Br J Surg 1999; 86(3): 332-7.
15. Yamamoto J, Sugihara K, Kosuge T, et al. Pathologic support for limited hepatectomy in the treatment of liver 
metastases from colorectal cancer. Ann Surg 1995; 221(1): 74-8.
16. Tanaka K, Shimada H, Kubota K, et al. Effectiveness of prehepatectomy intra-arterial chemotherapy for 
multiple bilobar colorectal cancer metastases to the liver: a clinicopathologic study of peritumoral 
vasculobiliary invasion. Surgery 2005; 137(2): 156-64.
17. Shirabe K, Takenaka K, Gion T, et al. Analysis of prognostic risk factors in hepatic resection for metastatic 
colorectal carcinoma with special reference to the surgical margin. Br J Surg 1997; 84(8): 1077-80.
18. Sasaki A, Aramaki M, Kawano K, Yasuda K, Inomata M, Kitano S. Prognostic significance of intrahepatic 
lymphatic invasion in patients with hepatic resection due to metastases from colorectal carcinoma. Cancer 
2002; 95(1): 105-11.
19. Okano K, Yamamoto J, Moriya Y, et al. Macroscopic intrabiliary growth of liver metastases from colorectal 
cancer. Surgery 1999; 126(5): 829-34.
20. Korita PV, Wakai T, Shirai Y, et al. Intrahepatic lymphatic invasion independently predicts poor survival and 
recurrences after hepatectomy in patients with colorectal carcinoma liver metastases. Ann Surg Oncol 2007; 
14(12): 3472-80.
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
9
Lymphatic invasion is an independent adverse prognostic factor in patients with CRLM
141
21. Okano K, Maeba T, Moroguchi A, et al. Lymphocytic infiltration surrounding liver metastases from colorectal 
cancer. J Surg Oncol 2003; 82(1): 28-33.
22. Kubo M, Sakamoto M, Fukushima N, et al. Less aggressive features of colorectal cancer with liver metastases 
showing macroscopic intrabiliary extension. Pathol Int 2002; 52(8): 514-8.
23. Bockhorn M, Sotiropoulos G, Neuhaus J, et al. Prognostic impact of intrahepatic lymphatic and microvascular 
involvement in cases of colorectal liver metastases. Int J Colorectal Dis 2009; 24(7): 845-50.
24. Okano K, Yamamoto J, Kosuge T, et al. Fibrous pseudocapsule of metastatic liver tumors from colorectal 
carcinoma. Clinicopathologic study of 152 first resection cases. Cancer 2000; 89(2): 267-75.
25. Brunner SM, Kesselring R, Rubner C, et al. Prognosis according to histochemical analysis of liver metastases 
removed at liver resection. Br J Surg 2014; 101(13): 1681-91.
26. Maru DM, Kopetz S, Boonsirikamchai P, et al. Tumor thickness at the tumor-normal interface: a novel 
pathologic indicator of chemotherapy response in hepatic colorectal metastases. Am J Surg Pathol 2010; 
34(9): 1287-94.
27. van der Pool AE, Marsman HA, Verheij J, et al. Effect of bevacizumab added preoperatively to oxaliplatin on 
liver injury and complications after resection of colorectal liver metastases. J Surg Oncol 2012; 106(7): 892-7.
28. Gervaz P, Rubbia-Brandt L, Andres A, et al. Neoadjuvant chemotherapy in patients with stage IV colorectal 
cancer: a comparison of histological response in liver metastases, primary tumors, and regional lymph nodes. 
Ann Surg Oncol 2010; 17(10): 2714-9.
29. Loupakis F, Schirripa M, Caparello C, et al. Histopathologic evaluation of liver metastases from colorectal 
cancer in patients treated with FOLFOXIRI plus bevacizumab. Br J Cancer 2013; 108(12): 2549-56.
30. Halama N, Spille A, Lerchl T, et al. Hepatic metastases of colorectal cancer are rather homogeneous but differ 
from primary lesions in terms of immune cell infiltration. Oncoimmunology 2013; 2(4): e24116.
31. Abengozar M, Fernandez-Acenero MJ, Chaves S, Celdran A. Prognostic utility of tumor thickness at the 
tumor-normal interface in chemotherapy-treated hepatic colorectal metastasis. Pathol Res Pract 2012; 208(4): 
235-9.
32. Brouquet A, Zimmitti G, Kopetz S, et al. Multicenter validation study of pathologic response and tumor 
thickness at the tumor-normal liver interface as independent predictors of disease-free survival after 
preoperative chemotherapy and surgery for colorectal liver metastases. Cancer 2013; 119(15): 2778-88.
33. Vlems F, van der Worp E, van der Laak J, van de Velde C, Nagtegaal I, van Krieken H. A study into methodology 
and application of quantification of tumour vasculature in rectal cancer. Virchows Arch 2004; 445(3): 263-70.
34. Mohammed RA, Martin SG, Gill MS, Green AR, Paish EC, Ellis IO. Improved methods of detection of 
lymphovascular invasion demonstrate that it is the predominant method of vascular invasion in breast cancer 
and has important clinical consequences. Am J Surg Pathol 2007; 31(12): 1825-33.
35. Van den Eynden GG, Van der Auwera I, Van Laere SJ, et al. Distinguishing blood and lymph vessel invasion in 
breast cancer: a prospective immunohistochemical study. Br J Cancer 2006; 94(11): 1643-9.
36. Lupinacci RM, Mello ES, Pinheiro RS, et al. Intrahepatic lymphatic invasion but not vascular invasion is a major 
prognostic factor after resection of colorectal cancer liver metastases. World J Surg 2014; 38(8): 2089-96.
37. August DA, Sugarbaker PH, Schneider PD. Lymphatic dissemination of hepatic metastases. Implications for 
the follow-up and treatment of patients with colorectal cancer. Cancer 1985; 55(7): 1490-4.
38. Angelsen JH, Horn A, Eide GE, Viste A. Surgery for colorectal liver metastases: the impact of resection 
margins on recurrence and overall survival. World J Surg Oncol 2014; 12: 127.
39. Vigano L, Capussotti L, Lapointe R, et al. Early recurrence after liver resection for colorectal metastases: 
risk factors, prognosis, and treatment. A LiverMetSurvey-based study of 6,025 patients. Ann Surg Oncol 2014; 
21(4): 1276-86.
40. John SK, Robinson SM, Rehman S, et al. Prognostic factors and survival after resection of colorectal liver 
metastasis in the era of preoperative chemotherapy: an 11-year single-centre study. Dig Surg 2013; 30(4-6): 
293-301.
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
Chapter 9
142
41. Ayez N, Lalmahomed ZS, Eggermont AM, et al. Outcome of microscopic incomplete resection (R1) of 
colorectal liver metastases in the era of neoadjuvant chemotherapy. Ann Surg Oncol 2012; 19(5): 1618-27.
42. Nathan H, Bridges JF, Cosgrove DP, et al. Treating patients with colon cancer liver metastasis: a nationwide 
analysis of therapeutic decision making. Ann Surg Oncol 2012; 19(12): 3668-76.
43. Vauthey JN, Zimmitti G, Kopetz SE, et al. RAS mutation status predicts survival and patterns of recurrence in 
patients undergoing hepatectomy for colorectal liver metastases. Ann Surg 2013; 258(4): 619-26; discussion 
26-7.
44. Nordlinger B, Sorbye H, Glimelius B, et al. Perioperative FOLFOX4 chemotherapy and surgery versus 
surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a 
randomised, controlled, phase 3 trial. Lancet Oncol 2013; 14(12): 1208-15.
CHAPTER 10
Summary of this thesis and future perspectives
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
Chapter 10
144
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
10
Summary of this thesis and future perspectives
145
Summary of this thesis
Incidence of liver metastases and liver resection 
Many newly diagnosed cancer patients present with liver metastases and even more patients 
develop liver metastases during the course of their disease. Knowledge about the origin of 
liver metastases is important, especially in those patients who present with metastases and 
where a primary tumour is not (yet) diagnosed. 
In chapter 2 more than 23,000 patients with histological confirmed liver metastases were 
analyzed during a 10- year period (2001-2010). Data were collected from the PALGA database 
(a nation-wide network and registry of cyto- and histopathology in the Netherlands), and 
demographics and primary tumour (sub)types were evaluated. Colorectal carcinoma (CRC) 
was the most common primary tumour location in patients with liver metastases (35%). 
This percentage might even be an underestimation because liver biopsies are not always 
performed in CRC patients with suspicious liver lesions, and (systemic) therapies are often 
started without histological confirmation of metastatic disease. 
Liver metastases were more observed in men (53%), with primary tumour locations mainly 
in the lung (squamous cell carcinoma) or in the colorectum. The majority of patients with 
liver metastases were older than 50 years (90.2%), although liver metastases from breast 
cancer and gynecological cancers (squamous cell carcinoma and neuroendocrine carcinoma) 
were relatively more diagnosed in women younger than 50 years. In older men (>70 years) 
liver metastases from the urological tract and squamous cell lung carcinoma were more 
common. 
This large overview of the origins of liver metastases, with regard to tumour types, age and 
gender, forms a basis for future research, and may be used for the development of diagnostic 
strategies.
The vast majority of the 23,000 patients, described in chapter 2, underwent liver biopsy only, 
while just over 3,900 patients underwent a liver resection. Chapter 3 describes all patients 
who underwent some form of liver resection for metastatic disease in the Netherlands 
between 2001 and 2010. As expected liver resection was most often performed in patients 
with colorectal liver metastases (CRLM) (88% of the patients who underwent liver surgery). 
During the study period, a significant increase of liver resections for CRLM was observed. 
Part of the increase can be explained by the increasing incidence of primary CRC and as 
a result more patients with CRLM. Additional explanations can be found in the fact that 
the indications for liver surgery seem to expand. An increase in patients’ age at the time of 
liver resection, as well as an increase in patients with multiple liver metastases point in this 
direction. 
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Non-colorectal liver metastases
The data from chapter 2 showed that almost half of the (histological confirmed) liver 
metastases originated from a non-colorectal primary tumour. The most common primary 
malignancies in this patient group were pancreatic cancer, lung cancer, breast cancer and 
melanoma. Despite the fact that almost half of the patients were diagnosed with non-
colorectal liver metastases (non-CRLM), the number of patients that undergo liver surgery 
for non-CRLM was low, and did not increase during the last decade, as described in chapter 
3. Several factors might be responsible for this low amount, such as: the lack of adequate 
follow-up to discover liver metastases in an early phase, a low number of patients with 
resectable liver metastases, and lack of evidence that liver surgery is improving outcome 
in patients with non-CRLM. Nevertheless, a small number of patients with non-CRLM did 
undergo liver surgery aiming to improve survival. 
In chapter 4 all patients with breast cancer liver metastases who underwent liver resection 
in the Netherlands between 1994 and 2010 (n=32) were evaluated. In this highly selected 
group of patients a median survival of 55 months was found. Factors associated with improved 
survival were estrogen-receptor-positivity of the primary tumour, solitary metastasis and 
unilobar distribution. 
Chapter 5 describes all patients in the Netherlands between 1994 and 2010 with metastatic 
melanoma, who underwent liver resection (n=32). In this, again, highly selected group of 
patients, median survival was 29 months. These results are similar to previous, generally 
single center, international studies and suggest that surgery seems to be associated with 
improved survival in this highly selected group of patients with non-CRLM.1-6 Factors 
associated with improved survival in patients with metastatic melanoma were solitary liver 
metastasis, unilobar distribution and minor liver resection. 
The challenge in patients with non-CRLM is to select those patients who would benefit 
from liver resection. Factors associated with improved survival have been described, but 
vary between the reports. For breast cancer liver metastases estrogen receptor status 1,7,8, 
number of liver metastases 7,8, and free resection margins9,10 were most often identified as 
prognostic factors for survival. In patients with metastatic melanoma free resection margins 
5,6,11,12, the number of liver metastases 4,6, and the length of the disease-free interval between 
treatment of the primary melanoma and diagnosis of the liver metastases 4,5,12,13 were the 
most described factors associated with survival. However, these prognostic factors have 
been derived from very small patient cohorts, which may very well lead to a high risk of bias. 
Therefore, these factors can be taken into account in individual cases, but they should not 
be used to exclude patients from liver surgery.
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Colorectal liver metastases
Almost 40% of all CRC patients develop CRLM and only few undergo liver surgery, although 
the number of liver resections significantly increased in recent years. In chapter 3, it was 
estimated that approximately 20% of patients with CRLM underwent liver resection in the 
Netherlands, which is in line with international data.14,15 Part of the problem is the assessment 
of resectability of liver metastases, and that not all patients with liver metastases are being 
referred to liver surgeons to evaluate potential surgical treatment options. In chapter 6 
fifty-six computed tomography (CT) scans of patients with CRLM, who were treated with 
systemic therapy (without surgery) in two Dutch multicenter randomised clinical trials, were 
retrospectively evaluated by three independent, experienced, liver surgeons. In 16 patients 
(29%) there was disagreement between these surgeons whether the CRLM were resectable 
or un-resectable. Two previous studies also demonstrated that decision-making in patients 
with CRLM is highly variable, even among experienced liver surgeons.16,17 Both studies 
described disagreement between liver surgeons in assessing resectability of the CRLM in 
almost half of the cases16,17 This highlights the heterogeneous nature of oncological liver 
surgery, where the decision-making process is influenced by the individual experience of 
the treating doctor (colorectal surgeon, liver surgeon or medical oncologist) and by the 
availability of various treatment options (such as induction systemic therapy, two-stage liver 
resection, portal vein embolisation (PVE) and various ablative techniques). The extent of 
treatment options for patients with CRLM is fueling the needs for multidisciplinary team 
approaches. 
Another part of the study in chapter 6 was comparing long term results between patients 
who underwent surgery or systemic treatment for CRLM. Patients who were treated with 
systemic therapy for CRLM and were retrospectively considered candidates for surgery by 
all three liver surgeons after reviewing the CT scans where identified. These 36 patients were 
case-matched (for gender, age, and the clinical risk factors according to Fong et al.18) with 
comparable patients who underwent liver resection. Patients who underwent liver surgery 
had a significantly better overall survival (OS) compared to patients who were treated only 
with systemic therapy (56 versus 26.5 months). Liver resection should therefore remain the 
‘gold standard treatment’ for patients with CRLM, and should always be aimed for. 
Prognostic factors
In chapter 7 the value of fluorine-18-deoxyglucose positron emission tomography (FDG-
PET) scan as a tool in patient selection for liver surgery was investigated. Survival was 
assessed in two patient groups with CRLM who underwent pre-operative FDG-PET (n= 
206) and who did not underwent pre-operative FDG-PET scan (n= 407). The results showed 
that pre-operative FDG-PET scan did not have an additional value in selecting patients for 
liver surgery, since patients selected with pre-operative FDG-PET scan did not have an 
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improvement in disease-free (median 17 versus 14 months) or overall survival (median 
64 versus 54 months). A recent clinical trial by Moulton et al. evaluated the changes in 
treatment of CRLM patients scheduled for surgery after a pre-operative FDG-PET scan.19 
They described a change in treatment plan in only 2.7% of the patients, and as a result, 
routine FDG-PET scan is not recommended in the standard pre-operative work-up in 
patients with CRLM. 
Prognosis of CRC patients after liver metastasectomy improved during the last decade with 
5-year overall survival rates above 50%.20 Nevertheless, the quest for new prognostic factors 
continues, because, unfortunately, these high survival rates do not count for every CRLM 
patient. Some patients suffer from early recurrences, leading to inferior survival rates.20 
In chapter 8 a study of the literature was performed for histopathological factors that might 
influence survival after resection of CRLM, such as intrahepatic spread, resection margins, 
and tumour response to neo-adjuvant systemic therapy. Meta-analyses demonstrated a 
correlation between OS and portal vein and lymphatic invasion, as well as resection margin. 
However, most studies were performed in heterogeneous patient populations. Therefore, in 
chapter 9, patients with solitary CRLM, without neo-adjuvant systemic treatment, and with 
sufficient follow up were retrospectively selected. A total of 124 liver resection specimens 
were re-examined by two independent observers for relevant histological factors. These 
histological factors were: tumour-thickness at tumour normal interface and presence of a 
tumour capsule that were examined in hematoxyline-eosine (HE) stained slides, intrahepatic 
vascular, lymphatic or angioinvasion, and perineural growth which were identified with 
immunohistochemistry. In addition to these histopathological factors, Fongs’ clinical risk 
factors were collected (e.g. size of the metastasis, CEA-level, interval between treatment of 
the primary tumour and detection of liver metastasis, and positive nodal status of the primary 
tumour).18 Intrahepatic lymphatic invasion by tumour cells was the only independent adverse 
histopathological prognostic factor in patients with solitary CRLM, especially in combination 
with intrahepatic vascular invasion, which may be an expression of aggressive tumour 
behavior. The value of lymphatic invasion as a prognostic factor needs further research in 
patients with neo-adjuvant systemic therapy and patients with multiple CRLM. 
R1
R2
R3
R4
R5
R6
R7
R8
R9
R10
R11
R12
R13
R14
R15
R16
R17
R18
R19
R20
R21
R22
R23
R24
R25
R26
R27
R28
R29
R30
R31
R32
R33
R34
R35
R36
R37
R38
R39
10
Summary of this thesis and future perspectives
149
Future perspectives 
In 2014 a nation-wide screening program for CRC was introduced in the Netherlands, for 
early detection and prevention of CRC. The identification of asymptomatic patients with 
early stage CRC will hopefully result in a decreased number of patients with CRLM and 
decreased need for liver surgery. On the other hand, as a result of expanding indications, it 
can be expected that the increase in the number of liver resections will continue. In this thesis 
it was demonstrated that, for example, older age seems to be no longer a contraindication 
for liver surgery, which is supported by other studies.21,22 Comorbidity and clinical condition 
remain most important in patient selection for major resection but in liver surgery, future 
liver remnant has become the most important factor. Methods to increase this remnant 
liver are portal vein embolisation (PVE) and portal vein ligation (PVL). By inducing liver 
hypertrophy in the non-embolised liver segments, the volume of future remnant liver is 
usually increased. After portal ligation or embolisation patients have to wait for several 
weeks for liver hypertrophy to occur, but in the meantime progression of liver metastases (in 
the non-embolised segments) might also be induced.  A new technique that deals with this 
potential problem is Associating Liver Partion and PVL for Staged hepatectomy (ALPPS).  At 
first, the liver parenchyma is transected along the intended line of resection and the future 
remnant liver is cleared by partial resection of all tumour tissue (in case of bilobar disease). 
A portal ligation to the lobe that will be removed is added.  After a waiting period of 1-2 weeks 
the second step is performed in which the deportalized liver is removed. A greater degree of 
growth of future remnant liver was observed after ALLPS compared to traditional methods 
(PVI/PVL) and less time was needed for the liver hypertrophy to occur.23 ALPPS seems a 
promising technique, however, a high morbidity, mortality, and increased early recurrences 
of liver metastases have been reported after ALPPS.24 A randomised clinical trial comparing 
ALPPS and two-stage liver resection is currently ongoing in Austria (NCT02758977) and will 
evaluate the clinical effect of both techniques. 
Currently, liver resection in CRLM patients is only performed when with a complete resection 
(R0) can be achieved. This concept might need adjustment since Ayez et al. described similar 
long-term results in CRLM patients with complete resection (R0) or microscopic incomplete 
resection (R1) who were treated with neo-adjuvant systemic therapy.25 Other patients with 
advanced CRLM have such a good response after neo-adjuvant systemic therapy that lesions 
disappear and only visible liver lesions are removed.26 These patients can have long-term 
survival and these findings could rise the question if surgical treatment on top of systemic 
therapy provides any survival benefit for patients with multiple and un-resectable colorectal 
metastases (liver and other metastatic locations). The ORCHESTRA trial (NCT01792934) 
is designed for those patients with un-resectable colorectal metastases and randomises 
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between maximal debulking surgery and continuing systemic therapy. The results of this 
study have to be awaited, but could potentially lead to debulking surgery as a treatment 
modality for un-resectable stage IV CRC patients. 
In this thesis patients who received neo-adjuvant systemic therapy were excluded from 
various studies, because it was intended to create and study a homogeneous group of 
patients. Neo-adjuvant systemic therapy might potentially improve survival, but could also 
influence prognostic factors for survival after liver surgery. The role of peri-operative systemic 
therapy in primary resectable CRLM patients was recently reported by Nordlinger et al., 
and demonstrated no survival benefit after 7-years of follow-up.27,28 In their study, patients 
were not stratified by clinical risk score, and it may be hypothesized that only patients 
with a ‘high risk’ of recurrence might benefit from peri-operative systemic therapy. A recent 
retrospective analysis of patients with CRLM demonstrated only a clinical benefit on survival 
of neo-adjuvant systemic therapy in patients with a ‘high clinical risk profile’.29 However, it 
should be taken into account that in this study, patients who had disease progression during 
neo-adjuvant systemic therapy did not undergo liver surgery, and therefore the results from 
this retrospective analysis are biased. A randomised clinical trial (CHARISMA-trial) could 
answer the question whether ‘high risk patients’ benefit from additional systemic therapy 
before or after liver surgery.30 
Pre-operative use of FDG-PET scan in patients with CRLM failed to select patients who were 
unlikely to benefit from liver resection. Therefore the search for new imaging techniques 
that can select patients, who are the wright candidates for liver surgery, continues. The 
optimal imaging technique should be able to diagnose small liver metastases, which might 
be responsible for early recurrences after liver surgery. One of these promising techniques 
might be diffusion-weighted magnetic resonance imaging (MRI) combined with gadoxetic 
acid –enhanced MRI, which has a high sensitivity in the detection of small (<1cm) liver 
metastases (CRLM as well as non-CRLM), as described in a recent meta-analysis.31 Other 
imaging techniques such as perfusion CT imaging also are promising new techniques that 
need further research.32 
A more extensive histopathological evaluation of CRLM might become important. Not only 
to identify prognostic factors for survival, but also in potential patient selection for adjuvant 
systemic therapy. In primary CRC, histological factors (e.g. extramural venous invasion, 
perineural growth, angioinvasion, lymphatic invasion and diffuse growth patterns) have been 
associated with poorer survival outcomes.33,34 Especially extramural venous invasion is a 
poor prognostic factor and as a result, patients with stage II colon carcinoma in combination 
with extramural venous invasion are candidates for adjuvant systemic therapy.35 Whether 
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these, or other histopathological factors are important for patient selection for adjuvant 
systemic therapy in case of CRLM has to be studied. 
In anticipation of the results of many studies conducted for patients with liver metastases, it 
remains of utmost importance that these patients are referred to, or at least discussed with 
liver specialist centers. Multidisciplinary treatment of patients with liver metastases, either 
colorectal or non-colorectal, is the patients’ only chance to receive the best, most up-to-
date and tailored treatment. 
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Samenvatting van dit proefschrift
De incidentie van levermetastasen en lever resectie 
Veel patiënten met een maligniteit presenteren zich met levermetastasen, daarnaast 
ontwikkelen veel patiënten levermetastasen tijdens het beloop van hun ziekte. Kennis over 
de herkomst van deze levermetastasen is belangrijk voor patiënten, zeker voor patiënten die 
zich presenteren met metastasen zonder bekende primaire tumor. 
In hoofdstuk 2 werden meer dan 23.000 patiënten met histologisch bevestigde levermetastasen 
geanalyseerd gedurende een periode van 10 jaar (2001-2010). Via de PALGA database 
(een nationaal registratie netwerk voor cyto- en histopathologie in Nederland) werden 
de demografische gegevens van deze patiënten en de kenmerken van de primaire tumor 
verzameld. Colorectaal carcinoom (CRC) was de meest voorkomende primaire tumor 
locatie in patiënten met levermetastasen (35%), hoewel dit percentage een onderschatting 
zou kunnen zijn, aangezien er niet altijd een lever biopt zal worden afgenomen bij CRC 
patiënten met een verdachte afwijking in de lever.  Vaak zal begonnen worden met systemische 
therapie zonder histologische bevestiging. 
In deze studie werden levermetastasen vaker gezien bij mannen (53%), waarbij primaire 
tumor locaties zich voornamelijk bevonden in de long (plaveiselcel carcinoom) of in het 
colon/rectum. De meerderheid van de patiënten met levermetastasen was ouder dan 50 jaar 
(90.2%), hoewel levermetastasen van het mammacarcinoom en gynaecologische maligniteiten 
(plaveiselcel carcinoom en neuroendocriene tumor) relatief vaker voorkwamen bij vrouwen 
onder de 50 jaar. Levermetastasen van urologische en pulmonale (plaveiselcel carcinoom) 
origine kwamen vaker voor bij oudere mannen (>70 jaar). 
Dit ruime overzicht aan primaire tumor locaties van levermetastasen (inclusief tumor type, 
geslacht en leeftijd) vormt een basis voor verder onderzoek en zou gebruikt kunnen worden 
in de ontwikkeling van diagnostische en follow-up strategieën. 
De meerderheid van deze 23.000 patiënten, beschreven in hoofdstuk 2, ondergingen alleen 
een lever biopsie, terwijl iets meer dan 3.900 patiënten een lever resectie ondergingen. 
Hoofdstuk 3 beschrijft deze patiënten die een lever resectie ondergingen in Nederland 
tussen 2001 en 2010. Zoals kon worden verwacht, werd een lever resectie het meest 
frequent uitgevoerd voor patiënten met colorectale lever metastasen (CRLM) (88% van alle 
patiënten die een lever resectie ondergingen). Gedurende de studie periode werd er een 
significante stijging gezien in het aantal lever resecties dat per jaar werd uitgevoerd voor 
CRLM. Deze stijging kan gedeeltelijk verklaard worden door een stijging in de incidentie 
van primair CRC, echter een andere verklaring zou kunnen zijn dat de indicaties voor lever 
chirurgie zich uitbreiden. Een stijging van de leeftijd van de patiënten ten tijde van de lever 
resectie en een stijging in het aantal lever resecties voor multipele levermetastasen geven 
een aanwijzing in deze richting. 
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Niet-colorectale levermetastasen
Uit de data van hoofdstuk 2 bleek dat bijna de helft van alle (histologisch bevestigde) 
levermetastasen afkomstig waren van niet-colorectale tumoren. De meest voorkomende 
primaire tumoren in deze groep waren: pancreascarcinoom, longcarcinoom, mammacarcinoom 
en melanoom. Ondanks het feit dat bijna de helft van de levermetastasen afkomstig was van 
niet-colorectale tumoren, was het aantal patiënten dat hiervoor een resectie onderging laag 
en steeg dit aantal ook niet (significant) gedurende de studie periode, zoals beschreven staat 
in hoofdstuk 3. Er zijn een aantal factoren te bedenken die waarschijnlijk van invloed zijn op 
dit lage aantal, te weten: het ontbreken aan adequate follow-up om de levermetastasen in 
een vroeg stadium te kunnen diagnosticeren, een klein aantal patiënten dat daadwerkelijk 
resectabele levermetastasen heeft en het gebrek aan bewijs dat lever chirurgie überhaupt 
de overleving van patiënten met niet-colorectale levermetastasen verbeterd. Toch onderging 
een klein aantal van deze groep patiënten een lever resectie met als doel de overleving te 
verbeteren. 
In hoofdstuk 4 werden alle patiënten met gemetastaseerd mammacarcinoom naar de lever 
die een lever resectie ondergingen (n=32) in Nederland tussen 1994 en 2010 bestudeerd. In 
deze uiterst geselecteerde groep patiënten werd een mediane overleving gevonden van 55 
maanden. De factoren in deze studie die geassocieerd bleken met een verbeterde overleving 
waren: een oestrogeen receptor positieve primaire tumor, een solitaire levermetastase en 
een unilobulaire lokalisatie van de levermetastasen. 
Hoofdstuk 5 beschrijft alle patiënten in Nederland die tussen 1994 en 2010 een leverresectie 
ondergingen voor gemetastaseerd melanoom (n=32). In deze, wederom, uiterst geselecteerde 
groep patiënten was de mediane overleving 29 maanden. Deze resultaten zijn conform 
de eerder beschreven overlevingscijfers, vaak afkomstig vanuit ‘single-center’ studies, en 
wekken de suggestie dat een lever resectie geassocieerd is met een verbeterde overleving 
in patiënten met gemetastaseerd melanoom.1-6 Factoren die in deze studie geassocieerd 
bleken met een verbeterde overleving na lever resectie waren: een solitaire levermetastase, 
unilobulaire lokalisatie en een beperkte lever resectie.
Bij patiënten met niet-colorectale levermetastasen is van belang om juist dié patiënten te 
selecteren die profijt hebben van leverchirurgie. Factoren die geassocieerd zijn met een 
verbeterde overleving zijn beschreven, maar variëren tussen studies. In patiënten met 
levermetastasen van gemetastaseerd mammacarcinoom zijn de volgende prognostische 
factoren het meest beschreven: oestrogeen receptor status van de primaire tumor1,7,8, het 
aantal levermetastasen7,8, en vrije resectie marges9,10. Bij patiënten met levermetastasen van 
een gemetastaseerd melanoom werden vrije resectie marges5,6,11,12, het aantal levermetastasen 
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4,6, en de lengte van het ziektevrije interval tussen behandeling van het primaire melanoom 
en de diagnose van de levermetastasen 4,5,12,13 het meest frequent beschreven als factoren 
die geassocieerd zijn met verbeterde overleving. Echter, deze factoren zijn afkomstig uit 
kleine cohort studies wat kan leiden tot een hoog risico op bias, daarom kunnen deze 
factoren meegenomen worden in de beoordeling van individuele patiënten, maar mogen zij 
niet gebruikt worden om patiënten lever chirurgie te ontzeggen.
Colorectale levermetastasen 
Bijna 40% van alle CRC patiënten ontwikkelen CRLM, terwijl maar een klein aantal van deze 
patiënten leverchirurgie ondergaat, ondanks dat het totale aantal lever resecties toeneemt 
over de jaren. In hoofdstuk 3 werd geschat dat ongeveer 20% van de patiënten met CRLM 
in Nederland een lever resectie ondergingen, wat overeenkomt met de internationale 
literatuur.14,15 Een deel van het probleem is de beoordeling van de resectabiliteit van de 
levermetastasen, naast het feit dat niet alle patiënten met levermetastasen worden verwezen 
naar een lever chirurg ter beoordeling van eventuele chirurgische behandel opties. 
In hoofdstuk 6 werden 56 CT scans van patiënten met CRLM die behandeld werden met 
(palliatieve) systemische therapie (zonder resectie) in twee Nederlandse multicenter 
gerandomiseerde klinische studies herbeoordeeld door 3 ervaren leverchirurgen. Bij 
16 patiënten (29%) was er geen overeenstemming of de CRLM resectabel, danwel niet-
resectabel waren. Twee eerdere studies toonden al aan dat de besluitvorming bij patiënten 
met CRLM erg variabel is, zelfs tussen ervaren leverchirurgen.16,17 Beide studies beschrijven 
een meningsverschil tussen leverchirurgen bij het beoordelen van de resectabiliteit van 
CRLM in bijna de helft van de patiënten.16,77 Dit benadrukt de heterogeniciteit van de 
oncologische chirurgie, waarbij de besluitvorming rondom patiënten met CRLM wordt 
beïnvloed door de ervaring van de behandelende artsen (colorectale chirurg, leverchirurg 
en medisch oncoloog) en door de beschikbaarheid van de verschillende behandelopties 
(zoals inductie chemotherapie, lever resectie in twee stadia, vena porta embolisatie en 
de verschillende ablatieve technieken). Deze grote hoeveelheid aan behandelopties voor 
patiënten met CRLM zorgt ervoor dat er een multidisciplinaire aanpak noodzakelijk is. 
In het tweede deel van de studie in hoofdstuk 6 werd de overleving vergeleken tussen 
patiënten met CRLM die behandeld werden met (palliatieve) systemische therapie of een 
lever resectie ondergingen. De patiënten die werden behandeld met systemische therapie 
en na herbeoordeling van de CT-scan door alle 3 de leverchirurgen als resectabel werden 
afgegeven werden geïncludeerd. Deze 36 patiënten werden gematched (voor geslacht, 
leeftijd, en klinische risico score volgens Fong et al.18) met vergelijkbare patiënten die 
een leverresectie ondergingen. De patiënten die een resectie ondergingen hadden een 
significant betere overleving in vergelijking met de overleving van de patiënten die alleen 
met systemische therapie behandeld werden (56 versus 26.5 maanden). Op basis van de 
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resultaten van deze studie, moet lever resectie als de gouden standaard worden beschouwd 
voor de behandeling van patiënten met CRLM.
Prognostische factoren
In hoofdstuk 7 werd de waarde van de fluorine-18-deoxyglucose positron emissie 
tomografie scan (FDG-PET scan) onderzocht, om deze mogelijk te kunnen gebruiken 
voor de preoperatieve patiënten selectie. De overleving van patiënten met CRLM die een 
preoperatieve FDG-PET scan (n= 206) ondergingen werd vergeleken met de overleving van 
patiënten zonder FDG- PET scan (n= 407). De resultaten toonden geen meerwaarde van 
de preoperatieve FDG-PET scan voor de patiënten selectie, aangezien de patiënten met een 
preoperatieve FDG-PET scan na lever chirurgie geen verbeterde ziektevrije overleving (DFS) 
(mediaan 17 versus 14 maanden) of overall overleving (OS) (mediaan 64 versus 54 maanden) 
hadden ten opzichte van patiënten zonder FDG-PET scan. Moulton et. al. evalueerden de 
veranderingen in behandelplan na een preoperatieve FDG-PET scan in patiënten met CRLM 
waar een lever resectie gepland was.19 In slechts 2.7% werd het behandelplan gewijzigd naar 
aanleiding van de FDG-PET scan. Dit maakt dat een FDG-PET scan niet standaard deel uit 
hoeft te maken van de preoperatieve work-up van patiënten met CRLM. 
Gedurende de laatste jaren is de prognose van patiënten met CRLM die een lever resectie 
ondergaan sterk verbeterd, met een 5-jaars overleving van meer dan 50%.20 De zoektocht 
naar nieuwe prognostische factoren gaat echter onverminderd door, omdat deze relatief 
hoge overlevingscijfers helaas niet voor iedere patiënt met CRLM gelden. Sommige patiënten 
hebben een vroeg recidief wat leidt tot een verslechterde overleving.20 
In hoofdstuk 8 beschreven wij een literatuur studie naar histopathologische factoren die van 
invloed kunnen zijn op de overleving van CRLM patiënten na lever resectie.  Voorbeelden 
van deze mogelijke factoren zijn: intrahepatische verspreiding van tumorcellen, resectie 
marges en tumor respons op neo-adjuvante systemische therapie. De meta-analyse toonde 
een correlatie tussen OS en vena porta en lymfatische invasie van tumor cellen en tussen 
OS en de resectiemarge. De meeste studies werden echter uitgevoerd in heterogene 
patiënten populaties. Om deze reden werden in hoofdstuk 9 (retrospectief) patiënten 
geselecteerd met een solitaire CRLM, die niet neo-adjuvant behandeld werden en waar 
een sufficiënte follow-up beschikbaar was. In totaal werden 124 lever resectie preparaten 
opnieuw beoordeeld door twee onafhankelijke onderzoekers. De histologische factoren 
waar naar gekeken werd met behulp van hematoxyline-eosine kleuring (HE) waren: tumor-
dikte op de overgang van metastase naar normaal lever weefsel en de aanwezigheid van 
een kapsel rondom de metastase. Intrahepatische vasculaire, lymfatische en galganginvasie 
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en perineurale groei werden geïdentificeerd met behulp van immunohistochemie. Naast 
deze histopathologische factoren werden de factoren uit de klinische risico score van Fong 
et al. verzameld (grootte van de metastase, het CEA, de lymfklierstatus van de primaire 
tumor en het interval tussen de behandeling van de primaire tumor en de diagnose van 
de levermetastase).18 Intrahepatische lymfvat invasie van tumorcellen was de enige 
onafhankelijke negatieve prognostische factor bij patiënten met een solitaire CRLM, zeker 
wanneer er ook nog sprake was van intrahepatische vasculaire invasie. Deze combinatie zou 
een expressie kunnen zijn van een agressieve tumor. De waarde van lymfatische invasie als 
een negatieve prognostische factor moet verder onderzocht worden in patiënten die neo-
adjuvant behandeld zijn, of die meerdere levermetastasen hebben. 
Toekomst perspectieven 
In 2014 is er een landelijk screeningsprogramma gestart voor colorectaal carcinoom(CRC) 
in Nederland, zodat de primaire tumoren hopelijk in een vroeg stadium opgespoord kunnen 
worden. De identificatie van asymptomatische patiënten met CRC zal hopelijk resulteren in 
een afname van patiënten met CRLM en daarmee de noodzaak tot leverchirurgie. 
Echter, door het verbreden van de indicaties kan verwacht worden dat de toename van lever 
resecties de komende jaren zal continueren. In dit proefschrift zien we bijvoorbeeld dat 
oudere leeftijd geen contra-indicatie meer is voor lever chirurgie, wat ook in andere studies 
naar voren komt.21,22 Co-morbiditeit en klinische conditie blijven belangrijk in de patiënten 
selectie, maar in de leverchirurgie is vooral het volume van de ‘rest lever’ van belang. Methoden 
om de rest lever te vergroten zijn embolisatie van de vena porta (PVE) en ligatie van de vena 
porta (PVL). Door het induceren van lever hypertrofie in het ‘niet geëmboliseerde’ lever 
deel, neemt het lever volume over het algemeen toe. Na ligatie of embolisatie van de vena 
porta moeten patiënten enkele weken wachten tot de lever hypertrofie optreedt, terwijl in 
de tussentijd ook progressie van de levermetastasen (in het ‘niet-geëmboliseerde’ lever deel) 
kan worden geïnduceerd. Een nieuwe techniek die dit probleem aanpakt is ‘Associating Liver 
Partion and PVL for Staged hepatectomy’ (ALPPS). Als eerste stap vindt bij deze procedure 
een transectie van het leverparenchym plaats (waarbij het wel in situ blijft), wordt de rest-
lever tumor-vrij gemaakt (in het geval van bilobulaire ziekte) en vindt vena porta ligatie 
plaats. Na een wachtperiode van 1 tot 2 weken wordt de patiënt opnieuw geopereerd en 
wordt het leverdeel waar de porta geligeerd is, verwijderd. Na ALLPS wordt een grotere 
toename van het volume van de rest lever gezien dan na PVE of PVL, en was er minder tijd 
nodig tot de lever hypertrofie optrad.23 ALPPS lijkt een veelbelovende techniek, maar na 
ALLPS wordt een hoge morbiditeit, mortaliteit en een verhoogde kan op vroege recidieven 
gerapporteerd.24 Een gerandomiseerde klinische studie die ALLPS vergelijkt met een lever 
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resectie in twee stadia wordt momenteel uitgevoerd in Oostenrijk (NCT02758977) en zal 
de klinische effecten van beide technieken evalueren. 
Lever resectie bij CRLM patiënten zal alleen uitgevoerd worden, indien een complete resectie 
(R0) kan worden bereikt. Deze benadering verdient mogelijk enige aanpassing nadat Ayez 
et al. gelijke lange termijn resultaten beschreven bij CRLM patiënten die een R0 resectie 
ondergingen en patiënten die een microscopisch niet radicale resectie (R1) ondergingen nadat 
zij neo-adjuvant behandeld waren.25 Andere patiënten met vergevorderde levermetastasen 
hebben soms zo’n goede respons op neo-adjuvante systemische therapie dat een aantal 
levermetastasen verdwijnen en alleen de zichtbare metastasen verwijderd worden.26 Deze 
patiënten kunnen een lange termijn overleving hebben, waarbij de vraag rijst of chirurgische 
therapie als aanvulling op deze systemische therapie overlevingswinst geeft voor patiënten 
met meerdere, niet-resectabele colorectale metastasen (lever en ook andere locaties). 
De ORCHESTRA trial (NCT01792934) is opgezet voor deze groep patiënten met niet-
resectabele colorectale metastasen en randomiseert tussen maximale dubulkings-chirurgie 
en het continueren van systemische therapie. De resultaten van deze studie moeten worden 
afgewacht, maar kunnen er potentieel toe leiden dat debulkings-chirurgie een belangrijke 
behandel optie gaat worden bij patiënten met niet-resectabel stadium IV CRC.
In dit proefschrift werden patiënten die neo-adjuvant behandeld waren geëxcludeerd in de 
verschillende studies, omdat het beoogd was een homogene groep patiënten te bestuderen. 
Neo-adjuvante therapie kan mogelijk de overleving van patiënten verbeteren, maar zou 
ook de prognostische factoren na chirurgie kunnen beïnvloeden. De rol van perioperatieve 
systemische therapie voor patiënten met primair resectabele CRLM werd recent beschreven 
door Nordlinger et al., en toonde geen overlevingswinst na 7 jaar follow-up.27,28 In deze 
studie werden patiënten echter niet ingedeeld in risico categorieën en het zou zo kunnen 
zijn dat alleen patiënten met een ‘hoog risico’ baat hebben bij perioperatieve systemische 
therapie. Een recente (retrospectieve) analyse van patiënten met CRLM toonde alleen een 
klinisch voordeel van neo-adjuvante systemische therapie bij patiënten met een ‘hoog risico 
profiel’.29 Echter, in deze studie ondergingen de patiënten met progressieve ziekte onder de 
neo-adjuvante systemische therapie geen leverchirurgie wat zorgt voor bias in de resultaten 
van deze retrospectieve studie. Een gerandomiseerde klinische studie (CHARISMA-studie) 
zal de vraag moeten gaan beantwoorden of ‘hoog risico patiënten’ baat hebben bij (neo)
adjuvante systemische therapie rondom leverchirurgie.30 
Het preoperatieve gebruik van een FDG-PET scan bij patiënten met CRLM bleek een 
ongeschikt middel om patiënten te selecteren die mogelijk geen baat hebben bij leverchirurgie. 
De zoektocht naar nieuwe beeldvormingstechnieken die wel in staat zijn de juiste patiënten 
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voor lever chirurgie te selecteren gaat verder. De optimale beeldvormingstechniek moet 
in staat zijn kleine levermetastasen te detecteren die mogelijk de oorzaak zijn van een 
vroeg recidief. Één van deze veelbelovende technieken is de diffusie MRI gecombineerd met 
gadoxetine zuur. Deze techniek heeft een hoge sensitiviteit voor wat betreft de detectie van 
kleine levermetastasen (<1cm) (CRLM en niet-colorectale metastasen), zoals beschreven 
in een recente meta-analyse.31 Andere technieken, zoals perfusie CT scan zijn eveneens 
veelbelovend en verdienen verder onderzoek.32 
Uitgebreidere histopathologische evaluatie van CRLM zou belangrijker kunnen worden. 
Niet alleen om prognostische factoren te identificeren, maar potentieel ook voor de 
patiënten selectie voor adjuvante systemische therapie. Bepaalde histologische factoren 
(zoals extramurale veneuze invasie, perineurale groei, lymfatische invasie en een diffuus 
groeipatroon) zijn geassocieerd met slechtere overleving in patiënten met primair colorectaal 
carcinoom.33,34 Vooral extramurale veneuze invasie is geassocieerd met een slechte prognose, 
om deze reden zijn patiënten met stadium II coloncarcinoom in combinatie met extramurale 
veneuze invasie kandidaten voor adjuvante systemische therapie.35 Of deze, danwel andere 
histopathologische factoren eveneens belangrijk zijn in de patiënten selectie voor adjuvante 
behandeling voor CRLM is een vraag die verder onderzoek nodig heeft. 
In afwachting van de resultaten van de vele studies die momenteel uitgevoerd worden voor 
patiënten met levermetastasen, blijft het van het grootste belang dat deze patiënten verwezen 
worden naar, of op zijn minst besproken worden met, een specialistisch levercentrum. Een 
multidisciplinaire behandeling van patiënten met levermetastasen (zowel colorectaal als niet-
colorectaal) is de enige kans voor deze patiënten op de beste ‘behandeling op maat’ met de 
meest moderne inzichten. 
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Dankwoord
Een dankwoord staat vrijwel altijd aan het einde van een proefschrift, terwijl het eigenlijk 
aan het begin zou moeten staan. Een proefschrift kan namelijk alleen ontstaan met (veel) 
hulp van anderen. Dat maakt dat dit op één na laatste hoofdstuk één van de belangrijkste 
hoofdstukken (en wellicht het meest gelezen) van dit proefschrift is. 
Professor dr. De Wilt, ‘hi prof’, als eerste wil ik jou bedanken voor je onuitputtelijke 
enthousiasme tijdens dit hele promotie-avontuur. Bedankt voor je geduld, want ondanks 
dat ‘alle data al klaar lag’ heeft het afschrijven van dit boek toch best een tijdje geduurd. 
De stimulerende, doch dwingende mails (later ingeruild voor appjes) hebben hun vruchten 
afgeworpen, het boek is klaar, mijn dank is groot! 
Professor dr. Nagtegaal, beste Iris, wanneer ik het even niet meer wist ging ik naar de 
afdeling pathologie waar jouw deur altijd open stond. Jij was altijd bereid om te ‘sparren’ 
over de lijn van een artikel, de Engelse taal of het commentaar van de reviewers. Jouw 
originele ideeën en kijk op de dingen hebben zeer veel bijgedragen aan dit proefschrift, 
waarvoor dank.
Mede auteurs, hartelijk dank voor jullie waardevolle inbreng aan de verschillende 
hoofdstukken uit dit boek. In het bijzonder wil ik een aantal mensen bedanken voor hun 
inbreng. Als eerste professor dr. Verhoef, ik weet dat u achter de schermen heel veel heeft 
bijgedragen aan dit proefschrift, waarvoor dank. Ninos Ayez, mijn Rotterdamse collega, veel 
dank voor je bijdrage. Bas Wiering, dank voor je database, je vrije tijd ten behoeve van de 
CT-her-beoordeling en je commentaren als co-auteur. Nikki Knijn, dank voor alle middagen 
dat je coupes hebt bekeken en mij hebt geleerd hoe dat moet. Succes met het afronden van 
jouw werk! 
Geachte leden van de manuscriptcommissie en leden van de promotiecommissie veel 
dank voor de beoordeling van mijn manuscript en uw bereidheid om zitting te nemen in de 
corona. 
De bewoners van de onderzoekskamer, (Guus, Ronald, Kim, Roger), heel veel dank voor 
alle grappen, taart, koffie, slimme (en soms minder slimme) ideeën! Jullie hebben mijn jaar 
onderzoek tot een mooie herinnering gemaakt! 
Hans van der Noort, in dit geval niet ‘even een vraagje’ maar een oprecht ‘dank je wel’ voor 
alles wat je voor mij en alle andere assistenten in het Radboud UMC regelt. Je wordt zeer 
gewaardeerd!
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Collega’s van het Radboud en ETZ, dank voor alle belangstelling, collegialiteit en 
samenwerking!
Dr. Vriens, Patrick, ik ben enorm blij dat ik door jou en de andere vaatchirurgen opgeleid 
word tot een echte Tilburgse vaatchirurg. Hiervoor wil ik jou als opleider in het bijzonder 
bedanken, maar ook de andere vaatchirurgen (Burger, de Fijter, Dinkelman, Heyligers en 
Vermeulen) heel erg bedankt voor alle kansen die jullie mij geven! 
Mijn lieve paranimfen, Mariette en Mirjam, dank dat jullie ja zeiden op ‘de vraag’. Mijn grote 
kleine zus, heel erg fijn en bijzonder dat je deze dag naast mij wilt staan. Ik ben heel erg trots 
op je en hoop dat al je toekomstdromen zullen gaan slagen. Je kunt het! Mirjam, ondanks 
dat we elkaar niet iedere week spreken, blijven we altijd betrokken bij elkaars leven en is 
het goed zodra we elkaar zien of spreken. Dit is wat mij betreft de definitie van vriendschap. 
Dank daarvoor. 
Pap en mam, ik zeg het te weinig, maar natuurlijk heb ik alles te danken aan jullie! Dank 
voor jullie eeuwige steun, interesse, humor en nuchterheid. Dank voor alles! 
Mijn grote broer, dank dat je op de voorste rij zit tijdens deze dag! Ondanks jouw drukke 
agenda weet ik dat ik je altijd kan bellen! Ik hoop dat jouw grote prestatie ook gaat slagen 
dit jaar. Thumbs up!! 
Omaatje, ik ben ontzettend blij en dankbaar dat jij deze dag nog mag meemaken. Ik hoop 
dat je nog heel lang van alle dingen mag genieten. En weet dat ik net zo trots ben op jou als 
jij op mij! Dikke pakkerd. 
Lieve vrienden en familie, ik wil jullie bedanken voor alle interesse, hulp en begrip als ik 
weer eens een verjaardag, etentje, house warming of feestje moest missen door onderzoek 
of dienst. Hoop op socialere tijden ;-) 
Het meest vervelend van een dankwoord is, dat er altijd mensen zijn die je vergeet te 
bedanken… Hierbij dus alvast voor iedereen die ik vergeet te noemen: bedankt! 
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Curriculum Vitae
Jannemarie de Ridder was born on the 3rd of November 1982 in Woudenberg (Utrecht), 
the Netherlands. After graduating from Ichthus College in Veenendaal, she started medical 
school in 2001 at Radboud University Nijmegen, where she graduated in 2008. 
After finishing medical school she worked for a year at an emergency department at Gelre 
Hospital, location Zutphen, where she decided to focus on surgery. In 2010 she started 
working at Radboud University Medical Center, which laid the foundations for this thesis 
with help of prof. dr. JHW de Wilt and prof. ID Nagtegaal. The results of the studies were 
presented at national and international meetings. 
She started her surgical training in 2013 at Radboud University Medical Center (prof.dr. 
CJHM van Laarhoven and dr. B Verhoeven). Her training continued at Elisabeth Tweesteden 
Hospital in Tilburg, under the supervision of dr. PWHE Vriens and dr. MS Ibelings. She will 
continue her surgical training to become a vascular surgeon in Tilburg (dr. PWHE Vriens).
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